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Abstract  
 
P2X7 receptors exhibit a mainly non-neuronal localisation on immune and glial cells and 
primarily function as non-selective cation channels. After prolonged or repeated exposure to 
agonist, functional and cellular changes occur: the formation of a large diameter pore, cell 
lysis and the release of mature, biologically active interleukin-1β (IL-1β) a potent 
inflammatory cytokine. It is this repertoire of functions, along with its localisation that 
underlies the hypothesis for its involvement in pain processing.  
The biophysics and pharmacology of rat P2X7 receptors were investigated using stable 
cell lines. Increases in the current amplitude were shown to be dependent upon the 
agonist concentration and current deactivation was agonist application number and 
voltage dependent. These results increased our understanding of the receptor, but have 
also had implications for the design of protocols to investigate antagonist potency and 
efficacy. GSK31418A was identified as a potent, reversible and voltage-independent 
antagonist of rat and human P2X7 receptors. GSK314181A was >10000 fold selective 
over P2X4 receptors and >1000 fold selective over P2X2/3 receptors. GSK314181A 
produced a significant reversal of FCA-induced hypersensitivity when profiled in vivo, 
providing further validation of the role of P2X7 receptors in inflammatory pain. 
Although the influence of glia cells on neuronal activity in the CNS is now well 
documented, the role of peripheral glia, Schwann cells and satellite cells of sensory ganglia, 
is less well established. Non-neuronal cells in DRG cultures were shown to express P2X7 
receptors by pharmacological, biophysical and immunofluorescence techniques. Native 
P2X7 receptors expressed on these cells were shown to have many of the properties of 
recombinant P2X7 receptors, in regards to the response to agonist activation and 
pharmacology. 
Finally, I have shown that Lamotrigine is an effective inhibitor of recombinant rat and 
human P2X7 receptors and native P2X7 receptors expressed in DRG. The potent 
inhibition of human P2X7 by Lamotrigine was replicated with the chemical analogue and 
neuroprotective agent Sipatrigine. However, little effect was recorded for a P2X7 
antagonist in two models of epileptiform activity studies.  
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Chapter 1: Introduction  
 
1.1 Purines and Purinergic receptors 
 
Purines are heterocyclic aromatic organic compounds, consisting of a pyrimidine ring 
fused to an imidazole ring. It is a term used to define any compound that contain this 
basic structure (Figure 1.1), often termed purine bases. The combination of a purine base 
attached to a pentose sugar, or ribose, forms a molecule known as a nucleoside. In Figure 
1.1, adenine is attached to a ribose, forming the molecule, Adenosine. With the addition 
of three phosphate groups attached at the 5' carbon atom of the pentose sugar, the 
molecule becomes adenosine 5′-triphosphate (ATP).  
 
 
   Purine           Adenine               Adenosine          Adenosine Triphosphate (ATP) 
 
 
Figure 1.1:Chemical Structures of key purines 
 
Puringergic transmission was first proposed in 1972 (Burnstock 1972), following the 
identification of ATP as the neurotransmitter in non-adrenergic and non-cholinergic 
nerves supplying the gut and urinary bladder (Burnstock et al. 1970). Purinergic receptors 
is a term that encompasses receptors that use purines as a ligand (Burnstock 1972). This 
form of neurotransmission was then dissected based on the main ligands for activation of 
puringeric receptors, and resulted in the separation into those that responded to the 
nucleoside, adenosine (P1) and those that were activated by ATP (P2) (Burnstock 1978). 
P1 receptors have since been further subdivided based on molecular, biochemical and 
pharmacological evidence into four subtypes labelled A1, A2A, A2B, and A3, and all of 
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which couple to G proteins and mediate their actions via adenylate cyclase (AC). The P2 
receptor family were divided into ionotropic P2X and metabotropic P2Y receptors on the 
basis of pharmacology (Gordon 1986) and molecular biology (Ralevic and Burnstock 
1998). There are now 7 subtypes of ionotropic P2X receptors, names P2X1-P2X7, and 8 
subtypes of metabotropic P2Y (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11-14) receptors known 
to exist (Koles et al. 2005; Abbracchio et al. 2006). The activation of neuronal P2Y 
receptors regulate both outwardly and inwardly recitfying K+ channels, voltage-activated 
Ca2+ channels and trigger IP3-mediated release of Ca2+ from endoplasmic reticulum Ca2+ 
stores (Illes and Alexandre 2004). See Table 1.1 for overview of P2Y receptors. 
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Table 1.1: Characteristics of P2Y Receptors and examples of their modification of ion channel function (Modified from 
Abbracchio et al. 2006; Burnstock 2008)  
P2YR
Agonist 
(human)a Main Distribution Main Function
Primary G-Protein 
coupling/2nd 
messenger
Ca2+ 
channel KM GIRK 
P2Y1 ADP Platelets, epithelial, endothelial, CNS, 
immune and glial cells
Smooth muscle relaxation, mitogenic actions, platelet 
aggregation, bone resorption
Gq/11; PLCβ activation Inhibition Inhibition  activation
P2Y2 ATP=UTP Epithelial, endothelial, immune and glial 
cells, osteoblasts
Vasodilatation and vasoconstriction; mitogenic actions; 
epithelial cell Cl- secretion; bone remodelling
Gq/11; PLCβ activation Inhibition Inhibition  activation
P2Y4 UTP Epithelial, endothelial cells; intestine, 
pituitary, CNS
Regulates epithelial Cl- transport; vasodilatation; mitogenic 
actions
Gq/11; PLCβ activation Inhibition Inhibition no effect
P2Y6 UDP Epithelial cells, placenta, T cells, thymus, 
spleen, kidney, activated microglia
NaCl secretion in colonic epithelium; role in epithelial 
proliferation
Gq/11; PLCβ activation Inhibition Inhibition no effect
P2Y11 ATP Spleen, intestine, brain, granulocytes Role in maturation & migration of dendritic cells;
granulocytic differentiation
Gq/11; PLCβ activation 
Gs; inhibition of AC
nd nd nd
P2Y12 ADP Platelets, glial cells, spinal cord Platelet aggregation; role in dense granule secretion Gi/o; inhibition of AC Inhibition no effect  activation
P2Y13 ADP Spleen, brain, lymph nodes, bone    
marrow, liver, pancreas, heart.
Function largely unknown, but present in both the
immune system and brain
Gi/o; inhibition of AC Inhibition nd nd
P2Y14 UTP-Glucose Placenta, adipose tissue, stomach, 
intestine, brain, spleen, lung, heart, 
immune cells, bone marrow, astroctyes
Chemoattractant receptor in bone marrow
hematopoietic stem cells; dendritic cell activation
Gi/o; inhibition of AC nd nd nd
 
a, Main agonist at human receptor. 
AC, adenylate cyclase; KM, M-current K+ channel; GIRK, G protein-activated inwardly rectifying K+ channels 
nd, Not Determined. 
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1.1.1 P2X receptors  
P2X receptors are membrane bound ion channels that are activated by the binding of 
extracellular ATP, resulting in the opening of a non-selective cation channel (Jahr and 
Jessell 1983; Krishtal et al. 1983). The P2X subunit proteins are 384 (P2X4) to 595 
(P2X7) amino acids long, and have two hydrophobic regions which span the plasma 
membrane (Brake et al. 1994; Valera et al. 1994; North 1996). Separating these 2 
transmembrane domains is the majority of the polypeptide on the extracellular side of the 
membrane, and the NH2 and COOH termini are cytoplasmic (See Figure 1.2 for a 
schematic representation of P2X receptor). The transmembrane regions are thought to 
form the ion conduction pore and undergo conformational changes during receptor 
activation (Silberberg et al. 2005). Transmembrane region 2 is thought to play a role in 
ion permeation and channel gating (Migita et al. 2001), and is involved in the assembly of 
subunits into oligomeric complexes (Samways et al. 2006). All the evidence to date 
indicates that the subunits of P2X receptors form trimeric receptor complexes (Nicke et 
al. 1998; Aschrafi et al. 2004).  
Transmembrane 
domains
TM2TM1
Disulphide bonds
Lysine amino acid residue
 
 
Figure 1.2: Schematic representation of P2X receptor subunit topology. 
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Within the large extracellular domain of P2X receptors a number of key residues have 
been identified. Firstly, the loop is known to contain 10 conserved cysteine residues 
(Cys117-Cys165, Cys126-Cys149, Cys132-Cys159, Cys217-Cys227, and Cys261-
Cys270) which participate in disulphide bond formation and may help define the tertiary 
structure (Ennion and Evans 2002). The disulphide bonds between Cys261-Cys270 and 
Cys117-Cys165 also have a role in receptor trafficking (Ennion and Evans 2002). 
Secondly, there are consensus sequences for N-linked glycosylation (Asn-X-Ser/Thr) in 
all of the P2X receptor subunits in the extracellular loop. Some glycosylation is essential 
for trafficking to the cell surface (Newbolt et al. 1998; Torres et al. 1998a; Rettinger et al. 
2000), and particular sites can also affect ATP potency (Asn210 in P2X1 receptors 
(Rettinger et al. 2000).  
 
The ATP binding site on P2X receptors is located in the extracellular domain, and there 
have been many studies detailing some of the residues involved in ATP binding to P2X 
receptors (reviewed in Roberts et al. 2006). As ATP is a charged molecule with negative 
charge on the phosphate groups, the conserved charged residues across the P2X receptor 
family were investigated for their interaction with ATP using alanine-scanning-based 
mutagenesis. This determined a number of residues and regions that play a role in 
mediating the action of ATP as measured by a significant reduction in the potency of 
ATP in these mutants. For the P2X1 receptor the positively charged Lysine (Lys) at 
position 68 and 309 are thought to bind the phosphate tail of ATP (See Figure 1.2 for 
schematic representation of the location of these residues), with possible involvement of 
the Arg292. Studies using mutagenesis and analysis of receptor polymorphisms supports 
a role of these charged amino acids in the binding of ATP to P2X7 receptors also (Jiang 
et al. 2000b; Worthington et al. 2002), with the Arg307 shown to regulate ATP potency 
(Gu et al. 2004). Based on the P2X1 receptor, the binding of the adenine ring of ATP is 
through interactions with 2 motifs; the Phe and Thr at positions 185 and 186 respectively; 
and Asn290, Phe291, and Arg292 (Ennion et al. 2000; Roberts and Evans 2004; Vial et 
al. 2004a). 
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Intracellularly, the amino acid sequence and length of the C-terminal domain vary across 
the P2X receptor family. However there is a conserved protein kinase C site in the NH2-
terminal domain, mutations of which led to a range of effects including a change in the 
kinetics of the response to agonist of P2X2 receptors (Boue-Grabot et al. 2000), and non-
functional P2X3 receptors (Paukert et al. 2001). A number of different residues have been 
identified in the intracellular C-terminus that are involved in regulating desensitisation or 
channel gating, in P2X2 receptors (Simon et al. 1997; Smith et al. 1999). Whereas the 
fast desensitisation of P2X1 and P2X3 was shown regulated within the two 
transmembrane domains (Werner et al. 1996) from chimeric studies. 
 
The seven P2X receptors identified and cloned to date, named P2X1-P2X7 (Koles et al. 
2005), are 36–48% identical to one another at the amino acid level and, with the possible 
exception of P2X6, all form functional homomeric channels. The P2X6 was cloned from 
superior cervical ganglion cDNA (Collo et al. 1996), but its expression has only been 
recorded in a small proportion of transfected cells (Collo et al. 1997), possibly indicating 
that the protein is not sufficiently glycosylated in heterologous expression systems to 
form functional channels. There is also evidence for heteromultimeric assemblies of P2X 
subunits, including P2X1/P2X2 (Brown et al. 2002), P2X1/P2X4 (Nicke et al. 2005), 
P2X1/P2X5 (Torres et al. 1998b), P2X2/P2X3 (Radford et al. 1997), P2X2/P2X6 (King 
et al. 2000), and P2X4/P2X6 (Le et al. 1998), and although until recently P2X7 receptors 
were thought to be homomeric only (Torres et al. 1999), there is now evidence for 
heteromultimerisation of P2X7 with P2X4 receptors (Guo et al. 2007). An overview of 
the P2X receptor homomers and heteromers is detailed in Table 1.2.  
  
 
 
Chapter 1 
 18
Table 1.2: Summary of distribution and general properties of P2X receptors 
 
Main Distribution ATP EC50 αβme-ATP  Antagonists
b Desensitisation Effect of Main Function
 (µM)a sensitive Ca2+ ionsc
Homomers
P2X1 Smooth muscle, platelets, spinal 
dorsal horn
1 yes NF449 Fast No effect Smooth muscle contraction, platelet 
aggregation
Hechler et al, 2003; 
Ruggieri, 2006 
P2X2 Smooth muscle, CNS, retina, 
autonomic and sensory ganglia
10 no NF023 Slow Inhibition Modulation of synaptic function & 
sensory transmission
Ren at al, 2003; 
Jarvis, 2003
P2X3 Sensory neurons, 1 yes TNP-ATP Fast No effect Sensory neurotransmission Jarvis, 2003
P2X4 CNS, testis, colon 7 no TNP-ATP Medium - Transmitter release, modulates chronic 
pain
Tsuda et al, 2003
P2X5 Gut, bladder, thymus, skin 0.5 no PPADS Slow Inhibition Cell proliferation and differentiation Greig et al, 2003
P2X6 CNS, motor neurons, spinal cord 0.5 yes - Slow - Not Known
P2X7 Immune and glial cells >100 no BBG Slow Inhibition Pro-inflammatory cytokine release, cell 
proliferation, apoptosis
Ferrari et al, 1997; 
Zheng et al, 1991
Heteromersd
P2X1/2e Sensory nerves, spinal dorsal horn 0.6 yes - Mixed - Not Known
P2X1/4f Brain - yes Suramin Slow - Not Known
P2X1/5g Ventral horn of spinal cord 5 yes TNP-ATP Mixed No effect Not Known
P2X2/3h CNS, Sensory neurones 1 yes TNP-ATP Slow Inhibition Sensory neurotransmission Jarvis, 2003
P2X2/6i Respiratory centres in brainstem 32 no Suramin Slow - Synaptic transmission Ren at al, 2003
P2X4/6j Brain 6 yes PPADS Slow - Synaptic transmission Le et al, 1998
P2X4/7k Immune cells and Microglia - - - Slow - Not Known
aNorth & Surprenant 2000; Li et al, 2008 dOverlapping distribution gTorres et al, 1999                            jLe et al, 1998
bMost potent commercially available antagonist eBrown et al, 2002 hRadford et al, 1997                         KGuo et al, 2007
cEffect on ATP activated currents fNicke et al, 2005 iKing et al, 2000
- data not available
PPADS pyridoxalphosphate- 6-azophenyl-28,48-disulfonate 
NF449 4,4’,4’’,4’’’-(carbonylbis(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid
TNP-ATP 2',3'-O-(2,4,6-Trinitrophenyl) adenosine 5'-triphosphate
NF023 8,8'-[carbonylbis(imino-3,1-phenylenecarbonylimino)]bis -1,3,5-naphthalene-trisulphonic acid
BBG Brilliant Blue G  
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1.1.1.1 P2X1 
The P2X1 receptor was cloned from rat vas deferens in 1994 (Valera et al. 1994; Valera 
et al. 1995). They are highly expressed in smooth muscle and activation in response to 
nerve stimulation results in smooth muscle contraction in vas deferens (Mulryan et al. 
2000) and bladder (Vial and Evans 2000; Ruggieri, Sr. 2006). P2X1 receptors are also 
expressed by platelets where they are involved in thrombosis (Hechler et al. 2003), and in 
the central nervous system (CNS), P2X1 subunits are expressed in the cerebral cortex, 
striatum, hippocampus and cerebellum (Kidd et al. 1995). The use of P2X1 knockout 
mice enabled the identification of functional P2X1 receptors in neurones of the superior 
cervical ganglion (Calvert and Evans 2004), and the medial nucleus of the trapezoid body 
(MNTB) (Watano et al. 2004) providing evidence for a functional role for P2X1 subunit 
containing receptors in the CNS. The response to agonist activation of P2X1 receptors 
results in rapidly activating currents which desensitise during the application, with slow 
(>15mins) recovery from desensitisation. The main features of P2X1 pharmacology are a 
high sensitivity to alpha-beta-methylene adenosine 5′-triphosphate (αβme-ATP) as well 
as ATP (Valera et al. 1994; Evans et al. 1995), although the most potent agonist is 2',3'-
(benzoyl-4-benzoyl)-ATP (BzATP) (Bianchi et al. 1999). P2X1 currents are inhibited by 
the pan-P2X antagonists, PPADS and Suramin, but more potently by the suramin 
analogue, NF449, which is also selective (Rettinger et al. 2005) and so has use in the 
identification of P2X1 currents. 
 
1.1.1.2 P2X2 
The P2X2 receptor was initially cloned from pheochromocytoma PC12 cells (Brake et al. 
1994). P2X2 receptors have a wide distribution throughout the peripheral nervous system 
and CNS, and are also found in smooth muscle in the bladder and intestine (North 2002). 
P2X2 receptors are involved in sensory neurotransmission and in the modulation of 
synaptic function (Sawynok et al. 1993; Jo and Schlichter 1999; Ren et al. 2003). A role 
for P2X2 receptors in mediating pain-related behaviour and mechanosensory transduction 
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in the urinary bladder were confirmed using P2X2 gene deleted mice (Cockayne et al. 
2005). Pharmacologically, the P2X2 receptor is activated by ATP but not by αβmeATP, 
and is sensitive to suramin, PPADS and TNP-ATP (King et al. 1997). P2X2 receptors are 
the only homomeric P2X receptor that shows an increased current response to ATP 
following acidification of the extracellular solution. This occurs by reducing the time 
spent in the closed state and so potentially increasing the agonist affinity (Ding and Sachs 
1999), and is a property of these receptors that can be useful in confirming their function. 
 
1.1.1.3 P2X3 
The P2X3 receptor cDNAs were isolated from rat DRG (Chen et al. 1995).  
P2X3 are found predominantly in sensory neurons, where they mediate sensory 
neurotransmission (Burnstock 2001). Clarification of the role of P2X3 receptors was 
found with the production of the P2X3 knockout mouse which had a reduced pain 
threshold in an inflammatory pain model, and reduced urinary bladder reflexes in 
response to bladder distension (Cockayne et al. 2000; Cockayne et al. 2005). The 
development of the selective P2X3/P2X2/3 receptor antagonist, A-317491, confirmed a 
key role in pain of these receptors when it was shown to reverse hypersensitivity induced 
in a number of pain models (McGaraughty et al. 2003). P2X3 receptors respond to 
αβmeATP and ATP to a similar degree. Receptor activation produces currents that are 
either sustained for several seconds (in low agonist concentrations) or show prominent 
desensitisation that is only recoverable following a 15 min washout phase, a profile 
similar to that recorded following P2X1 activation. NF023, a suramin analogue, is around 
40 times more potent an antagonist at P2X3 receptors (Soto et al. 1999), and the Abbott 
compound, A-317491, shows even greater selectivity over P2X and P2Y receptors (Jarvis 
et al. 2002), and so is a particularly useful antagonist for distinguishing P2X3 currents 
from P2X1.  
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1.1.1.4 P2X2/3 
The P2X2/P2X3 heteromer is activated by αβmeATP as well as ATP and the currents 
produced have the same kinetic profile as P2X2 currents, with fast activation and little 
desensitisation within the agonist activation. They are blocked by the non-selective P2X 
antagonists, Suramin, PPADS, but also by NF023 and TNP-ATP, and are potentiated by 
low pH, indicating a hybrid pharmacological profile incorporating elements from both 
P2X2 and P2X3 receptors. There have been numerous studies detailing the importance of 
P2X2/3 (along with P2X3) receptors in pain (Jarvis 2003 for review). P2X2/3 
heteromeric receptors are highly expressed on primary afferent neurones (Lewis et al. 
1995) and may also be important in bladder reflexes, mimicking the profile of that of 
P2X3 receptors (Cockayne et al. 2000; McGaraughty et al. 2003; Cockayne et al. 2005) 
 
1.1.1.5 P2X4 
The P2X4 receptor was cloned by a number of different groups at the same time, among 
the first were Buell and colleague who used superior cervical ganglion (Buell et al. 1996) 
and Bo et al, who isolated P2X4 from brain tissue (Bo et al. 1995). They are the most 
ubiquitously expressed of all the P2X receptors, found on immune cells and throughout 
the peripheral and central nervous systems (North 2002). P2X4 receptors are involved in 
promoting an inflammatory response through upregulation of expression on activated 
microglia (Tsuda et al. 2003). This also leads to the enhancement of pain behaviours after 
nerve injury (Tsuda et al. 2003), and formalin-induced inflammation (Guo et al. 2005). 
There is also evidence for a role of P2X4 receptors in long term potentiation (LTP) in the 
hippocampus, confirmed using P2X4 knockout mice (Sim et al. 2006), and indicating a 
role for these receptors in synaptic strengthening. Homomeric P2X4 receptors are 
activated by ATP and the resultant current is rapidly activating and shows little 
desensitisation throughout the application. There is much species variability in the 
pharmacology of P2X4 receptors with αβmeATP and Adenosine-5'-tetraphosphate (AP4) 
acting as partial agonists at mouse and human orthologues (Jones et al. 2000). Ivermectin 
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potentiates currents at P2X4 receptors, but has no effect at homomeric P2X2, P2X3, or 
P2X2/3 heteromers (Khakh et al. 1999b). 
 
1.1.1.6 P2X5 
P2X5 receptors were cloned from rat heart (Garcia-Guzman et al. 1996), and are 
expressed in skeletal muscle, skin, gut, bladder, and thymus (North 2002), where they 
may play a regulatory role in cell proliferation and differentiation (Greig et al. 2003). 
P2X5 currents resemble those recorded through P2X2 receptors, in that they show little 
desensitisation and are blocked by the generic P2X antagonists. However rat P2X5 
currents are of a considerably smaller amplitude compared with current observed 
following activation of other P2X receptors expressed under similar conditions (Collo et 
al. 1996; Garcia-Guzman et al. 1996), and despite equivalent protein expression as 
observed using Western blotting (Bo et al. 2003).  
 
 
1.2 P2X7 receptor 
 
1.2.1 The structure of the P2X7 receptor 
The presumed endogenous form of the P2X7 receptor was first described as the receptor 
that mediated the permeabilising action of ATP on mast cells (Dahlquist and Diamant 
1974) and large conductance in macrophages (Buisman et al. 1988), and was initially 
known as the P2Z receptor (Gordon 1986). The full length cDNAs were first cloned from 
rat brain in 1996 (Surprenant et al. 1996), followed by human monocytes (Rassendren et 
al. 1997) and mouse microglia (Chessell et al. 1998b). The human P2X7 receptor gene 
was localized by in situ hybridization to chromosome 12q24, within 130 kb of the gene 
for the homologous P2X4 receptor (Buell et al. 1998b). The P2X7 subunit protein is 595 
amino acid long, the longest of the P2X family, and is the least similar, sharing only 35–
40% homology with the other six members (Surprenant et al. 1996). The P2X7 subunit is 
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unique structurally as it has an extended C-terminal domain, (239 amino acids) 27-129 
amino acids longer than any other P2X subunit. Several apparent protein-protein 
interaction motifs, potentially important to macrophage signalling have been identified 
(Denlinger et al. 2001). A lipopolysaccharide (LPS)-binding site has also been identified 
close to the carboxy terminus of the receptor (Denlinger et al. 2001), whereby the 
receptor could translate inflammatory signals to signal transduction events. The region 
between residues 551 and 581 has been identified as essential for trafficking (Wiley et al. 
2003), and cell surface expression of the P2X7 receptor (Smart et al. 2003). The ATP 
binding site is suggested to be located within an antiparallel six-stranded beta-pleated 
sheet (Freist et al. 1998), nearby a cysteine-rich region of the extracellular domain of the 
receptor, with residues K193 and K311 having particularly importance (Worthington et 
al. 2002; Gu et al. 2004). 
 
1.2.2 Pharmacology  
As mentioned above, the pharmacology of P2X receptors overlaps considerably when 
considering most of the tool compounds available, and hence causes difficulties when 
trying to identify and isolate receptors subtypes. There are also considerable differences 
between the potency of antagonists at the P2X7 receptor orthologues See Table 1.3 
(Chessell et al. 1998a; North and Surprenant 2000; Hibell et al. 2001b). This has been 
detailed throughout the literature and can cause complication when comparing between 
studies.  
 
1.2.2.1 Agonists 
P2X7 receptors response to agonist activation differs from that of other P2X receptors in 
a number of ways. Firstly, activation of P2X7 receptors requires a concentration of ATP 
greater than 100 µM, much higher than for other P2X receptors, and the ATP analogue 
BzATP is a more potent agonist at these receptors (Surprenant et al. 1996; Rassendren et 
al. 1997; Chessell et al. 1998b). Other agonists are less effective than ATP including 
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2MeSATP, ATPγS, ADP, or ineffective such as βγmeATP, UTP, and adenosine (North 
and Surprenant 2000). The need to use concentrations of ATP around 1 mM to activate 
P2X7 receptors means that the ATP solutions used are often acidic and will contain other 
nucleotides (North and Surprenant 2000) which may activate other receptors that are 
present, therefore BzATP is often used instead. The endogenous agonist for P2X7 
receptors is the free acid form of ATP (ATP4-), which was first put forward following the 
assumption that the inhibition of P2X7 by divalent cations represented an alteration in the 
concentration of ATP (Dahlquist and Diamant 1974), or through a direct blockade of 
permeation (Surprenant et al. 1996). However, the primary mechanism is likely to be via 
modulation of the agonist binding site, resulting in a reduction in the agonist affinity for 
the P2X7 receptor (Virginio et al. 1997), and possibly through a direct effect on the P2X7 
receptor itself (Jiang 2008; Liu et al. 2008b). Two histidine residues, H130 and H210, 
have been implicated in the inhibitory actions of Mg2+ ions, suggesting that this cation 
acts at a defined allosteric site involving these two residues (Acuna-Castillo et al. 2007). 
 
The potency of agonists varies across species, with greater potency recorded for agonists 
at rat and human P2X7 receptors compared to mouse receptors (Surprenant et al. 1996; 
Rassendren et al. 1997; Chessell et al. 1998b), and this theme of pharmacological species 
variability is found across ligands for P2X7 receptor modulation. Site-directed 
mutagenesis studies revealed the Asn at residue 284 are responsible for higher ATP 
sensitivity in the rat P2X7 receptor, where as differences in the potency of BzATP 
between rat and mouse receptors was found to be dependent upon residues Lys127 and 
Asn284 (Young et al. 2007), indicating that the variability in the potency of agonists at 
different P2X7 receptors orthologues can be altered by changes in single amino acids.  
 
1.2.2.2 Antagonists 
The generic P2X antagonists, Suramin, PPADS, oxidised-ATP and TNP-ATP all block 
P2X7 receptors but at lower potency than their effects at the other subtypes (Surprenant 
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et al. 1996; Evans et al. 1996; Chessell et al. 1998a; Chessell et al. 1998b; North and 
Surprenant 2000). There are a number of more selective antagonists including KN-62 (1-
[N, O-bis(5-isoquinolinesulphonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine), Brilliant 
Blue G (Jiang et al. 2000a) and Calmidazolium (Virginio et al. 1997). KN-62, is an 
antagonist of Ca2+/calmodulin-dependent protein kinase II (CaMKII), but it also potently 
antagonises human P2X7 receptors, with IC50 values of around 12 nM (Gargett and 
Wiley 1997). Brilliant Blue G is also a potent antagonist of P2X7 receptors, exhibiting a 
higher potency at rat (IC50=10nM) than human receptors (IC50= 200 nM). It does have 
activity at other P2X receptors, but with inhibitory concentrations around 2 to >30µM at 
these subtypes, it can be considered selective at P2X7 receptors at lower concentrations 
(Jiang et al. 2000a). Calmidazolium, an inhibitor of cyclic nucleotide-gated receptor, 
inhibits the ionic channel of rat P2X7 receptors by up to 90% (IC50 = 15 nM), but 
interestingly, with no effect on the large diameter pore form (Virginio et al. 1997).  
 
Although many of these antagonists are potent inhibitors of P2X7 function and so useful 
in in vitro studies, they often differentiate between the species orthologues, with many 
exhibiting a much greater potency at the human P2X7 orthologues and limited rodent 
P2X7 activity (North and Surprenant 2000). Examples of this are seen with the 
commonly used tool compounds such as PPADS, Suramin (see Table 1.3) and the more 
potent suramin analogue, NF279, which show 5 to10 fold greater potency at human P2X7 
receptors than at rat (Klapperstuck et al. 2000b) and as mentioned above, KN-62 only 
inhibits human receptors and is ineffective at other P2X7 orthologues (Humphreys et al. 
1998).  However this problem has extended to some of the newer tool P2X7 antagonists 
produced through drug discovery research, like AZ116453743 which shows a similar 
potency reduction at the rat receptor (> 500-fold less effective at inhibiting rat P2X7 
currents (Stokes et al. 2006)) and the Triazole-based compounds (Carroll et al. 2007). 
Conversely, BBG and Calmidazolium are examples of compounds that show greater 
potency to inhibit rat P2X7 receptors compared to human P2X7 (Virginio et al. 1997;  
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Jiang et al. 2000a). The inter-species differences in activities of these compounds is 
surprising given there is 80% similarity between the amino acid sequences of the human 
and rat P2X7 receptors (Rassendren et al. 1997). However, this is also a facet of the P2X4 
receptor pharmacology, where marked differences in sensitivity to suramin and PPADS 
have been recorded between orthologues despite their 89% homology (Garcia-Guzman et 
al. 1997).  
 
 
 
 
 
Table 1.3: Summary of Antagonist Pharmacology of P2X receptors  
(IC50 values in µM) 
 
Ca2+ Uptake YOPRO/EthBr IL-1β release
hP2X7a rP2X7b rP2X7 rP2X7 hP2X7 (THP-1) P2X1 P2X2 P2X3 P2X4 P2X5
PPADSc 1 45 8 1.3 3.5 1 1 1 >300 3
Suramind 70 78 16 1 10 3 >300 4
KN-62e 0.015 >3 >100 >100 0.075  >100 
BBGf 0.2 0.01 8.1 0.6 >5 1.4 >10 >10
Calmidazoliumg 0.1 0.013 - >10
A-740003h 0.018 0.138 0.156 >100 >100 >100 >100
AZ11645373i 0.007 >10 >10 0.092 >10 >10 >10 >10 >10
WC Patch-clamp
 
 
a Activated by 300 µM BzATP 
b Activated by 30 µM BzATP 
c (Surprenant et al. 1996; Chessell et al. 1998a; North and Surprenant 2000; Donnelly-Roberts et al. 2008) 
d (Surprenant et al. 1996; Chessell et al. 1998a; North and Surprenant 2000) 
e (Chessell et al. 1998a; Donnelly-Roberts et al. 2004; Donnelly-Roberts et al. 2008) 
f (Jiang et al. 2000a; Honore et al. 2006; Donnelly-Roberts et al. 2008) 
g (Virginio et al. 1997; Chessell et al. 1998a) 
h (Honore et al. 2006) 
i (Stokes et al. 2006) 
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P2X7 function is also voltage-independently inhibited by many different ions, including 
Ca2+, Mg2+ (Surprenant et al. 1996), Zn2+, Cu2+ and protons (H+) (Virginio et al. 1997; 
Michel et al. 1999). The inhibition of P2X7 function by divalent cations was thought to 
be mediated via the chelation of the effective agonist, ATP4-, thereby reducing the 
relative concentrations of ATP (North 2002). However, there may also be a direct effect 
on the P2X7 receptor itself, that could account for the inhibition (Jiang 2008; Liu et al. 
2008b). The inhibition produced with zinc and copper ion application is potent; with IC50 
values 11.2µM and 0.5µM respectively at rat P2X7 activated by 30 µM BzATP (Virginio 
et al. 1997), and has been shown to be via a direct interaction with residues in the 
extracellular domain of the P2X7 receptor, specifically involving His62 and Asp197 
residues (Liu et al. 2008b). These effects allow the P2X7 receptor to be distinguished 
from other family members as these ions have been shown to potentiate P2X2 and P2X4 
responses to agonist (North and Surprenant 2000). They also provided direct evidence 
against the previous view of divalent cation interaction with ATP4- (Liu et al. 2008b). 
 
The studies detailed in the literature using these antagonists are often quite difficult to 
compare, even between the same species. This is due to many of the antagonists effects 
being agonist concentration dependent. Also agonist potency can variable following 
multiple applications and is dependent upon the divalent cation concentrations of the 
bathing solution (Hibell et al. 2001b). Preincubation times for antagonists may also affect 
potency, as is the case for PPADS, and incubation times often vary from study to study 
(Chessell et al. 1998a). 
 
1.2.3 Expression/localisation 
P2X7 receptors are expressed on cells of haematopoietic lineage including mast cells, 
lymphocytes, erythrocytes, fibroblasts, and macrophages (Surprenant et al. 1996), and 
schwann cells (Colomar and Amedee 2001). Within the central nervous system, 
functional P2X7 receptors are localized on microglia (Collo et al. 1997) and astrocytes 
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(John et al. 2001; Panenka et al. 2001). The existence of functional P2X7 receptors on 
peripheral or central neurons remains controversial owing to the poor specificity of both 
antibodies and ligands targeting the rat P2X7 receptor (Anderson and Nedergaard, 2006) 
and is detailed below. 
 
1.2.3.1 Neuronal P2X7 Receptors 
The existence of functional P2X7 receptors on peripheral or central neurons is still 
subject to some debate. P2X7 receptor expression on neurones was first identified in a 
number of layers of rat retina (Brandle et al. 1998b). P2X7 mRNA has been identified in 
several different CNS areas including the cortex, (Papp et al. 2004), brainstem and spinal 
cord (Deuchars et al. 2001), and in peripheral neurons, such as cultured sympathetic 
(Allgaier et al. 2004), and dorsal root ganglion (Kobayashi et al. 2005) neurons. P2X7 
receptor immunoreactivity has been reported to selectively target excitatory nerve 
terminals of the spinal cord (Deuchars et al. 2001; Atkinson et al. 2004; Wang et al. 
2004b), and has also been reported in a number of brain regions including, medulla 
oblongata, cerebellum, striatum, thalamus, amygdala (Deuchars et al. 2001; Atkinson et 
al. 2004; Hervas et al. 2005) and hippocampus (Armstrong et al. 2002; Sperlagh et al. 
2002; Kang et al. 2004). (See Sperlagh et al. 2006 for review). Further evidence for 
neuronal localisation was obtained following co-localization studies revealing co-
expression of P2X7 receptor immunoreactivity with vesicular glutamate transporters, 
VGLUT1 and VGLUT2, GABA transporter, vGAT, and vesicular acetylcholine 
transporter, vAChT, immunoreactivity in many areas of the brain and spinal cord 
(Atkinson et al. 2004).  
 
However the pattern of immunostaining in neurones detailed in these studies has been 
inconsistent and more recent work has suggested that the most commonly used antibodies 
may not be as specific as first thought (Sim et al. 2004; Kukley et al. 2004).  P2X7 
immunoreactivity was present in hippocampal sections taken from two different P2X7 
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knockout mice, but was absent in non-brain tissue, such as submandibular gland, and 
microglia (Sim et al. 2004). This has been postulated to be either due to a failure to 
eliminate brain P2X7 expression in the knockout mice; deemed unlikely due to two 
different knockout mice strains; or the existence of a ‘P2X7-like’ protein in neurones that 
these antibodies recognise (Sim et al. 2004). Interestingly, the epitopes recognised by the 
antibodies are identical to the genuine P2X7 receptor but differ in the sequence that has 
been disrupted by genetic manipulation in the Pfizer knockout mouse (Sanchez-Nogueiro 
et al. 2005).  
 
Functionally, P2X7 activation following BzATP application, increased the firing rate of 
glutamatergic neurones in spinal cord (Deuchars et al. 2001), possibly through 
presynaptic glutamate release, increased evoked EPSC amplitude in brainstem slices 
(Ireland et al. 2004), and enhanced the release of GABA in hippocampus (Sperlagh et al. 
2002), an effect that is attenuated in hippocampus from P2X7 knock-out mice (Papp et al. 
2004). Conversely a long-lasting inhibition of neurotransmission was observed following 
P2X7 receptor activation in mossy fibre–CA3 synapses (Armstrong et al. 2002). A role 
for P2X7 receptors postsynaptically has also been shown in the paraventricular nucleus, 
where their activation leads to an increase in synaptic strength through AMPA receptor 
insertion (Gordon et al. 2005). Although pharmacological characterisation of BzATP- or 
ATP-activated currents were reported in some of these experiments (Armstrong et al. 
2002; Sperlagh et al. 2002), caution should be used when interpreting data, as the 
inhibition of synaptic transmission recorded in hippocampal slices (Armstrong et al. 
2002), has been mimicked in slices from P2X7 knock-out mice (Kukley et al. 2004), and 
there is evidence that some of the effects detailed above may be mediated through 
neuronal adenosine A1 receptors (Ireland et al. 2004; Kukley et al. 2004). Finally 
astrocytic glutamate and GABA release can often not be discounted as a source of these 
neurotransmitters. It has been shown that cultured astrocytes can release Glutamate and 
GABA following the activation of P2X7 receptors (Wang et al. 2002; Duan et al. 2003).  
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Therefore it is as yet unclear as to whether P2X7 receptors are expressed on neurones. It 
is clear that P2X7 receptor activation can modulate synaptic transmission, regardless of 
their location.  
 
1.2.4 Response to agonist activation 
The low affinity of ATP for P2X7 receptors, the lowest of all the P2X receptors, infers a 
potential pathological role for P2X7 receptors when large amounts of ATP are released. 
In vitro, P2X7 receptors have been shown to have an almost unique response to ATP. 
During a brief activation, P2X7 receptors behave as (1) a classical non-selective cation 
channel. However, after a prolonged or repeated exposure to agonist, functional and 
cellular changes occur: (2) formation of a large diameter pore and cell lysis and (3) the 
release of mature, biologically active interleukin-1β (IL-1β), a potent inflammatory 
cytokine. Each of these responses to activation will be discussed below. 
However there are also a number of other cellular processes that occur, including the 
activation of caspases (Perregaux and Gabel 1994), cytokine release (Ferrari et al. 1997a) 
and apoptosis (Zanovello et al. 1990; Zheng et al. 1991). 
 
1.2.4.1 Channel opening 
The main action following brief activation of the P2X7 receptor is the opening of a cation 
channel that allows the bidirectional flux of Na+, Ca2+ and K+ ions (Surprenant et al. 
1996). The channel activates rapidly and currents show little desensitisation during 
applications lasting for many seconds. However, the current response to multiple agonist 
activations is not static. The time course of closure of the channel following agonist 
activation, deactivation, slows with each subsequent agonist application. It is related to 
the agonist potency and is thought to be due to a slow dissociation of agonist from the 
receptor rather than being an intrinsic property of the ion channel (Hibell et al. 2001a). 
Interestingly, it is much less evident when ATP is the agonist and the slowest channel 
Chapter 1 
 
 31
closure times were recorded for the rat P2X7 receptor (Hibell et al. 2001a) indicating 
species variability. The peak current amplitude is also not stable, and often steady 
increases are recorded with each addition of agonist. The extent of these changes is 
species dependent (Michel et al. 1999; Hibell et al. 2000; Hibell et al. 2001a).  
 
1.2.4.2 Pore formation 
Changes to the agonist response occur with prolonged or high concentration agonist 
applications, producing perhaps the most interesting phenomenon related to P2X7 
function; that of the formation of a “pore” that allows the passage of large diameter 
molecules into, or out of, the cell (Surprenant et al. 1996), and often resulting in cell lysis. 
The large diameter pore that forms in macrophages, microglial cells and mast cells is 
typically permeable to molecules of molecular mass up to 900 Da (Steinberg et al. 1987; 
Tatham and Lindau 1990), but in lymphocytes this is reduced to around 300 Da (Wiley et 
al. 1993). This formation of a large diameter pore in the membrane is often measured 
using plate-based fluorescence readers as an increase in the permeation of extracellular 
dyes, such as YO-PRO-1 (YOPRO) and Ethidium Bromide (EthBr), that fluoresce once 
bound to nucleic acids within the cell. There has been much discussion with regards to 
the nature of the pore form of the P2X7 receptor and two main theories have been put 
forward in the last 8 years. These two will be outlined and discussed separately and are 
exemplified in the schematic in Figure 1.3. 
 
“Dilation theory” 
It was initially hypothesised that the channel of the receptor undergoes a progressive 
dilation, resulting in an increase in the size of the transmembrane pathway and hence 
allows the permeation of larger molecules (Virginio et al. 1999a; Virginio et al. 1999b; 
Figure 1.3). The fact that the pore may form when P2X7 receptors are expressed in many 
different expression systems; HEK293 (Surprenant et al. 1996; Rassendren et al. 1997), 
mouse microglial cell line (Chessell et al. 1998b), granulocytic cells (HL-60 and 
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neutrophil-like cells) (Suh et al. 2001), rat peritoneal mast cells (Tatham and Lindau 
1990) and human THP-1 cells (Donnelly-Roberts et al. 2004) inferred that it was likely to 
be mediated through P2X7 receptors themselves. There is also considerable overlap in the 
pharmacology of the channel and pore forms, with MAP kinases (Faria et al. 2005), 
Brilliant blue G (Jiang et al. 2000a), and many of the newer tool molecules such as A-
740003 (Honore et al. 2006), and AZ11645373 (Stokes et al. 2006) blocking both forms 
of the P2X7 receptor. The formation of large diameter pores has also been associated 
with the expression of the P2X2 and P2X4 subtypes (Khakh et al. 1999a; Virginio et al. 
1999b). It is more difficult to induce pore formation in cells expressing these other P2X 
receptors and so difference between their structures was investigated. The most obvious 
difference between the P2X subtypes is the elongated C-terminal domain of P2X7 
receptor and so this became the focal point for manipulation. Truncation of the C-
terminus of P2X7 receptors by deletion of residues 419 to 595 resulted in a functional 
cation channel, but a much reduced uptake of YOPRO (Surprenant et al. 1996), and no 
ethidium bromide uptake into cells (Smart et al. 2003). Conversely, an augmentation in 
pore-forming ability was conferred to human P2X7 receptor by the substitution of C-term 
region with corresponding region of rat receptor, an orthologue that undergoes pore 
formation more readily than the human. These data again provided evidence that it is the 
P2X7 receptor itself, and specifically residues located in the C-terminal domain, that 
participate in pore formation (Rassendren et al. 1997). 
 
“Separate pore hypothesis” 
The main alternative theory for P2X7-induced pore formation centres around the 
hypothesis that P2X7 activation initiates the formation of a separate pore-forming protein 
in the membrane, and was discussed once it emerged that in some expression systems, 
particularly xenopus oocytes, the activation of P2X7 only produced the opening of a non-
selective cation channel and not a large pore (Petrou et al. 1997; Watano et al. 2002; 
Ramirez and Kunze 2002). Also pharmacological differences were identified when the 
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P2X7 ionic channel was shown to be blocked by Calmidazolium and a monoclonal 
antibody, with no effect on YOPRO uptake (Virginio et al. 1997; Chessell et al. 2001). 
The discovery that maitotoxin, a potent cytolytic agent, activated a non-selective cation 
channel and a large diameter pore, allowing the uptake of ethidium bromide and YOPRO, 
strengthened the separate pore hypothesis (Schilling et al. 1999a; Schilling et al. 1999b; 
Lundy et al. 2004). Maitotoxin does not bind or interact with P2X7 receptors and yet 
produced similar effects on the membranes of cells over a similar time scale to that seen 
following P2X7 activation, and raises the possibility that Maitotoxin and P2X7 receptors 
activate a common cytolytic pore. More recent work has shown P2X7-induced pore 
formation to be dependent upon a cascade of events involving the release of second 
messengers (Coutinho-Silva and Persechini 1997; Faria et al. 2005), and in particular  
p38 MAP Kinase (Donnelly-Roberts et al. 2004), but also caspase pathways (Donnelly-
Roberts et al. 2004).  
 
The formation of the pore has been measured electrophysiologically as a progressive 
increase in the permeability of a large cation N-Methyl-D-Glucamine (NMDG) (Virginio 
et al. 1999a), and using plate based fluorescence readers as an increase in the permeation 
of extracellular dyes (YOPRO and Ethidium Bromide) that bind to nucleic acids once 
they enter cells. These two mechanisms are widely used and the uptake of both NMDG 
and dyes was considered to be occurring via the same route. However, Jiang and 
colleagues cast doubt on this with work that indicated a common pathway for NMDG and 
Na+ ion permeation, where as the influx of dyes such as YOPRO, may be occurring via 
another route (Jiang et al. 2005). It has also been shown that other stimulants can result in 
YOPRO/Ethidium Bromide uptake into cells, including maitotoxin application, but that 
these channels are not permeable to NMDG (Martinez-Francois et al. 2002; Lundy et al. 
2004). The biphasic currents recorded following prolonged agonist applications to P2X7 
receptors were suggested to be indicative of dilation of the P2X7 receptor channel and 
has been shown to be influenced by the C-terminal (Yan et al. 2008). Therefore these data 
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suggest that the NMDG-permeable pore is part of the P2X7 receptors, whereas the 
YOPRO entry pathway is via a molecular mechanism distinct from the P2X7 receptor, 
but is switched on as a consequence of P2X receptor activation (Jiang et al. 2005; Yan et 
al. 2008). 
 
Recent work has focused on the involvement of pannexin-type hemichannels in the 
formation of the pore, particularly centring on pannexin-1 (Pelegrin and Surprenant 2006; 
Locovei et al. 2007). Pannexins are mammalian proteins that are similar, in general 
structure, to the non-mammalian innexins that form gap junctions in invertebrates 
(Panchin et al. 2000). There are 3 Pannexins (Panx1, Panx2, Panx3) that have been 
identified (Panchin 2005; Barbe et al. 2006). The expression of Panx1 cDNA in single 
oocytes resulted in hemichannel-like membrane currents, and in paired oocytes 
expressing Panx1, junctional coupling was observed (Barbe et al. 2006). Panx1 mRNA 
was found in a variety of different cell types, including human and mouse monocytes, 
macrophages, astrocyte cells and non-immune cell lines such as HEK and HeLa cells and 
it was co-immunoprecipitated with the P2X7 protein following co-expression in HEK293 
cells (Pelegrin and Surprenant 2006). Functional evidence that Panx1 is the molecular 
correlate of the P2X7-activated pore form was obtained using small interference RNA 
(siRNA), a Panx1-mimetic inhibitory peptide, or over-expression techniques, to show a 
modification of dye uptake, but not receptor activation or its resulting ionic current 
(Pelegrin and Surprenant 2006). 
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Figure 1.3: Schematic representation of the 2 theories of what underlies the large diameter 
pore following P2X7 receptor activation. 
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1.2.4.3 IL-1β production and release  
Uniquely, the activation of the P2X7 receptor also results in the release of mature, 
biologically active IL-1β (Perregaux and Gabel 1994; Solle et al. 2001; Ferrari et al. 
2006). IL-1β is a pro-inflammatory cytokine that is part of the Interleukin-1 family 
(Discussed in 1.3.9 Cytokines). It is synthesised by cells as an inactive precursor 
molecule, pro-IL-1β, and following cleavage by a cysteine protease, caspase-1 
(previously known as Interleukin-1 converting enzyme, ICE), (Kostura et al. 1989; 
Thornberry et al. 1992), the 17 kDa mature, active form is produced.  
 
The process of the production and release of IL-1β is tightly controlled. Many different 
inflammatory mediators such as viruses, endotoxins (e.g. lipopolysaccharide (LPS)), 
Tumour necrosis factor α (TNF-α) or phorbol esters (e.g. PMA) prime cells through 
inducing the synthesis of pro-IL-1β, which is normally absent from cells under normal 
conditions (Martinon and Tschopp 2004), and possibly increasing the expression of pro-
Chapter 1 
 
 36
caspase-1 (Le Feuvre et al. 2002b). If halted at this stage more than 95% of the pro-IL-1β 
will remain unprocessed in the cytoplasm of cells, and so a second stimulus is also 
required to, indirectly, produce IL-1β. The second stimulus has been shown to be the 
binding of ATP to the P2X7 receptor, resulting in the opening of the non-selective 
cationic channel. The movement of Na+ and Ca2+ ions into cells is accompanied by a K+ 
ions efflux, and it is this reduction of intracellular K+ ions that activates the caspase-1 
enzyme (Perregaux and Gabel 1994; Kahlenberg and Dubyak 2004). Caspase-1 is 
constitutively expressed in many cells as a 45-kDa inactive precursor (pro-caspase-1), 
which requires cleavage before being active (Wilson et al. 1994). 
 
The release of IL-1β is a tightly controlled process that is not dependent upon cytolysis 
and does not require P2X7-mediated pore formation (Chessell et al., 2001). Although 
pore formation itself is not required, the activation of Panx1 is required for the cleavage 
of caspase-1 and the subsequent release of IL-1β, indicating a downstream signalling link 
between Panx1 and the processing and release of IL-1β in vitro (Pelegrin and Surprenant 
2006; Pelegrin and Surprenant 2007). IL-1β release can also be prevented by the 
inhibition of the caspase-1 enzyme (Watanabe et al. 1998), and the inhibition of the ATP-
binding cassette-1 (ABC-1), suggesting a role of anion flux in the release of IL-1β 
(Hamon et al. 1997). 
 
The main routes for IL-1β release are proposed to be by secretion via endosomes (Andrei 
et al. 1999), secretion via microvesicle shedding (Mackenzie et al. 2001), or the 
exportation by transporters, such as ABC transporters (Hamon et al. 1997); Figure 1.4.  
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Figure 1.4: Schematic depicting proposed mechanisms of ATP stimulated IL-1β processing 
and release. 
 
 
 
Once mature IL-1β is released it has downstream effects on other cells including the 
induction of nitric oxide synthase (iNOS), cyclooxygenase 2 (COX-2) (Samad et al. 
2001), the production of superoxide products (Parvathenani et al. 2003) TNF- α (Woolf et 
al. 1997), all of which have well described roles in the generation or maintenance of pain. 
(This is discussed in section 1.4.6 Role of P2X receptors in pain) 
 
1.2.4.4 Membrane disruption 
P2X7 receptor activation is also associated with membrane blebbing (Virginio et al. 
1999a), and cytoskeletal and cellular changes, which occur within 2-30 seconds of 
receptor activation. These events are reversible, although a prolonged activation will 
eventually lead to cell death by necrotic and apoptotic mechanisms (Ferrari et al. 1999). 
Membrane blebs start with the appearance of numerous small vesicles which can be shed 
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from the cell, or develop into large hemispherical protrusions of the plasma membrane 
(Mackenzie et al. 2001). These membrane blebs or microvesicles, are characterised by 
phosphatidylserine translocation (Mackenzie et al. 2001) and actin/β-tubulin 
rearrangements (Pfeiffer et al. 2004). Although the functional consequences of membrane 
blebbing following P2X7 activation is unknown, in other systems it is associated with 
mitosis, apoptosis and secretion (Hagmann et al. 1999). P2X7-mediated membrane 
blebbing involves epithelial membrane protein interaction with the C-terminus of the 
P2X7 receptor (Wilson et al, 2002).  
 
Studies in vitro show that concentrations in the range of 0.5-5 mM ATP are required to 
fully activate P2X7 and induce IL-1β release. This is similar to cytosolic concentrations 
of ATP, but is high for function in the extracellular compartment. Therefore doubts were 
raised about the physiological relevance of this mechanism as it is unlikely that high (0.5-
5 mM) concentrations of ATP would be in the vicinity of target cells for an extended 
time. However, although prolonged activation of the P2X7 receptor will produce cell 
death, continuous exposure to ATP is not a requirement. In susceptible cells, once P2X7 
receptor activation has occurred, some cells will recover their integrity and function 
normally, only to die sometime later (Hogquist et al. 1991). This suggests that once 
activated, the P2X7 receptor sets in motion an irreversible intracellular cascade of events 
leading to cell death (Di Virgilio 1995).   
 
1.3 Pain 
 
The current definition of pain is “An unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, or described in terms of such damage”, 
as put forward by an International Association for the Study of Pain (IASP) 
Subcommittee on Classification in 1986 (Lindblom et al. 1986) and now used as an 
official definition by the IASP. Acute pain is an essential component of the body’s 
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normal defence mechanism, alerting the body to danger and protecting it from further 
damage. However the development of abnormal sensitivity in the somatosensory system, 
results in pain of a more chronic nature. Pain is classed as chronic when the symptoms 
outlast the normal time required for healing following tissue damage, or when it is 
associated with a pathological condition that does not heal. Chronic pain affects millions 
of people worldwide, and is regarded by the World Health Organisation (WHO) as a 
major reason for health related absence from work. In addition, chronic pain can lead to 
depression, anxiety and insomnia which have detrimental effects on the patients’ quality 
of life (Gureje et al. 1998; Ashburn and Staats 1999).  
 
1.3.1 Treatment of Pain 
Inflammatory pain is produced following an insult to tissues resulting in the release of 
inflammatory mediators from damaged cells, activation of the arachidonic acid pathway 
and the recruitment of immune cells, which may release further mediators including 
cytokines and growth factors. Non-steroidal anti-Inflammatory drugs (NSAIDs) such as 
Aspirin and Ibuprofen are the most commonly prescribed drugs for inflammatory pain. 
These compounds inhibit arachidonic acid metabolism and prostaglandin production 
through inhibition of cyclo-oxygenase (COX) (Vane 1971; Kawai 1998), thereby 
eliminating the direct hyperalgesic effects of these compounds but also their sensitising 
effect . However NSAIDs have limited efficacy in severe pain, due in part to the many 
different inflammatory mediators capable of sensitising neurones, and also to side effects 
from prostaglandin inhibition in other tissues. Adverse effects include gastrointestinal 
bleeding (Goodwin 1987), renal failure (Lifschitz 1983) and cardiovascular effects 
(Waksman et al. 2007). Paracetamol, not conventionally classed as an NSAID, is one of 
the most popular analgesic and anti-pyretic drugs, but the mechanism by which it 
achieves its effects is still debated. Although its analgesic and antipyretic effects are 
similar to those of aspirin, it does not have significant anti-inflammatory activity. 
Therefore it is has been reasoned that although it may have effects on COX enzymes, 
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they are different from that seen with NSAIDs. There is evidence for alternative 
mechanisms of action including inhibition of the nitric oxide pathway, increase in 
descending inhibitory serotonergic pathways and cannabinoid receptor agonism 
(Reviewed in Anderson 2008). 
 
The other main type of chronic pain is classed as neuropathic pain. Neuropathic pain is 
defined as “Pain initiated or caused by a primary lesion or dysfunction in the peripheral 
or central nervous system” by IASP. It is found in a number of conditions including post-
herpetic neuralgia (PHN), diabetic neuropathy, HIV-related neuropathies and trigeminal 
neuralgia. Neuropathic pain often responds poorly to commonly used analgesics and to 
standard doses of opioid analgesics (Tremont-Lukats et al. 2000), and so antiepileptic 
drugs, such as Carbamazepine, Lamotrigine, Gabapentin and Pregabalin, or tricyclic 
antidepressants, e.g. amitripytline, and selective mono-amine re-uptake inhibitors such as 
Duloxetine, are often used to treat a wide range of neuropathic pain disorders (Zaremba et 
al. 2006; Mico et al. 2006). Although there are treatments available, the efficacy of these 
drugs in this condition is poor and can be limited by poor tolerability. When this is 
combined with a low responder rate, as often seen, the result is a large patient group with 
unmet need, therefore highlighting the requirement for novel effective analgesics in this 
area.  
 
1.3.2 Nociceptive processing  
The ability to sense pain has two main purposes; 1) it allows the organism to detect 
potential injury and triggers an appropriate protective response and 2) it alerts the 
organism to previously injured tissue with an aim to prevent further injury. Nociceptive 
information is transmitted from the periphery via primary afferents into the dorsal horn of 
the spinal cord. From here nociceptive information moves up to supraspinal sites mainly 
through the spinothalamic pathway, but also via the spinoreticular, spinomesencephalic, 
spinoparabrachial, and spinohypothalamic pathways (Bernard et al. 1996; Willis and 
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Westlund 1997; Gauriau and Bernard 2004). Non-nociceptive sensory information is 
transmitted in the dorsal column. See Figure 1.5 for a schematic representation. 
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Figure 1.5: Schematic showing the main pathway for sensory information from the 
periphery to the cortex. (Modified from Clinical Anesthesiology (Morgan et al. 
2005)). 
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1.3.3 Primary afferents 
Somatosensory fibres innervate the skin, muscle, joints and viscera and detect 
information regarding the surrounding environment and the condition of the tissue. Fibres 
that innervate regions of the head and body arise from cell bodies in the trigeminal and 
dorsal root ganglia (DRG) respectively.  
 
Primary afferent fibres transmit sensory information from the periphery to the spinal 
cord. Unlike other types of receptors in the skin, nociceptors can respond to multiple 
stimulus modalities, including temperature, mechanical and chemical stimuli (Bessou and 
Perl 1969; Beck et al. 1974; Van and Gybels 1981). They are categorised based on their 
myelination, the modality of stimulation that evokes a response and the characteristics of 
the response. Aβ-fibres are large, myelinated fibres that respond predominantly to light 
touch and have a fast conduction velocity. Aδ-fibres are lightly myelinated fibres with a 
medium axon diameter and a slower conduction velocity (Table 1.4). Aδ-delta fibres 
carry responses to strong noxious stimuli that are potentially or actually damaging tissues 
and represent approximately 10% of all primary afferents. Activation of Aδ-fibres leads 
to a well localised, sharp and acute pain sensation (Dubner 1978; Handwerker and Kobal 
1993). C-fibre make up the majority of fibres within the DRG (70%), and these have the 
smallest diameter axons, and are non-myelinated, and hence have slow conduction 
velocities (Table 1.4; Millan 1999). C-fibre activation produces a more diffuse, poorly 
localised pain sensation (Dubner 1978; Handwerker and Kobal 1993).  
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Table 1.4: Characteristics of Primary Afferent Fibres 
Fibre Type
Fibre diameter 
(µm) Myelination
Conduction 
Velocity (m/s)
% Primary 
Afferents
Sensation following fibre 
activation
Aβ >10 thick 30-100 20 non-noxious light touch
Aδ 2-6 thin 12-30 10 noxious, sharp, prickling pain
C 0.4-1.2 none 0.05-2 70
noxious, diffuse, persistent, 
and poorly localised pain
 
 
 
1.3.4 The spinal cord 
Primary afferent fibres enter the spinal cord and immediately ascend or descend one or 
two segments in Lissauer’s tract before terminating in the grey matter. The areas of 
termination were segregated into 10 laminae based on density and type of cell bodies and 
myelination (Rexed, 1952, see Fig 1.2) (Willis and Coggeshall 1991). The first six 
lamina, which make up the dorsal horn, represent the principal site of modulation of pain 
by ascending and descending pathways. The different nociceptive primary afferent fibres 
terminate in specific laminae within the spinal cord. The termination of Aβ-fibres is the 
most widespread, with most synapsing in laminae III, IV and V. Aδ-fibre afferents 
predominantly synapse onto lamina I neurones, and to a lesser extent into laminae II, V 
and X. C-fibres terminate in lamina I, II and V (Millan 1999), (Willis and Coggeshall 
1991). All of these primary afferent fibres synapse onto second order neurones which 
have their cell bodies in the dorsal horn. 
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Figure 1.6: Diagram of Rexed’s laminae of the spinal cord indicating the main laminae for 
the termination of fibres 
 
 
 
 
1.3.5 Peripheral Sensitisation 
Peripheral sensitisation is a reduction in threshold and an increase in responsiveness of 
the peripheral nociceptors. It occurs when primary afferents become directly activated 
following tissue injury or inflammation. Sensory and sympathetic neurones, blood vessels 
and immune cells can all release mediators of inflammation in response to tissue injury. 
Bradykinin and prostaglandins are released from injured tissues, along with serotonin 
from activated platelets. The walls of blood vessels undergo an increase in permeability, 
inducing the release of nitric oxide by plasma extravasation. These chemical and 
inflammatory mediators along with others such as adenosine, ATP and protons can act 
directly on primary afferent neurones, causing pain or sensitisation (Kress and Reeh 
1996). There is also indirect sensitisation of neurones through the release of cytokines 
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such as IL-1β and TNF-α (Bianchi et al. 1998). IL-1β is produced by a variety of non-
neuronal cells (including macrophages, mast cells, fibroblasts and synoviocytes) during 
inflammation (Bianchi et al. 1998). Once released, IL-1β has the potential to cause 
sensitisation of afferents by a variety of different mechanisms including; stimulating the 
release of PGE2 from inflammatory cells (Dayer et al. 1986), the induction of Nerve 
Growth Factor (NGF) (Yoshida and Gage 1992) and the upregulation of substance P 
levels in neurones (Jonakait et al. 1990). The resulting increase in activation of primary 
afferent neurones leads to neurogenic inflammation through the release of pro-
inflammatory neurotransmitters such as calcitonin-gene related peptide (CGRP) and 
substance P (Lynn 1996). The sensitisation induced by these peptides can lead to a 
change in the excitability of sensory nerves, and nearby postganglionic sympathetic 
fibres. In areas of primary hyperalgesia, primary afferents innervating inflamed tissues 
have a reduced threshold for activation, an increase in the response to a given stimuli and 
an increase in spontaneous firing. The overall effect of this leads to an increase in the 
input into the spinal cord, a greater release of glutamate and substance P from central 
afferent terminals and results in hyperexcitability of dorsal horn neurones (Woolf 1983; 
Woolf and Thompson 1991). 
 
1.3.6 Central Sensitisation 
Central sensitisation manifests itself by (1) a reduction in the threshold for activation of 
dorsal horn neurones; (2) an increases in the responsiveness of dorsal horn neurones; (3) 
an expansion of the receptive field (Woolf 1991). This occurs following prolonged 
nociceptive fibre input as a result of tissue damage or peripheral inflammation. This 
results in a state of hypersensitivity where low-intensity stimuli, which are innocuous 
under normal conditions, are able to initiate pain sensations. This mechanism has a 
protective purpose by sparing injured body parts from further injury while healing occurs 
(Woolf and Walters 1991).  
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1.4 Glia  
Until very recently, spinal central sensitisation as detailed above, was thought to be 
predominantly the result of a cascade of neuronal events in the spinal cord (Woolf and 
Salter 2000). However there is now compelling evidence that spinal cord glial and 
immuno-competent cells and their cross-talk with neurones play a key role in the 
induction and maintenance of central sensitisation (Watkins et al. 1997; Colburn et al. 
1999; Colburn and DeLeo 1999; Milligan et al. 2003).  
 
Non-neuronal cells were first identified in the mid-19th century by Rudolph Virchow, a 
German anatomist, and were called ‘glia’, the Greek for ‘glue’. It is now know that the 
term glial cells encompasses 3 cell types, called microglia, astrocytes and 
Oligodendrocytes, and that these cells make up around 70% of the total cell populations 
in the CNS.  
 
1.4.1 Oligodendrocytes 
Oligodendrocytes are the myelinating cells of the central nervous system. However 
unlike the peripheral nervous system, where one schwann cell myelinates one axon, a 
single oligodendroglial cell synthesises myelin sheaths for multiple neurones (Peters 
1964) allowing fast nerve conduction. 
 
1.4.2 Microglia 
Microglia are known as the resident macrophages of the CNS and account for 5-10% of 
the total glial cell population (Kreutzberg 1996; Stoll and Jander 1999). Quiescent 
microglia have small cell bodies and short processes, but they are not passive cells, rather 
they actively sense their environment with their ramified processes (Nimmerjahn et al. 
2005; Hanisch and Kettenmann 2007). Following even minor pathological changes in the 
CNS, such as in response to infectious diseases, inflammation, trauma, ischemia, brain 
tumours and neurodegeneration, microglia become activated. Microglial activation 
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manifests itself in a number of ways, including a change in morphology from ramified to 
amoeboid shape (Eriksson et al. 1993), an increase in the expression of markers such as 
MHC II and CD 11b (Hayes et al. 1987; Eriksson et al. 1993), and proliferation (Tsuda et 
al. 2005). Once activated, microglia perform a variety of functions in tissue repair and 
neural regeneration, as well as phagocytosis and the release of proinflammatory cytokines 
such as TNF-α, IL-1β and interleukin-6 (IL-6) (Hanisch and Kettenmann 2007; for 
review) 
 
1.4.3 Astroctyes 
Astrocytes are the most numerous of all glial cells in the CNS and are star-shaped cells 
with a central cell body, approximately 15–17 µm in diameter, and long processes 
extending in all directions. These processes make contact with neuronal synapses and the 
vasculature, allowing bi-directional communication between these two tissues, and the 
connections with the endothelial cells of the capillaries form the basis of the blood-brain 
barrier (Abbott et al. 2006). Connections are also formed between astrocytes through gap 
junctions, thereby forming networks of coupled astrocytes (Blomstrand et al. 1999; 
Guthrie et al. 1999). Astrocytes also have important roles at synapses, and one astrocyte 
may make contact with over 100,000 synapses (Bushong et al. 2002). They enwrap nerve 
terminals (Peters et al. 1964), which positions them perfectly to influence synaptic 
transmission. This led to the concept of the Tripartite synapse (Araque et al. 1999). At the 
synapse of pre- and post-synaptic neurones they are responsible for the clearance of 
transmitters such as glutamate and GABA from synaptic clefts, but also have the ability 
to release gliotransmitters (Araque et al. 1999). Astrocytes are activated by several 
substances including excitatory amino acids (Kettenmann and Schachner 1985), nitric 
oxide (Mollace et al. 1998), substance P (Wienrich and Kettenmann 1989), 
prostaglandins (Bezzi et al. 1998) and ATP (Neary et al. 1988). They can also be 
activated by invading organisms, such as bacteria and viruses (Meller et al. 1994; 
Milligan et al. 2001), which do not directly activate neurones. The gliotransmitters they 
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release include proinflammatory cytokines such as IL-1β, IL-18 and TNF-α, excitatory 
amino acids and growth factors, all of which are neuroactive (Wienrich and Kettenmann 
1989; Mollace et al. 1998; John et al. 2001; Haydon 2001). Therefore they are ideally 
placed to influence synaptic transmission and play a role in neuronal activity. 
 
1.4.4 Glial activation in Pain models 
Initially the literature around glial activation was focused around the observation that 
peripheral nerve damage led to CNS glial activation (Sjostrand 1971; Hall et al. 1989; 
Hajos et al. 1990) without making any link back to pain. It was in 1991 that Garrison and 
colleagues first made a link between nerve damage-induced pain and nerve damaged-
induced glial activation. Using the astrocyte-specific marker Glial-Fibrillary Acidic 
Protein (GFAP) they demonstrated astrocyte activation in a neuropathic pain model, and 
then the reversal of the activation following the administration of an analgesic 
compounds (Garrison et al. 1991).  
 
Since then the activation/proliferation of spinal cord glia and immune cells have been 
identified in a wide range of preclinical models of chronic pain, such as inflammation 
(Sweitzer et al. 1999; Raghavendra et al. 2004a), nerve injury (Colburn et al. 1999) and 
bone cancer (Schwei et al. 1999; Zhang et al. 2005a). It has also been shown that 
inhibition of glial activation can block or prevent pain. Fluorocitrate is a general glial 
inhibitor, blocking the activity of both astrocytes and microglia. It takes advantage of the 
fact that glia, and not neurones, take up extracellular citrate for metabolism in the Krebs 
cycle (Fonnum et al. 1997). Low doses must be used in order to only target glia as higher 
dose result in irreversible and toxic effects on glial cells and so affects neuronal cell 
function also (Paulsen et al. 1987). Fluorocitrate has been shown to be an effective 
blocker of pain states induced in a range of models including sciatic inflammatory 
neuropathy (Milligan et al. 2003), intrathecal delivery of viral components (Milligan et al. 
2000; Milligan et al. 2001) and subcutaneous formalin (Watkins et al. 1997).  
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More specifically, Minocycline, a semi-synthetic tetracycline derivative, also inhibits 
microglial function (Tikka et al. 2001). The administration of Minocycline pre-emptively 
blocked the production and release of pro-inflammatory cytokines in neuropathic pain 
models (Raghavendra et al. 2003), and could block the induction of hypersensitivity 
(Raghavendra et al. 2003; Ledeboer et al. 2005). However, minocycline has little, or no 
effect on hypersensitivity once it is established (Raghavendra et al. 2003; Ledeboer et al. 
2005), indicating a necessity for microglial activation in the development of such pain 
states, but little role in their maintenance. These data have led to the proposal that early 
microglial activation leads in turn to activation of astrocytes, and that astrocyte activation 
serves to maintain the hypersensitivity and consequently the pain. It is also important to 
note that the involvement of glia in pain processing seems to be limited to 
hypersensitivity, and has no effect on basal, acute pain processing.  
 
Interestingly, an upregulation of markers of glial activation is recorded following chronic 
morphine treatment (Song and Zhao 2001), and the tolerance associated with morphine 
was attenuated following dual dosing with Fluorocitrate. This lead to speculation that 
glial activation may account in some way for the tolerance seen with prolonged opioid 
use, highlighting another possible mechanism by which glial cells influence chronic pain. 
 
1.4.5 Cytokines 
Cytokines are soluble proteins that are released by a variety of cells such as fibroblasts, 
synoviocytes and mast cells (Watkins et al. 1995). They are classically associated with 
cell proliferation, differentiation and changes in gene expression (Janeway et al. 2001), 
but in addition, they are essential in fighting infection and responding to injury. 
Cytokines are chemical messengers that regulate the balance between cell mediated and 
antibody mediated immune responses, and produce either a proinflammatory or an anti-
inflammatory response. Inflammatory cytokines include TNFα, IL-1, IL-6 and IL-8 are 
often released in a cascade, where an initial release of TNF is followed first by IL-1 and 
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then by IL-6. Less than 10 IL-1 receptors are estimated to need occupation to induce a 
physiological response, highlighting the exceptionally powerful ability of these 
proinflammatory cytokines (Gallis et al. 1989). 
 
1.4.6 Role of P2X receptors in pain 
Following inflammation or nerve injury, release of ATP by neuronal and non-neuronal 
cells is greatly increased in the periphery as well as in the CNS (Chizh and Illes 2001; for 
review). In spinal dorsal horn, ATP can increase the release of glutamate, GABA and 
glycine via the activation of presynaptic P2X2, P2X3 and P2X2/3 receptors (Sawynok et 
al. 1993; Gu and MacDermott 1997; Rhee et al. 2000). There have been numerous studies 
detailing the importance of P2X2/3 and P2X3 receptors in pain (Jarvis 2003, for review). 
P2X3 receptors are highly expressed on primary afferent neurones and preferentially on 
nociceptive C-fibers (Lewis et al. 1995; Chen et al. 1995), were as P2X2 receptors are 
mainly expressed on medium to large diameter fibres, with overlap of these two subtypes 
on small diameter neurones (Petruska et al. 2000). The expression of P2X3 receptors has 
been shown to increase following a peripheral nerve injury (Novakovic et al. 1999). More 
recently, the novel dual P2X2/3 and P2X3 antagonist, A-317491, has been shown to 
reduce hypersensitivity associated with inflammatory and neuropathic insult in animals 
(Jarvis et al. 2002; McGaraughty et al. 2003; McGaraughty and Jarvis 2005), providing 
useful in vivo data confirming a key role of these receptors in pain processing. 
 
ATP also activates non-neuronal cells such as astrocytes, microglia and macrophages, 
and once activated, these cells release cytokines and other pro-inflammatory mediators 
(Interleukin-6, interleukin-1β, tumour necrosis factor α, prostaglandins, and excitatory 
amino acids) which are known to induce or increase hyperexcitability of spinal neurones 
(Watkins and Maier 2002). P2X4 receptors are expressed on a wide variety of cells types, 
including both neurons (Buell et al. 1996) and microglia (Tsuda et al. 2003). There is 
increasing evidence for their involvement in mediating neuropathic and inflammatory 
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pain. P2X4 expression levels change in spinal microglia following nerve injury (Tsuda et 
al. 2003) and formalin-induced inflammation (Guo et al. 2005), and intrathecal 
administration of P2X4 antisense oligoucleotide was able to suppress the tactile allodynia 
caused by a peripheral nerve injury (Tsuda et al. 2003). The activation of P2X4 receptors 
on microglia results in the release of cytokines that can enhance synaptic transmission 
(Tsuda et al. 2003), therefore preventing P2X4 receptor function may represent a novel 
therapeutic approach for treating pain hypersensitivity.  
 
There is also increasing evidence for a substantial role of P2X7 receptors in pain 
pathology. The repertoire of responses to agonist activation, along with their localisation 
on non-neuronal cells makes them ideally placed to influence nociceptive functioning.  
 
1.4.6.1 P2X7 receptors and Pain processing 
There is substantial evidence to indicate a role for P2X7 receptors as a key mediator of 
the inflammatory response (Ferrari et al. 2006) and so as a potential therapeutic target 
with which combat chronic inflammatory pain (Romagnoli et al. 2008). The proposed 
role for P2X7 receptors in inflammatory and neuropathic pain centres on the maturation 
and release of IL-1β following receptor activation (Ferrari et al. 2006). 
The role of IL-1β in pain is well defined in vivo, where blockade of IL-1 receptors with 
an IL-1 receptor antagonist (IL-1ra), reduced thermal hyperalgesia and mechanical 
allodynia in a mouse neuropathic pain model (Sommer et al. 1999). The release of IL-1β 
initiates a signalling cascade leading to the up-regulation of various other inflammatory 
mediators such as COX-2, IL-6, TNFα, nitric oxide synthase (iNOS) (Woolf et al. 1997; 
Samad et al. 2001), and the production of superoxide products (Parvathenani et al. 2003), 
all of which have a role in pain (Lister et al. 2007). IL-1β may be of further importance as 
its release, after P2X7 activation, caused an increase in the expression levels of P2X7 
receptors in astrocytes (Narcisse et al. 2005). This is also mimicked in satellite cells in 
nerve and DRG sections from patients suffering with persistent neuropathic pain 
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(Chessell et al. 2005). The increase in P2X7 receptor expression seen under these 
conditions may well result in a larger cationic current into cells following activation, 
influencing neuronal processing via a greater release of inflammatory cytokines; and the 
release and uptake of neurotransmitters such as glutamate (Colburn et al. 1997; Haydon 
2001).  
 
The production of P2X7 gene deleted mice showed a reduction or a removal of the 
release of IL-1β following ATP/BzATP stimulation of LPS primed blood samples or 
plated cells from P2X7 knockout mice compared to control animals (Solle et al. 2001; 
Labasi et al. 2002; Chessell et al. 2005). There is also an overall reduction in the release 
of inflammatory mediators following Freunds Complete Adjuvant (FCA) treatment in 
these animals (Chessell et al. 2005). Behaviourally, P2X7 knockout mice showed reduced 
pain sensitivity following both a partial nerve injury and FCA treatment (Chessell et al. 
2005), indicating a role for P2X7 in mediating the hypersensitivity associated with 
inflammatory and neuropathic pain. Importantly, no changes in nociceptive responses 
were recorded for these P2X7 knockout mice (Chessell et al. 2005). Following on from 
this the effect of antagonists of P2X7 receptors were profiled. The possibility of P2X7 
antagonists being anti-hyperalgesic was first introduced when oxidised ATP was used in 
a model of arthritis and reversed the deficit in paw withdrawal threshold recorded 
following the adjuvant injection (Dell'Antonio et al. 2002b). More recently a number of 
small molecule selective P2X7 antagonists have been shown to be efficacious in models 
of inflammatory and neuropathic pain, providing more evidence for the key role of this 
receptor in mediating pain (Lappin et al. 2005; Honore et al. 2006; Carroll et al. 2007; 
Nelson et al. 2008). 
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1.5 Satellite Cells in DRG 
The cell bodies of primary afferent fibres that innervate the skin and viscera congregate 
in the dorsal root ganglia (DRG) found just before the dorsal root of the spinal cord. The 
DRG consists of these sensory neurone cell bodies, glial derived satellite cells, dendritic 
cells, macrophages, and endothelial cells (Olsson 1990). In the DRG, each neuronal cell 
body is encapsulated by a layer of satellite cells, usually consisting of several satellite 
cells, that forms a distinct morphological unit (Pannese 1981).  
 
Satellite cells are glial-like and so possess many of the regulatory and immune-like 
functions recorded in glial cells. They have been shown to be important controllers of the 
contents of the ganglia extracellular space, exhibiting mechanisms for neurotransmitter 
uptake (Keast and Stephensen 2000) or breakdown (Braun et al. 2004) and can therefore 
exert a tight control over the neuronal microenvironment. Specifically, they are involved 
in the uptake of glutamate and aspartate and also provide the precursor to glutamate 
production, glutamine, to DRG neurones (Duce and Keen 1983; Kai-Kai and Howe 
1991). They are also known to release proinflammatory cytokines and growth factors 
(Ramer et al. 1998; Ramer et al. 1999; Zhou et al. 1999). 
 
Like glial cells in the CNS, satellite glial cells are stimulated following peripheral nerve 
injury or inflammation, exhibiting cell proliferation (Pannese 1981; Lu and Richardson 
1991) and upregulation of GFAP labelling (Woodham et al. 1989). Whether this increase 
in GFAP is due to cell proliferation, hypertrophy or an increase in synthesis is not yet 
known and would be useful to know to determine the reasons for this change. As 
mentioned above, they also release cytokines that are pro-inflammatory, although it is not 
clear whether there is an enhancement of release under conditions of injury (Ramer et al. 
1998; Ramer et al. 1999; Zhou et al. 1999). Satellite glial cells are often electrically-
coupled to each other, in most cases between the cells that envelope a particular neuron 
(Hanani et al. 2002). However the number of gap junctions is expanded following nerve 
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injury (Hanani et al. 2002), a change that is seen in glia in the spinal cord and is 
correlated with hyperalgesia (Spataro et al. 2004). Thus these satellite cells are well 
positioned both anatomically and physiologically, to regulate neuronal activity in the 
DRG. 
 
1.5.1 Role of P2X receptors on Satellite Cells  
P2X receptors have been shown to be present on satellite cells from peripheral ganglia, 
specifically, P2X3, P2X2/3 (Kumagai and Saino 2001) in superior cervical ganglia 
(SCG), and P2X2 (Vulchanova et al. 1997) and P2X7 receptors (Zhang et al. 2005b) in 
DRG. However the exact roles of these receptors in the functioning of satellite cells in 
physiology and pathophysiology is unclear. Functionally, there is evidence for somatic 
release of ATP from DRG neurones and that this plays an important role in bi-directional 
communication between satellite cells and neurones in DRG (Zhang et al. 2007). The 
activation of P2X7 receptors on satellite cells can also lead to the release of TNF-α, 
which can in turn increase the excitability of neurones (Zhang et al. 2007). This suggests 
that neuronal somata have a significant role in inter-cell signalling and satellite cells can 
influence neuronal activity. The increased expression of P2X7 receptors on satellite cells 
from neuropathic pain patients and following IL-1β release (Chessell et al. 2005; Narcisse 
et al. 2005), mentioned earlier, provides further indirect evidence for a specific role of 
P2X7 receptors expressed in these cells. As well as the effects of satellite cells on 
neuronal functioning through release of mediators of inflammation, it has been proposed 
that the electrical coupling of satellite cells may influence sensitisation associated with 
pain (Spataro et al. 2004). In chronic pain, an augmentation of coupling among satellite 
cells has been recorded (Dublin and Hanani 2007), and there is evidence that ATP release 
via P2X7 receptor activation may amplify Ca2+ signalling between spinal cord astrocytes 
(Suadicani et al. 2006). 
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In summary, there is evidence for changes in satellite cells functioning and coupling 
following nerve injury or inflammation, and also evidence for upregulation of P2X7 
receptors on these cells, although much of it indirect and further work is needed (Dublin 
and Hanani 2007).  
 
1.6 Epilepsy 
Epilepsy affects about 1% of the world’s population and describes a group of 
neurological disorders characterized by the periodic occurrence of spontaneous seizures. 
Although there are a good range of anti-epileptic agents available, about 30% of epileptic 
patients do not respond to these therapies and are defined as pharmaco-resistant.  
 
1.6.1 The neurophysiology of epilepsy 
EEG recordings from epilepsy patients have identified two broad categories of 
paroxysmal neuronal discharge: inter-ictal and ictal epileptiform discharge. Inter-ictal 
discharges are brief (<1s) bursts of synchronous neuronal activity occurring between 
seizures. Ictal discharges occur during seizures and often last several seconds to minutes 
(Prince 1978).  
 
Broadly speaking, epilepsy is thought to arise from an imbalance between excitatory and 
inhibitory synaptic transmission, which results in excessive excitation and leads to 
synchronous discharges of large neuronal populations. Recent experimental and clinical 
evidence supports a crucial role of inflammation in epilepsy (Vezzani and Granata 2005) 
and in particular in the mechanisms underlying the generation of seizures (ictogenesis) 
and the development of seizure-generating neural network from a normal one 
(epileptogenesis) (Pitkanen and Sutula 2002). There is also evidence for a marked 
reactive gliosis in epileptogenic tissue, and alterations in the functioning of specific glial 
membrane channels, receptors and transporters (Steinhauser and Seifert 2002). Until the 
bidirectional communications between neurones and glial cells are completely 
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understood, it is not clear whether the glial changes are an accompanying facet of the 
disease or have a role in the production of epilepsy. 
 
1.6.2 P2X7 receptors and epilepsy 
The proposed role for P2X7 receptors in epileptogenesis is based on their properties and 
localisation. Firstly, even though the localisation of P2X7 receptors is still under some 
debate, their activation has been shown to increases neurotransmitter release from 
presynaptic excitatory nerve terminals in the hippocampus (Deuchars et al. 2001; 
Sperlagh et al. 2002). Secondly P2X7 receptors are expressed on astrocytes (Ballerini et 
al. 1996; Kukley et al. 2001) and activation of P2X7 receptors results in the release of 
Glutamate and GABA (Wang et al. 2002; Duan et al. 2003). Data from hippocampal 
slices shows that glutamate release from astrocytes activates neuronal NMDA receptors, 
and can lead to neuronal network synchronisation (Angulo et al. 2004; Fellin et al. 2004). 
Thirdly, there is growing evidence for the role of cytokine, in particular IL-1β, in 
epileptogenesis. Seizures have been shown to stimulate the release of this cytokine 
(Vezzani and Baram 2007; for review). Inflammatory cytokines, including IL-1β, have 
been shown to be over-expressed during epileptogenesis in astrocytes, but not in 
microglia, suggesting a predominant role of astrocytes in sustaining chronic inflammation 
before the onset of spontaneous seizures (Ravizza et al. 2008). They have also been 
shown to be pro-convulsant in a large variety of seizure models (Vezzani et al. 1999). 
Finally, there may be a change in the responsiveness of P2X7 receptors in epilepsy. There 
are conflicting reports from in vivo models of epilepsy, showing an upregulation of P2X7 
receptor expression in some rat models (Vianna et al. 2002; Rappold et al. 2006), but also 
a decrease in P2X7 receptor immunoreactivity in seizure sensitive gerbil hippocampus 
(Kang et al. 2004). 
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1.7 Aims of this thesis 
 
In this thesis, I have used electrophysiological and immunocytochemical techniques to 
investigate P2X7 receptors stably expressed in cell lines and native P2X7 receptors 
expressed in non-neuronal cells from DRG cultures.  
 
The main aims were; 
• To assess some of the defining characteristics of this receptor, focusing on the 
response to agonist activation. What differences, if any, are there in the functioning 
of the receptor when it is expressed in a recombinant system compared to in native 
cells? 
• To investigate the pharmacology of P2X7 receptors and assess the activity of a novel 
compound at recombinant and native P2X7 receptors. Using potency and selectivity 
data for this compound in order to support the conclusion that P2X7 antagonists may 
provide a novel mechanism to target inflammatory pain.  
• To investigate P2X responses recorded in non-neuronal cells in DRG cultures and 
confirm P2X7 receptor expression in these cells through receptor biophysics, 
pharmacological assessment and immunocytochemical techniques. 
• To identify the specific cell type of non-neuronal cells that expresses the P2X7 
receptor using immunocytochemistry.  
• To investigate the activity of the anticonvulsant Lamotrigine at P2X7 receptors, 
and whether P2X7 inhibition could account for some of Lamotrigine’s efficacy by 
assessing the effect of a selective P2X7 antagonists in in vitro models of 
epileptiform activity.  
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Chapter 2: General Materials and Methods  
 
2.1 Methods for Cell Lines 
Experiments were performed using HEK293 cells stably transfected with rat P2X7, 
human P2X7, rat P2X4 or human P2X4 receptors; or CHO-K1 cells stably transfected 
with human P2X2/3 receptors. 
 
2.1.1 Production and maintenance of stable cell lines 
All cell lines were available from GSK cell line storage system. HEK293 cells were 
stably transfected with rat or human P2X7 or P2X4 cDNA, contained on plasmids with 
Geneticin resistance genes on them. CHO-K1 cells were stably transfected with human 
P2X2 and human P2X3 cDNA, contained on plasmids with Geneticin and Hygromycin 
resistance genes on them.   
 
2.1.2 Recombinant Cell culture  
2.1.2.1 Materials and Solutions 
HEK293 cells stably expressing rat or human P2X7 receptors were maintained in a 1:1 
mixture of Dulbecco's modified Eagle's medium (DMEM) and Hams F12 containing 10% 
foetal bovine serum and supplemented with 0.6 mg/ml geneticin sulphate (G418). 
HEK293 cells stably expressing rat or human P2X4 receptors were maintained in 
Dulbecco's modified Eagle's medium nutrient mix supplemented with FBS (10%) and 
0.6 mg/ml G418. CHO-K1 cells stably expressing human P2X2 and human P2X2/3 
receptors were maintained in Dulbecco's modified Eagle's medium nutrient mix 
supplemented with FBS (10%), 0.6 mg/ml G418, and 0.4mg/ml hygromycin. All cells 
were grown as monolayer cultures at 37°C in a humidified atmosphere containing 95% 
air and 5% CO2. 
 
2.1.2.2 Cell Passage  
Cells were passaged when they were between 70-90% confluent with a 1:10 dilution, 
approximately every 3-4 days. For all cell lines the solutions were used cold, straight 
from the fridge (~4ºC). The media was removed from the flask with care taken not to 
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dislodge the cells. The cells that were adhered to the flask were washed twice with 
phosphate buffered saline without calcium or magnesium ions (5mls) and then 2mls of 
accutase was added to enzymatically digest the cell linkages, allowed to cover the cells. 
For P2X7 cell lines the flask was left in the cell culture hood while the accutase was 
incubated for 5 -10 minutes. For all other cells lines, it was placed into the incubator at 
37°C for 5-10 minutes. The flask was then agitated to aid the removal of cells stuck to the 
flask. 8 ml of media was added and used to wash the bottom of the flask, ensuring the 
removal of any other cells still stuck to the flask. The 10mls of cells suspension was 
placed in a 50ml falcon tube and centrifuged at 200g for 5 mins in order to pellet the 
cells. The excess media was then removed and the cell pellet resuspended in 1 ml of fresh 
growth media using a P1000 Gilson pipette to ensure the cells were dispersed and then a 
further 9 mls of media was added. For a 1:10 dilution, 1ml of the cell suspension was 
added to a T75 cell culture flask (Nunclon) containing 20 mls of media. 
 
2.1.2.3 Preparation of cells for electrophysiology  
Cells were passaged and plated out onto glass coverslips (13 mm; Chance Propper Ltd, 
West Midlands, U.K.) 2-48 hours prior to electrophysiological recordings. These 
coverslips were autoclaved and then pre-coated with a 2 µg/ml solution of poly-D-lysine 
before being washed in double distilled water and then individually placed into 35mm 
diameter petri dishes. They were then stored at 4 ºC until needed. 40,000 cells in 2mls of 
media was used for each coverslip, and in order to obtain the correct volume of cells 
required for electrophysiological recording, 1 ml of the cell suspension was analysed in 
the CEDEX cell counter (Innovatis; Bielefeld, Germany) and a viable cell count for the 
sample was obtained. Once the cells had stuck down to the coverslips, the cells could be 
used for electrophysiological recordings. They were broken into smaller sections using a 
diamond tipped pen and then transferred to the recording chamber. 
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2.2 Methods for Native cells  
 
2.2.1 Coverslip preparation 
Glass coverslips were coated with 100 µg/ml poly-L-lysine in sterile water. The solution 
was washed off with sterile water and left at 37oC. On the morning of the preparation, the 
coverslips were coated with 5 µg/ml Laminin in PBS (50 µl of 1 mg/ml laminin in 10 ml 
PBS) and left at room temperature. The laminin was removed just before DRG cells were 
plated onto the coverslips. 
 
2.2.2 Dorsal Root Ganglia Dissociation and culturing 
Sprague-Dawley rat pups (7-10 days old) were decapitated in accordance with UK home 
office guidelines. A laminectomy was performed and the dorsal root ganglion neurons 
(DRGs) were isolated and collected into 5ml Hanks Buffered Salt Solution (HBSS). The 
meninges and roots were removed and the DRGs were incubated in trypsin (5mls) for 20 
minutes at 37°C. Dulbeccos Modified Eagle’s Medium (DMEM, + 10% FCS; 5mls) was 
added to inactivate the enzyme, and then the cells in 10mls of medium were centrifuged 
at 100g for 3 min. The supernatant was removed and replaced with a 0.1% collagenase 
solution (1ml of 0.5% stock plus 4ml HBSS) which was incubated with the ganglia for 50 
min at 37°C. After incubation, 5mls of the DMEM and 10% FCS mixture was added and 
then the solution was centrifuged for 3 min at 100g. The supernatant was removed, 
replaced with 2ml DMEM (+ 10% FCS) and then cells were triturated up to 20 times with 
a long fire polished Pasteur pipette to mechanically dissociate the ganglia. The solution 
was made up to 10mls with an additional 8ml DMEM (+ 10% FCS), and then plated onto 
a 100 mm tissue culture dish for 1 hour at 37oC to allow the removal of the excess of non-
neuronal cells and large diameter DRGs which stick to the bottom of the dish. The media 
containing unattached neurones and some non-neuronal cells was then collected and 
centrifuged at 200g for 5 minutes. The supernatant was removed and the cells 
resuspended in 2ml serum-free DMEM (supplemented with 50 ng/ml NGF, N2 
supplements and 0.05% BSA). Cells were counted with a haemacytometer and plated at 
the required density for electrophysiological experiments, of 100,000 cells in 0.5ml onto 
poly-L-lysine and laminin coated coverslips. The cells were then incubated for 1 hour at 
37oC to allow the cells to attach to the coverslip after which time the culture dish was 
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flooded with 2 ml of medium. This method has been modified from Lindsay et al 
(Lindsay 1988). 
 
2.3 Electrophysiology 
 
2.3.1 The Equipment and Set up 
2.3.1.1 Microscope 
The microscope, a Nikon ECLIPSE TE2000-S (Nikon UK Limited, Surrey, UK), was 
isolated from vibration by placing it on an air table (Technical Manufacturing 
Corporation, MA 01960, USA). Phase contrast optics was used to identify healthy cells. 
Fragments of coverslips with cells attached were visualised initially with a 10X objective 
and the electrode was positioned above an appropriate cell using a coarse manual 
manipulator (LBM-7 manual manipulator, Scientifica Ltd, East Sussex, UK). Cells were 
approached using the 20X objective using a fine manipulator (PatchStar 
Micromanipulator, Scientifica Ltd, East Sussex, UK). 
 
2.3.1.2 Chambers and perfusion systems 
All experiments used an open diamond bath perfusion chamber (RC-26G, Warner 
Instruments Corp.) in which a vacuum grease (Dow Corning) sealed coverslip (22 x 40 
mm coverslip, Chance Proper Ltd) formed the floor. This was electrically isolated from 
the microscope using a plastic stage adapter (PH-1, Warner Instruments Corp). Both the 
ground wire and pipette electrode were AgCl, made by soaking silver wire in household 
bleach for a few hours and then rinsing in distilled water. Extracellular solution was fed 
by gravity from a 50ml syringe (Becton Dickinson) to the recording chamber and was 
aspirated from the chamber by a vacuum system into a container below the anti-vibration 
table. Different solutions were applied to cells under investigation using a Warner Fast-
step drug delivery system (SF-77B, Warner Instruments Corp, Figure 2.1). 25ml syringes 
were connected via 3-way taps to tubing that led into to perfusion manifolds (ML series, 
Warner Instruments Corp), and finally into single-walled 3-barrel glass tubing (3SG700, 
Warner Instruments Corp). This allowed solutions to be exchanged within 20ms. 
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antagonist
Patch Electrode
 
Figure 2.1: Schematic representation of drug delivery system 
 
2.3.1.3 Patch-clamp 
Positive pressure was applied to recording pipettes before they were placed into the bath 
solution close to an appropriate cell. Any current offset from zero was negated by 
manually adjusting the pipette offset control. A voltage step of 5 mV was used to monitor 
the resistance between the pipette and bath electrodes. The pipette was then moved onto 
the cell using the micromanipulator and contact with the cell was indicated by an increase 
in the resistance. The positive pressure was then released and gentle suction applied 
resulting in the formation of a giga-ohm seal between the cell and the pipette. Fast 
capacitance transients were neutralised and the voltage was stepped down to -60mV. On 
the application of further suction, the membrane under the electrode was ruptured and the 
whole-cell configuration was obtained. The capacitance transients were neutralised and 
the series resistance compensated up to 80% (compensated lag time = 10µs). All 
experiments were performed at 21°C and once whole cell recording had been established, 
cells were lifted up from the coverslips to speed solution exchange.  
 
2.3.1.4 Electronics 
The voltage protocol was generated by pClamp9 Clampex Software, originating from the 
computer in digital form and was converted to an analogue signal following input into the 
Analogue-Digital board (A-D board, Axon Instruments Palo Alto, Calif., USA). The 
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analogue data was then amplified by the amplifier Axopatch200B (Axon Instruments) 
before being applied to the cell. Currents across the membrane recorded in response to 
changes in voltage or ligand application were amplified by the Axopatch200B before 
being digitised by the A-D board and recorded by the computer for subsequent analysis. 
 
2.3.1.5 Amplification and Filtering 
Data was low pass filtered between 2 and 5 kHz and sampled at 2-5x the filter corner 
frequency using pClamp9 Clampex acquisition programs. Analysis appropriate for the 
voltage protocol is detailed below. 
 
2.3.2 Solutions  
All solutions were made up in double distilled Millipore water. The pH was adjusted 
using a Titan pH meter (Sentron, The Netherlands) and the osmolarity determined by 
vapour pressure using Vapro Vapor Pressure Osmometer (Vapro 5520, Wescor Inc.).  
 
2.3.2.1 Extracellular Solutions 
RAT AND HUMAN P2X7 - (mM) 135 NaCl, 2 KCl, 0.5 MgCl2, 1 CaCl2, 10 HEPES, 12 
D-Glucose, pH 7.3 with NaOH, osmolarity 290-300 mOsm  
 
DRG NON-NEURONAL CELLS – (mM) 147 NaCl, 2 KCl, 0.3 CaCl2, 10 HEPES, 12 
D-Glucose, pH 7.3 with NaOH, osmolarity 300-310 mOsm. 
 
RAT AND HUMAN P2X4 – (mM) 145 NaCl, 2 KCl, 1 MgCl2, 2 CaCl2, 10 HEPES, 10 
D-Glucose, pH 7.3, osmolarity 300 mOsm.  
 
HUMAN P2X2/3 – (mM) 135 NaCl, 2 KCl, 1 MgCl2, 2 CaCl2, 12 HEPES, 10 D-
Glucose, pH 7.3, osmolarity 305 mOsm.  
 
2.3.2.2 Intracellular Solutions 
RAT AND HUMAN P2X7 – (mM) 150 NaCl, 10 HEPES, 10 BAPTA, pH 7.3 with 
NaOH, osmolarity 320 mOsm. 
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DRG NON-NEURONAL CELLS – (mM) 150 NaCl, 10 HEPES, 10 BAPTA, pH 7.3 
with NaOH, osmolarity 320 mOsm. 
 
RAT AND HUMAN P2X4 – (mM) 145 Cs aspartate, 11 EGTA, 5 HEPES, 2 NaCl, pH 
7.3, osmolarity 310 mOsm. 
 
HUMAN P2X2/3 – (mM) 150 CsCl, 2 EGTA, 10 HEPES, pH 7.3, osmolarity 312 
mOsm. 
 
2.3.3 Electrodes  
Glass microelectrodes were pulled from thick wall borosilicate glass capillaries with an 
inner filament (inner diameter: 0.69mm; outer diameter: 1.2mm; 120F-10; Clark 
Electromedical Instruments, UK) using a horizontal micropipette puller (Flaming-brown 
P-97, Sutter Instruments Co., USA). Electrodes were back-filled with an intracellular 
solution and had resistances ranging from 1-5 MΩ. Electrodes were fitted into a universal 
electrode holder (HL-U, Axon Instruments, USA), so that the pipette solution was in 
contact with a silver chloride coated silver wire. The holder was attached to a unity gain 
headstage and connected to the amplifier. A silver-silver chloride reference electrode was 
submerged in the recording chamber and connected to the headstage. 
 
2.3.4 Recording Protocols and Data Analysis  
All data were captured using pClamp9 software (Axon Instruments Ltd) and analysed 
off-line using the Clampfit (Axon Instruments) programme. 
 
2.3.4.1 Standard agonist activation protocol for P2X4 and P2X7 receptors 
Cells were exposed to a 2s application of agonist every 2 minutes using the Warner drug 
delivery system (Figure 2.1). 
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2.3.4.2 Standard agonist activation protocol for P2X2/3 receptors 
Cells were exposed to αβme-ATP in a dual 1.5s application with 3.5s between pulses and 
this was repeated every 3.5 minutes until a stable baseline of peak current was established 
(see Chapter 4, Figure 4.7Ai). To uncover the P2X3 current component, the current from 
the second agonist application was subtracted from the first, resulting in the removal of 
the P2X2/3 current component, leaving a purely P2X3 mediated current. 
 
2.3.4.3 Agonist Concentration-response Curves 
Data for agonist concentration–response curves were obtained by an individual cell being 
exposed to 2 concentrations, 1 test concentration and 1 standard concentration. Responses 
were normalised to the standard concentration for each cell. In order to measure the peak 
current amplitude in response to agonist activation, cursors were first placed over the 
baseline region, defined as a 1 second time before the application of the agonist. A 
second set of cursors were placed across the application area and the data was measured 
relative to this baseline or ‘leak’ current level. Data were then placed into Excel 
spreadsheet and Origin (Oirgin Software) and curves were constructed. This was done 
using raw data fitted using the following logistic equation: 
 
Y =      A1-A2     + A2  
        1 + (x/x0)p 
  
Where x is the concentration of the drug, X0 is the EC50 or IC50, p is the power and A1 
and A2 are the minimum and maximum values respectively. 
 
2.3.4.4 Antagonist Concentration-response Curves 
Data for antagonist concentration–response curves were obtained by an individual cell 
being exposed to 1 or 2 concentrations of antagonist once a stable baseline response to 
agonist had been obtained where possible. Antagonists were preincubated for 2 minutes 
and co-applied with the agonist. Concentration response curves were constructed as 
detailed above. 
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2.3.4.5 Kinetics of Agonist Response 
Deactivation rates for inward currents were measured as the time taken for each response 
to decay from 95% to 50% of its maximum and the slope was calculated using 
exponential fitting (Clampfit). Data were compared using the students T test, with P < 
0.05 being taken as a measure of statistical significance. All data are expressed as means 
± S.E.M;  n refers to the number of cells studied.  
 
2.3.4.6 Baseline adjustment 
In some cases multiple agonist applications led to unstable peak current responses, with 
some currents consecutively increasing and others decreasing. These cells had the 
baseline gradient adjusted to enable the effects of the compounds to be more accurately 
analysed. To calculate the gradient the following equation was used: 
 
Gradient = [(First response (pA) - Last response (pA)) / (Last agonist application number 
– First agonist application number)] 
 
The original recorded peak current amplitudes were then converted to new, adjusted peak 
current amplitudes by the following equation: 
 
Adjusted peak current amplitude = Original peak current amplitude + (Gradient * Agonist 
application number) 
 
2.4 Hippocampal Slice Recordings 
 
2.4.1 Tissue preparation 
Male Lister-Hooded rats (150-250 g) were anaesthetised with halothane and subsequently 
cervically dislocated and decapitated in accordance with UK Home Office guidelines. 
The brain was removed and placed in ice cold (~4ºC) artificial cerebrospinal fluid 
(aCSF). The whole brain was placed on filter paper to remove excess fluid and then fixed 
to a polypropylene slate using cyanoacetate. An agar block was placed at the caudal end 
of the brain and stuck down using cyanoacetate. The polypropylene slate was then placed 
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in a chamber containing ice cold aCSF. The brain was then sectioned to produce 400 μm 
thick horizontal sections using a Leica VT1000S automatic slicer (Leica Microsystems, 
Milton Keynes, UK). The slices were transferred to a petri dish containing room 
temperature (~21ºC) aCSF continuously bubbled with 95% O2, 5% CO2. The 
hippocampus was cut away from the rest of the slice and transfered to a recording 
chamber where they were placed on a nylon mesh at the interface of a warmed (32¯34°C), 
perfusing (1¯2 ml min-1) artificial cerebrospinal fluid (aCSF) and an oxygen-enriched 
(95% O2, 5% CO2), humidified atmosphere. The slices were allowed to equilibrate for at 
least 1 hour prior to the start of the experiment. The standard perfusion medium (aCSF) 
comprised (mM): NaCl, 124; KCl, 3; NaHCO3, 26; NaH2PO4, 1.25; CaCl2, 2; MgSO4, 1; 
D-glucose, 10; and was bubbled with 95% O2, 5% CO2. The aCSF was made up from a 
10X stock solution. 
 
2.4.2 Set-up for Extracellular recordings 
The interface recording chamber was based on a design by Spencer et al, 1976 (Spencer 
et al. 1976), and consists of an outer water bath fitted with a lid, and an inner recording 
chamber. The distilled water in the outer chamber is heated to 32 ± 1 ºC by a metal plate 
fitted to the bottom of the chamber, which is connected to a constant power source. The 
water is bubbled with 95% O2, 5% CO2 creating a humidified atmosphere over the 
recording chamber. The aCSF was pumped (1-3 ml/min), via a peristaltic pump, to a 
gravity feed which then flowed into the main recording chamber, under a nylon mesh, 
and was then removed by suction through a syringe needle. The level of the flow was 
adjusted to bathe the bottom of the slice, but not submerge it. The slices were illuminated 
in the recording chamber by a fibre optic system connected to a light source. Electrodes 
were mounted on micromanipulators and the slice was visualised using a dissecting 
microscope (World Precision Instruments, UK) mounted above the recording chamber. 
The setup was mounted on a stainless steel anti-vibration table (Scientifica, UK) and 
enclosed in a Faraday cage (Scientifica, UK) which was grounded through the amplifier 
(Axoclamp-2B, Axon Instruments, CA, USA) in order to isolate the system from ambient 
noise. 
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2.4.3 Electrodes.  
Glass microelectrodes (1-5 MΩ) were filled with standard aCSF before being connected 
to the headstage. The recording electrodes used for extracellular recording are detailed in 
section 2.3.3. 
 
2.4.4 Extracellular Recording 
Following a 1 h equilibration period, the perfusing solution was changed to induce 
epileptiform activity. Extracellular field potential recordings were obtained from the CA3 
region of stratum pyramidale and measured as the potential difference between the 
recording microelectrode and the bath reference electrode.  Epileptiform activity was 
induced by modification of the perfusing solution by (a) the combined addition of the 
GABAA and GABAB receptor antagonists gabazine (10 μM) and CGP55845 (10 μM), or 
(b) removal of extracellular magnesium. Once a stable baseline period of bursting was 
established, the compound of interest (compound A or Lamotrigine) was added to the 
bathing medium.  
 
2.4.5 Amplification and Filtering 
The recordings that were made using the ME1 channel on the AxoClamp-2B were 
amplifier 10 times by an internal gain. Signals were further amplifier and filtered using a 
Brownlee precision Instruments amplifier giving a further 100 times amplification (total 
gain = 1000) and a band width of 0.1 Hz to 5 KHz. The signal was passed through a 
Humbug (Digitimer, UK) noise subtraction device which removed signals occurring at 
50Hz, conventionally known as ambient noise. The resultant signal was digitised using a 
Digidata 1322A interface (Axon Instruments). 
  
2.4.6 Data storage 
All data were captured using pClamp8 software (Axon Instruments Ltd) and digitized 
records were stored on the hard disk of a PC for off-line analysis using Clampfit 
software. 
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2.4.7 Data Analysis 
The epileptiform bursting induced via manipulations of the aCSF was analysed by 
measuring the frequency of bursting and burst duration. Once the epileptiform activity 
was stable, a baseline period of activity was measured before the application of drugs of 
interest. The final 4 minutes of each application; Control, drug addition 1, drug addition 
2, etc. were used to measure the frequency of bursting. To evaluate the effects on the 
duration of individual bursts, the last 6 bursts were analysed prior to the change in the 
solution and measurements of the duration of the burst were taken from the start of the 
event to the end of the afterhyperpolarisation (Figure 2.2). 
 
The analysed data was then transferred into Microsoft Excel and Microcal Origin 
software packages for further analysis and generation of graphs. Data are presented as 
means ± standard error of the mean (SEM) and statistical significance was assessed using 
paired or unpaired Student's t-tests performed on raw data with P<0.05 being taken as 
indicating statistical significance. n values refer to the number of times a particular 
experiment was performed, each in a different slice prepared from a different rat.  Where 
concentration-response relationships have been determined, the data were fitted as 
detailed above (2.3.4.3 Agonist Concentration-response Curves) 
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Figure 2.2: Example recording showing parameters used for analysis 
 
2.5. Drugs  
All drugs were stored frozen (at -20°C) in aliquots and were dissolved in deionised water, 
or dimethyl sulphoxide (DMSO). Drugs were added to the extracellular 
solution/perfusing medium up to desired concentration. For hippocampal slice 
preparations, drugs were perfused for at least 30 minutes to allow sufficient time for full 
equilibration with the slices. The final DMSO concentration was never greater than 0.3%.  
 
Adenosine Triphosphate (ATP), 2',3-O-(4-benzoyl)benzoyl-ATP (BzATP), α,β-
methylene ATP (αβmeATP), TNP-ATP, PPADS and Coomassie brilliant blue G, were 
obtained from Sigma.  
 
CGP55845A and Bicuculline methiodide (referred to as Bicuculline) were obtained from 
Tocris-Cookson Ltd (Bristol, UK). Bicuculline was dissolved in distilled water to 10mM 
and CGP55845 was dissolved in 100% DMSO to form a stock solution before being 
diluted into the perfusing medium.  
500 ms 
Frequency 
Duration 
0.2 mV 
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GSK314181A, Compound A, Compound X, Lamotrigine (Lamictal) and Sipatrigine were 
synthesised in the medicinal chemistry laboratories in Harlow, Essex, and was made up to 
10 mM in 100% dimethyl sulphoxide (DMSO) or distilled water. 
 
 
2.6 Immunocytochemistry  
 
2.6.1 Preparation of Cells 
HEK293 or CHO cells stably expressing P2X7, P2X4 or P2X2/3 receptors were cultured 
and plated onto glass coverslips as described above (section.2.1.2). DRGs were removed, 
cultured and plated onto glass coverslips as described above.  
Glass coverslips were placed into individual 5 mm petri dishes. Each coverslip was 
washed twice with 2mls of phosphate buffered saline (PBS) for 5 minutes before being 
fixed with paraformaldehyde (4% in PBS) for 20 minutes on ice. Following this 
coverslips were rinsed in PBS and permeabilised with 0.05% Tween 20, added for 10 
minutes at room temperature. Then coverslips were washed 3 times with 2 mls of 
blocking solution containing 10% donkey serum, and left overnight. 
 
2.6.2 Immunocytochemistry 
Coverslips were washed twice in PBS standard blocking solution containing normal 
donkey serum (NDS, 2%). This solution was then removed and the appropriate primary 
antibody raised against specific tissue antigens (human P2X7, β3-tubulin, S100β or 
glutamine synthetase) diluted as appropriate in blocking solution was applied to the 
coverslip, flooding the petri dish and covering all the cells. Petri dishes were then placed 
in a humid box (sealed, damp filter paper lined tray) and left in an incubator at 37oC for 
30 mins. Following the primary phase, coverslips were rinsed in PBS 3 times, for 5 
minutes per rinse. The labelled secondary antibody against the relevant immunoglobulin 
of the animal species in which the primary antibody was raised in, was diluted as 
appropriate with PBS and applied to the cells. The coverslips were then placed in the 
incubator at 37oC for 30 minutes. Following the secondary phase, slides were washed in 
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PBS 3 times, 5 minutes per wash. In some cases the solution used for the middle wash 
step also contained To-Pro-3 (1:1000 of 1 mM), or Sytox Green (1:5000-10,000) to label 
the cell nuclei, and was applied for 10 mins. Glass coverslips were inverted into 
mounting medium (ProLong Gold antifade reagent, Invitrogen), on microscope slides 
(Super Frost Slides; Agar Scientific) and left to dry in the dark. Incubations using primary 
anti-sera in the absence of secondary anti-sera and vice versa were also performed, as 
negative controls.  
 
2.6.2.1 P2X7 selectivity immunocytochemistry  
The human P2X7 monoclonal mouse antibody (GSK antibody) was diluted 1:1000, 1:500 
and 1:250 in PBS (2% NDS) solution. The secondary antibody used was Donkey anti-
mouse Alexa 488 (Molecular probes, UK) diluted at 1:200 with PBS. 
 
2.6.2.2 P2X7 DRG immunocytochemistry 
The human P2X7 monoclonal mouse antibody (GSK antibody) was diluted 1:1000, 
1:500, 1:250 in blocking solution. The secondary antibody used was Donkey anti-mouse 
Alexa 488 (Molecular probes, UK) diluted at 1:200 with PBS. 
 
The anti-β3-tubulin antibody was used at dilutions of 0.5 µg/ml, 1 µg/ml and 3 µg/ml. 
The anti-S100β antibody was used at dilutions 1:100, 1:200, and 1:400, and the anti-
glutamine synthetase antibody was used at dilution 1:2000. The secondary antibody used 
was Donkey anti-rabbit Alexa 647 (Molecular probes, UK) diluted at 1:200 with PBS.  
 
2.6.3 Microscope analysis 
All slides were observed under a Leica Confocal microscope using filters appropriate for 
Alexa Fluor 488 illumination (excitation 450-490 nm; emission 515-565 nm) and Alexa 
Fluor 647 illumination (excitation 650 nm; emission 665 nm). Digital images were 
generated using Leica Confocal Software (Leica Microsystems, GmbH, Heidleberg).  
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2.6.4 Reagents 
Rabbit polyclonal antibody to β3-tubulin, rabbit monoclonal antibody to S100 beta and 
rabbit polyclonal antibody to Glutamine Synthetase were purchased from Abcam, MA, 
USA. 
To-Pro3 Iodide, Sytox Green, Alexa Fluor Donkey anti-mouse 488, Alexa Fluor 647 
Donkey anti-rabbit, Prolong Gold antifade reagent were all purchased from Invitrogen, 
Paisley, UK.  
Normal Donkey Serum 10mls freeze dried powder was purchased from Stratech 
Scientific Limited, Suffolk, UK
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Chapter 3: Biophysics and Pharmacology of the rat P2X7 receptor stably expressed 
in HEK293 cells 
 
3.1. Introduction 
 
The P2X7 receptor was initially cloned from a cDNA library from rat brain in 1996 
(Surprenant et al. 1996), followed by isolation of human P2X7 cDNA from monocytes 
(Rassendren et al. 1997) and finally the mouse receptor was cloned from microglia 
(Chessell et al. 1998b). Stable cell lines expressing rat, human or mouse P2X7 receptors 
were then produced following initial transient transfections (Surprenant et al. 1996; 
Chessell et al. 1998a; Chessell et al. 1998b), allowing the investigation of the biophysical 
properties and pharmacology of these receptors in isolation. 
 
There has been much work reported previously on the biophysical properties of rat P2X7 
receptors (rP2X7) when they are stably expressed in a recombinant system (Surprenant et 
al. 1996; Virginio et al. 1997; Bianchi et al. 1999; Hibell et al. 2000; Hibell et al. 2001a). 
However there is not a consensus as to the kinetics of P2X7 receptor activation. 
Activation of P2X7 receptors have been described as biphasic with fast and slowly 
activating components (Klapperstuck et al. 2001), partially inactivating (Virginio et al. 
1997), or as being kinetically even more complex (Chessell et al. 2001). Similarly, 
current deactivation was observed to follow a mono-exponential time course 
(Klapperstuck et al. 2000a), or to occur with a delay of up to several minutes (Surprenant 
et al. 1996; Chessell et al. 2001). Repeated long term agonist stimulations of rP2X7 
receptors have been found to elicit either successively increasing currents (Surprenant et 
al. 1996) or decreasing currents (Hibell et al. 2000). These contrary results may be due to 
differences in host cell type (native cells such as lymphocytes compared to recombinantly 
expressed receptors), but could also be interpreted to result from activation-dependent 
changes to the P2X7 receptor conformation, or activation of other channels downstream 
of the P2X7 receptor. The experimental conditions employed can play a role in these 
differences. For example, agonists concentrations, divalent cation concentration, agonist 
addition and inter-agonist addition times and the consequences of receptor activation can 
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all causes difficulties when comparing data from different sources. Therefore the aim of 
the experiments detailed here was to characterise rat P2X7 receptors stably expressed in 
HEK293 cells, focusing on the changes that occur following multiple agonist additions. 
This was with a view to determining a stable set of experimental conditions that can be 
employed to allow accurate pharmacology assessments to be performed (see Chapter 4) 
and enable comparison studies with native receptors (see Chapter 5). 
 
3.2 Methods Summary 
Methods are described in Chapter 2 (Materials and Methods).  
 
3.3 Results  
 
3.3.1 Characterisation of rat P2X7 receptors stably expressed in HEK293 cells 
 
3.3.1.1 Agonist evoked currents  
Whole cell patch clamp recordings were made from single cells stably expressing rat 
P2X7 receptors. All cells studied responded to BzATP, were as an application of BzATP 
(30 μM) to untransfected HEK293 cells produced no currents (Fig3.1A). Activation of rat 
P2X7 receptors by a 2s application of BzATP (30 μM) produced a rapidly activating 
inward current, with a rise time (10-90%) of 207 ± 13 ms (n=17). The current showed 
little desensitisation throughout the 2s application and deactivated on removal of the 
agonist (Fig 3.1B and 3.1C). To confirm that the channel was acting as a non-selective 
cation channel, cells were voltage clamped at -60mV before a voltage ramp from -80mV 
to +40 mV was injected. A small current, termed non-specific leak current, was produced 
in control solution (standard extracellular solution), and a linear increase in the current 
amplitude was produced by the application of BzATP (Figure 3.1D). Mean data showed 
BzATP activated currents that were almost linear and reversed at 0.2 ± 0.4 mV (n=4), as 
expected for a non-selective cation channel (Figure 3.1E).  
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Figure 3.1: Effect of BzATP on recombinant P2X7 receptors 
A. Representative trace recorded from ‘wild-type’ HEK293 cells. No currents are activated 
following a 15s addition of BzATP (30 µM). 
B. Representative trace recorded from HEK293 cells stably expressing rat P2X7 receptors in 
response to an application of 30 µM BzATP. Rise time (10-90%) is 207 ± 13 ms (n=17). 
Deactivation time (95-50%) is 117 ± 7 ms (n=14). 
C. Overlayed representation of currents in response to multiple applications of BzATP (30 µM), 
note current growth and slowing of deactivation. 
D. Voltage ramps (-80 mV to +60 mV, 500 ms) applied in the presence of BzATP (30 µM) 
resulted in linear currents that reversed at 0.2±0.4 mV (n=4). 
E. Pooled, leak-subtracted data from voltage ramps applied in the presence of 30 μM BzATP. 
Current responses recorded at each holding potential were normalised to the current recorded at 
−60 mV. BzATP-activated whole cell currents have a reversal potential close to 0 mV (0.2 ± 0.4 
mV (n=4). 
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To study the concentration-response relationship of agonist activation of rat P2X7 
receptors, each cell was normalised to a test concentration of agonist; 300 μM BzATP or 
3 mM ATP; and only exposed to one additional concentration of agonist, in order to 
minimise the activation-dependent changes in the receptor (discussed later). 
Concentration response curves were generated for BzATP (Figure 3.2A) and ATP 
(Figure 3.2B) and resulted in EC50 values of 33 ± 4 µM (Hill slope = 1.7 ± 0.4, n = 3-5) 
and EC50 values of 670 ± 50 µM (Hill slope = 2.2 ± 0.3, n= 4-7), respectively, 
demonstrating the greater potency of BzATP, than the natural ligand ATP, at rat P2X7 
receptors. 
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Figure 3.2: Concentration-response curves for ATP and BzATP on recombinant rat P2X7 
receptors 
A. The graph illustrates the mean concentration response curve to BzATP for rat P2X7 currents. 
Each cell was normalised to 300 µM BzATP application and was exposed to one other 
concentration of BzATP after a 2 minute interval. EC50 = 33±4µM (n = 3-5), Hill slope = 1.7±0.4. 
B. The graph illustrates the mean concentration response curve to ATP for rat P2X7 currents. 
Each cell was normalised to 3 mM ATP application and was exposed to one other concentration 
of ATP after a 2 minute interval. EC50 = 670 ± 50 µM (n= 4-7) Hill slope = 2.2 ± 0.3. 
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3.3.1.2 Concentration- and time-dependence of current amplitude increase 
The increase in the peak current following each application of agonist is an interesting 
phenomenon associated with P2X7 receptors. In Figure 3.1C a single cell has been 
exposed to BzATP (30 μM) for 2 seconds every 2 minutes and the traces have been 
overlayed to illustrate the increasing current amplitude produced for the same 
concentration of agonist. To further quantify this effect, multiple applications of BzATP 
were applied to 12 separate cells and the resulting peak current amplitude values were 
plotted (Figure 3.3A). The first application of BzATP activated currents that had peak 
current amplitudes ranging from 803pA to 2110pA (giving a mean of 1247 ± 116 pA 
(n=12), and the final current amplitudes (7th application) produced a wide range of values 
from 2032pA to 7633pA (Figure 3.3A). Peak current amplitudes were normalised to the 
first response and the mean data plotted against time in Figure 3.3B, illustrating a gradual 
increase in the current amplitude that peaked at 335 ± 49% of control (ranging from -
2122pA to -7627pA) at the 6th application. There is no further significant increase in the 
mean current following the 6th application of BzATP, a trend that is also visible from the 
individual current amplitude plot (Figure 3.3A). Due to the large variability in the final 
current amplitudes, the correlation between initial current density (current 
amplitude/whole cell capacitance) and the percentage increase observed after 6 BzATP 
applications was investigated. No correlation was found (Linear regression line, R=0.11), 
indicating the lack of relevance of the current density to the changes in current amplitude. 
 
To establish if the current amplitude increase was agonist concentration dependent, 
further experiments were performed across a range of BzATP concentrations (3-1000 
µM). Cells were exposed to 6 applications of a concentration of agonist, and the 
percentage change in the peak current amplitude from the first response was plotted 
(Figure 3.3D). 6 applications of agonist were chosen because the current amplitude in 
response to 30 µM BzATP peaked at this application number. The increase in current 
amplitude diminished as the concentration of BzATP increased, with no significant 
increase produced by multiple applications of 1 mM BzATP (127 ± 23%, n=5). However 
the largest increases in current amplitude was produced by 10 µM BzATP (336 ± 110%, 
n=5, p=0.003), rather than the lowest concentration tested, 3 µM BzATP. The current 
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amplitude change in response to 3 µM BzATP was variable across the cells recorded, 
ranging from 64% to 177% of control, and resulted in a mean non-significant increase in 
current amplitude of 129 ± 13%, (n= 9), Figure 3.3D.  
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Figure 3.3: Concentration- and time-dependence of current amplitude increase 
A. Graph illustrating the increase in the peak current response to 30 µM BzATP recorded 
following multiple applications of BzATP every 2 min to 12 different cells expressing rat P2X7.  
B. Graph showing the normalised mean data for the peak current recorded in response to multiple 
applications of BzATP (30 µM) over 14 minute period, n=9-12. Note the plateau of the response 
after the sixth application. 
C. Graph showing the lack of correlation between the current density of the initial response to 
BzATP (30 µM) and the increase in the current amplitude after 6 applications, R=0.11. 
D. Graph illustrating the percentage change in the current amplitude after 6 applications, 2 min 
apart, of different concentrations of BzATP on rat P2X7 receptors. The peak current on the 6th 
application is expressed as a percentage of the initial application. (n=3-7; * = p<0.05).   
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3.3.1.3 Changes in the potency of BzATP at rat P2X7 receptors 
 
Divalent Cations 
The effect of the divalent cations, Ca2+ and Mg2+ ions on BzATP-activated currents 
through rat P2X7 receptors was investigated using the ‘antagonist’ protocol detailed in 
the methods. As Ca2+ and Mg2+ ions are present in the standard extracellular solution, the 
concentrations were reduced or increased in the same concentration of agonist, once a 
stable response to BzATP was obtained (Figure 3.4A). The BzATP activated current 
increased to a plateau of 2.9 nA (data shown once plateau was recorded), and the removal 
of Mg2+ ions from the agonist solution resulted in a further increase in peak current 
amplitude to 3.6nA, 116 ± 3% (n=3) increase, which reversed back to pre-zero Mg2+ level 
(100 ± 3% of control) on the reintroduction of Mg2+ ions into the agonist solution (Figure 
3.4A). Therefore the BzATP-activated current can be potentiated with the removal of 
Mg2+ ions after it has reached an assumed maximum. The concentration-response 
relationship for Ca2+ and Mg2+ ion modulation/inhibition of BzATP evoked current was 
then established. The peak current amplitude of the response was normalised to currents 
in the presence of control Ca2+ or Mg2+ ion concentrations, and concentration response 
curves for Ca2+ and Mg2+ ions (0mM to 5 mM) were plotted and yielded IC50 values of 1 
± 0.1 mM (n= 3-4, Hill slope n = 1.9 ± 0.3) for Mg2+ ions, and 2 ± 0.1 mM (n= 4-5, Hill 
slope n = 2.7 ± 0.4) for Ca2+ ions (Figure 3.4B).  
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Figure 3.4: Change in BzATP potency – divalent cations 
A. Representative trace showing multiple applications of 30 µM BzATP to rat P2X7 cell. Clear 
bars are agonist with normal (0.5 mM MgCl2 and 1 mM CaCl2) solutions and dark bars are 30 
µM BzATP with 1 mM CaCl2, but no added MgCl2. 
B. Concentration response curve for Ca2+ and Mg2+ ions at rP2X7 activated by 30 µM BzATP. 
Responses are expressed as a percentage of the control current which is the normal extracellular 
solution containing 0.5 mM MgCl2 and 1 mM CaCl2. IC50 = 1 ± 0.1 mM for Mg2+ ions, n= 3-4, 
Hill slope n = 1.9 ± 0.3, and IC50 = 2 ± 0.1 mM for Ca2+ ions, n= 4-5, Hill slope n = 2.7 ± 0.4. 
C. Representative trace showing current in response to a 30 µM (clear bars) or 1 mM (black bar) 
BzATP application to rat P2X7 cell. 
D. Graph illustrating the peak current recorded in response to 30 µM BzATP. Once a maximal 
current was recorded the cell was exposed to 1 mM BzATP resulting in 161 ± 16% (n=4) increase 
in the current amplitude that returned to pre-1mM levels on return to 30 µM BzATP.   
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Agonist potency 
The increase in the current amplitude produced by multiple applications of the same 
concentration of agonist may represent an increase in the potency of the agonist at the 
receptor (Hibell et al. 2000; Michel et al. 2000). Therefore, with each application of 
agonist and subsequent activation of P2X7 receptors, the current growth may reflect an 
increase in receptor occupancy leading to an increase in open channel probability. In 
order to investigate whether the changes in current amplitude in the absence of divalent 
cations represents a change in the potency of the agonist at the P2X7 receptor the effect 
of a high concentration of BzATP was assessed once the response to 30 µM BzATP had 
increased to a plateau. On average current amplitudes elicited by BzATP application 
reached a plateau after 6 applications (Figure 3.3B), but was variable across cells. The 
application of 1 mM BzATP following this resulted in a larger current amplitude (Figure 
3.4C), 161 ± 16% (n=4) of the control response, and reversed to pre-addition levels on 
return to 30 µM BzATP (Figure 3.4D).  
 
 
3.3.1.4 Deactivation kinetics  
Unlike many channels, the rate of deactivation of BzATP-activated current, defined as 
the time taken for current to return to baseline following removal of the agonist, varies 
dramatically over time. To add further complication, it is also a species dependent effect, 
with successive BzATP applications causing the deactivation rate to slow at the rat P2X7 
receptor (Surprenant et al. 1996), to a lesser extent with the human receptor (Rassendren 
et al. 1997) and no obvious changes are seen for the mouse orthologues (Chessell et al. 
1997).  
The effect of multiple applications of BzATP to the deactivation of rat P2X7 receptors is 
shown in Figure 3.5A, where responses have been normalized to the pre-deactivation 
point and overlayed to illustrate the slowing of the deactivation and the changing kinetics 
after the first response. The rate of deactivation slows with each subsequent application 
of agonist to a point where the closure of the channel is so slow it results in cell lysis 
(possibly due to excessive calcium ion influx).  
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Figure 3.5: Slowing of deactivation of BzATP-activated rP2X7 currents 
A. Representative recording from HEK293 cells stably expressing rP2X7 receptors in response to 
a series of applications of BzATP. Currents are normalized to the pre-deactivation point and 
overlayed to illustrate the slowing of the deactivation and the changing kinetics after the first 
response  
B. Graph illustrating the 95-50% decay time for individual cells in response to 2s applications of 
BzATP 30 µM every 2 minutes (n=14). 
C. Graph showing the mean normalised data for the effects of BzATP applications on the 95-50% 
decay time (n=5-13). Data are normalised to the 95-50% decay time of the first application. 
D. Graph showing the mean data for the 95-50% decay time (n=7-14) in comparison to the mean 
peak current amplitude. Note the continuing increase in deactivation rate as the peak current 
plateaus.  
 
 
Chapter 3 
 85
To quantify P2X7 receptor deactivation, the time for the current to return to 50% of its 
maximum was determined (95-50%) and was 117 ± 7 ms (n=14) following the 
application BzATP to previously unstimulated (naïve) P2X7 receptors. The rate of 
slowing of deactivation is dependent upon the individual cell and varies greatly, with the 
deactivation time ranging from 222ms to 2060ms after 8 BzATP applications (Figure 
3.5B). The mean data for the deactivation time is shown in Figure 3.5C, and although 
there is variability in the absolute values, the trend for a continual increase in the time for 
deactivation is consistent across all cells (also see Figure 3.5B). As the deactivation rate 
slows (to the point of constant activation – data not shown), the peak current will 
continue to increase until a maximum level is reached for that cell. The slowing of the 
increase in the peak current can be seen in Figure 3.5D where the 95-50% decay times are 
plotted against this value. 
 
The slowing of deactivation time is also voltage-dependent, where the P2X7 channel 
deactivates more slowly at +60 mV compared to the deactivation rates at -60 mV.  
Cells were voltage clamped at -60mV for the first 3 and last applications of BzATP and 
for the 4th application the voltage command was changed to +60mV. Traces were then 
normalised and inverted, in the case of the -60mV traces (Figure 3.6A). The deactivation 
times (95-505%) were measured in all cases and plotted for each application number, 
against the same data recorded for cells voltage clamped at -60mV only (Figure 3.6). The 
BzATP-activated current at +60mV had a deactivation time of 2462 ± 1020 ms (n=6), 
significantly longer than the corresponding application at -60mV of 465 ± 85 ms (n=22; 
p=0.001).  
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Figure 3.6: Slowing of deactivation of BzATP-activated rP2X7 currents 
A. Deactivation is voltage dependent. Representative recording of consecutive response to 
BzATP (30 µM), normalised to the peak current within each responses. The cell was voltage 
clamped at -60mV for sweep 1-3 and sweep 5, and at +60 mV for sweep 4. Note the slowing of 
deactivation at +60 mV compared to the decay at -60 mV. 
B. Graph illustrating the mean deactivation time of P2X7 receptors following BzATP (30 µM) 
activation. Cells were voltage clamped at -60mV (Black bars) for 5 successive BzATP 
applications, or voltage clamped to +60mV for the 4th application (white and shaded bars). 
Deactivation time (95-50%) was significantly slowed when cells were voltage-clamped at +60mV 
(465 ± 85 ms (n=22) compared to 2462 ± 1020 ms (n=6), p= 0.001) 530% of -60mV. 
 
 
The deactivation of P2X7 was also investigated by fitting the rate of decay with an 
exponential function using Origin software. The deactivation following agonist activation 
of previously unstimulated cells is biexponential, and the tau (τ) values that are produced 
from curve fitting can be separated into a slow and fast τ values based on their kinetics. 
The mean slow τ value is 2206 ± 278 ms, and the faster τ is 188 ± 10ms. As the BzATP 
application number increases, the relative influence of the two components alters (see 
Figure 3.7A). The rate of these two components also changes; the fast component slows 
(118ms to 567ms) and the slow component has a trend towards slowing, possibly 
indicating multiple closed states of the P2X7 receptor that unbind ATP as different rates. 
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Figure 3.7: Deactivation of rat P2X7 current is biexponential 
A. Graph showing the mean normalised time constant for the decay of the current after the 
application of BzATP (30 µM; n=3-14). Decay is biexponential and data are normalised to the 
decay time constants of the first application. The fast Tau value exhibits a slowing with each 
subsequent application of agonist. 
B. Graph showing the changing role of the 2 components of the decay with multiple applications 
of BzATP.  
 
 
 
Although it has been shown that the deactivation time of the P2X7 receptor slows with 
each subsequent application of the agonist BzATP, it is not clear whether the change in 
the deactivation time is dependent upon repeated agonist activation or simply dependent 
upon time. To address this, the standard experimental protocol for recording P2X7 
currents has been used; exposing the cell to agonist for 2s every 2 minutes. However, 
between the first response at time zero and the 5th response, 8 minutes later, the cell was 
not exposed to BzATP. Previously, the 95-50% decay time of the first response to 
BzATP (30 µM) is 117 ± 7 ms (n=14). The 95-50% decay time of the fifth response, after 
8 minutes is 336 ± 36 ms (n=14), which is 287 % longer and significantly (p<0.0001) 
different from the first exposure (Figure 3.8A and 3.8Ai). When the second BzATP (30 
µM) application was 8 minutes after the first application, the current decayed with a 95-
50% time of 155 ± 28 ms (n=4). This was 128% longer than the first exposure (121 ± 17 
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ms (n=4), (p=0.8 from 117 ± 7 ms control data), but significantly slower than the 95-50% 
decay time of the first application (p=0.08). However it was significantly different from 
the previous value at this time point of 336 ± 36 ms (n=14) (p=0.002) (Figure 3.8B and 
3.8Bi). Therefore the slowing of deactivation with agonist addition is application 
dependent and not time dependent. It is a progressive change with each application of 
agonist and does not continue significantly in time interval between agonist additions. 
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Figure 3.8: Slowing of rat P2X7 receptor deactivation requires repeated receptor activation  
A. Representative recording of responses to a 2s application of BzATP (30 µM), normalised to 
the current prior to agonist removal within each responses. BzATP 1 is agonist addition at time 
zero and each further agonist addition is at an interval of 2 minutes.  
B. Representative recording of responses to a 2s application of BzATP (30 µM), normalised to 
the current prior to agonist removal within each responses. BzATP 1 is agonist addition at time 
zero and BzATP 2 is the response to agonist after an interval of 8 minutes. The cell was not 
exposed to agonist between these 2 responses. 
Note the change in deactivation rate seen in (A) after 8 minutes and the lack of change in the rate 
in (B). 
Ai and Bi. Schematic representation of agonist application protocol for each experiment. 
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3.4 Discussion 
 
The rat P2X7 receptor stably expressed in HEK293 cells that has been characterised here 
exhibits a number of characteristics expected for rat P2X7, with rapid activation (10-90% 
rise time 207 ± 13 ms (n=17)), little or no desensitisation during the agonist application 
and a slow deactivation on removal of the agonist. The changes in the functioning of 
P2X7 receptors following multiple agonist applications were investigated. Increases in 
the current amplitude were shown to be dependent upon the agonist concentration. 
Current deactivation was shown to be dependent upon the agonist application number and 
on the voltage, and the slowing of deactivation was shown to require repeated receptor 
activation, rather than be dependent upon the time post agonist addition. 
 
3.4.1 Agonist evoked rat P2X7 receptor currents  
The EC50 values (EC50 = 33 ± 4 µM BzATP; and EC50 = 670 ± 50 µM ATP) produced 
from the concentration-response curve fitting show BzATP to be a much more potent 
agonist at rP2X7 receptors than ATP. The actual values are very similar, although slightly 
higher, than those reported previously (6.5-58 µM; Surprenant et al. 1996; Hibell et al. 
2000; Jiang et al. 2005 for BzATP and 115 -407 µM for ATP). This is likely to be due to 
differences in the agonist application protocol used to construct the curves as changes to 
the current amplitude is dependent upon the application time and intervals between 
agonist additions (discussed later). The Hill slope of the concentration-response curve for 
BzATP and ATP activated rP2X7 currents were 1.7 and 2.2 respectively. These values 
are similar to those reported by Hibell and colleagues (Hill slope = 2.2 and 2.3 for 
BzATP and ATP respectively; Hibell et al. 2000) and fit with the proposed trimeric 
assembly of P2X receptors (Nicke et al. 1998), where one would expect a Hill slope of 
around 2-3 when measured from an agonist concentration-response curve.  
 
3.4.2 Changes in the potency of BzATP at rat P2X7 receptors 
The increase in the current amplitude produced by multiple applications of the same 
concentration of agonist is an interesting property of rat P2X7 receptors stably expressed 
in HEK293 cells (Figure 3.3). The extent of the increase in the current amplitude was cell 
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dependent. From the lack of correlation between the current density (in response to the 
first agonist application) and the percentage change over 6 agonist applications, we can 
conclude that it is not influenced by the number of P2X7 channels present in the cell 
(Figure 3.3C). The increase in current amplitude over multiple agonist applications was 
found to be concentration dependent, inline with previously reported data for this cell line 
(Hibell et al. 2000), where more applications were needed in order to elicit significant 
changes in the peak current amplitude at lower agonist concentrations. For example, 
significant changes were recorded at the 5th application with 3 µM BzATP, but not until 
the 14th application of 1 µM BzATP (Hibell et al. 2000). In the experiments reported 
here, the lack of change with the 3 µM concentration may be due to limiting the 
recording to 6 applications. Differences between these two studies may be due to the 
extracellular solution composition which differs from the ones used here in the absence of 
Mg2+ ion and a reduction in the Ca2+ ions to 0.5 mM. A plateau in the current increase 
seen at 30 µM BzATP was replicated at 10 µM BzATP and also for 1 mM ATP in other 
studies (Hibell et al. 2000).  
 
Current growth is an increase in the net movement of ions across the membrane, either 
via an increase in the open channel probability or through an increase in the available 
permeation pathway, and can occur through a number of mechanisms. Initially it was 
thought to be associated with dilation of the P2X7 channel (Chessell et al. 1997; Chessell 
et al. 1998b). However, it is unlikely to be via the YOPRO permeation pathway, as the 
addition of supramaximal concentrations of agonist to rP2X7 receptors produced no 
current growth, but robust YOPRO uptake (Hibell et al. 2000). Although the NMDG 
permeation pathway is likely to be distinct from the one allowing YOPRO uptake, there 
is evidence that this may only form under non-physiological conditions such as in the 
presence of low extracellular Na+ concentrations (Jiang et al. 2005), and so it is 
improbable that it is occurring under the recording conditions employed here. Secondly, 
there is also evidence for a change in the phosphorylation status of the P2X7 receptor 
following agonist activation. In HEK cells this is through a complex of the P2X7 protein 
with a receptor protein tyrosine phosphatase (RPTPβ) that is activated following the 
binding of ATP with the receptor, and could indicate a direct effect on the channel 
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conformation (Kim et al. 2001a). This is also true for other P2X receptors, with basal 
phosphorylation of P2X1 receptors (Vial et al. 2004b), and phosphorylation of T18 in the 
P2X2 receptor detected with an anti-phosphothreonine antibody (Boue-Grabot et al. 
2000). Dephosphorylation of P2X7 receptors at Tyr343 has been shown following 
exposure to supramaximal concentrations of agonist (Kim et al. 2001a), and so such 
processes could underlie the change in current amplitude. Further work would be needed 
to be done to explore these possibilities further and assess the impact of preventing 
phosphorylation on the current amplitude. 
 
Finally, it was demonstrated that the potency of agonist for the P2X7 receptor increases 
following repeated or prolonged agonist application, in rP2X7-HEK cells (Hibell et al. 
2000), native P2X7 in NTW8 cells (Chessell et al. 1997) and hP2X7-HEK cells (Michel 
et al. 1999). Therefore the current growth may represent a progressive increase in the 
potency of agonists at the receptor. If this is correct, then once maximum current 
amplitude is reached for a given agonist concentration, no further increases in current 
should be able to be produced. Theoretically, this should be neither via the enhancement 
of agonist concentration directly (greater concentration), or indirectly by increasing the 
effective agonist concentration through the removal of Mg2+ or Ca2+ ions. However, in 
both cases the current amplitude could be increased after a proposed maximum (plateau 
of the current) was reached (Figure 3.4). Therefore, although there are changes in the 
potency of the BzATP at P2X7 receptors, this does not represent a complete shift in the 
concentration-response curve such that further increases in current are not possible.  
 
3.4.3 Inhibition of BzATP by divalents 
The inhibition of P2X7 receptor function by Ca2+ and Mg2+ ions was confirmed here and 
produced IC50 values of 2 mM, and 1 mM respectively (Figure 3.4B). Although the 
values for Ca2+ and Mg2+ ions are more potent than those previously reported (Ca2+ 3.2 ± 
0.4mM; Mg2+ 0.5 ± 0.04mM; Virginio et al. 1997), the rank order is the same and 
differences are likely to be due to differences in the protocols used to construct these 
curves, such as a higher divalent ion concentration in the standard extracellular solution 
and up to 6 applications of ions per cell used in the Virginio et al, study. The inhibition of 
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P2X7 function by divalent cations was initially thought to be mediated via a reduction in 
the concentration of ATP (Dahlquist and Diamant 1974), or through a direct blockade of 
permeation (Surprenant et al. 1996). However, the primary mechanism is likely to be via 
modulation of the agonist binding site, resulting in a reduction in the agonist affinity for 
the P2X7 receptor (Virginio et al. 1997), and possibly through a direct effect on the P2X7 
receptor itself (Jiang 2008; Liu et al. 2008b). Two histidine residues, H130 and H210, 
have been implicated in the inhibitory actions of Mg2+ ions, suggesting that this cation 
acts at a defined allosteric site involving these two residues (Acuna-Castillo et al. 2007).  
 
3.4.4 Deactivation kinetics of rP2X7 receptors 
Deactivation is dependent upon the time of agonist removal from cells, as well as agonist 
unbinding and channel closure. In this study, as in others (Surprenant et al. 1996; Hibell 
et al. 2001a), the deactivation of rP2X7 receptors in response to BzATP applications 
slowed following each activation of the receptors (Figure 3.5). The slowing of the 
deactivation time of rP2X7 receptors occurs through an application-dependent 
mechanism rather than a time-dependent mechanism (Figure 3.8), and could arise from 
either changes in agonist dissociation or changes in the channel closing rates. The 
deactivation of P2X7 receptors has been shown to be related to the agonist potency 
(Hibell et al. 2001a), and so suggest it reflects agonist dissociation from the P2X7 
receptor rather being an intrinsic property of the ion channel. As mentioned above, the 
potency of agonists has been shown to increase after repeated agonist applications and 
deactivation, and hence channel closure time, increased after repeated agonist 
applications. The deactivation time following agonist removal from rP2X7 receptors was 
fit with 2 exponential functions, possibly indicating multiple closed states of the P2X7 
receptor. Data from hP2X7 receptors expressed in Xenopus oocytes indicated that these 
receptors possess at least two types of activation sites, which differ in ATP sensitivity and 
can influence activation and deactivation kinetics (Klapperstuck et al. 2001). Changes to 
the relative importance of these two states have been suggested here by the differing 
degree to which they contribute to overall deactivation (Figure 3.7).  
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Deactivation also possesses some voltage-dependence, with much slower closure times 
produced when cells are voltage clamped at +60mV rather than -60mV (Figure 3.6). This 
may be due to the slower agonist unbinding from the receptor at +60mV, or slower 
channel closure times, prolonging net current movement. Mechanistically this may be due 
to an influence of the electric field of the membrane on the unbinding of agonist or 
channel closure. The agonist binding site is situated on the extracellular portion of the 
receptor and although does not reside in the transmembrane sections, a number of 
charged residues have been identified that are important in agonist binding (See 
Introduction, Chapter 1). It is possible that the channel may undergo a conformational 
change following agonist gating that allows the binding site to move within the electric 
field of the membrane. Similar effects have been reported for other ligand-gated channels 
such as the nicotinic acetylcholine receptor (Auerbach et al. 1996) and GABAA receptors 
(Mellor and Randall 1998). Further work could be done to investigate the voltage-
dependence of deactivation over a range of voltages and also assess the effect, if any, of 
different agonist application times. 
 
The influence that agonist addition times and solution constituents can have on rat P2X7 
receptor function highlights some of the dangers when comparing literature data that may 
utilise a number of different protocols or techniques. The investigations into the 
deactivation and current growth have been important for increasing our understanding of 
the receptor, but have also had implications for the design of protocols used to investigate 
antagonist potency and efficacy. The work here has shown the importance of completing 
subsequent studies using a standard set of protocols, and has defined such a set of 
conditions for pharmacological assessment of rat P2X7 receptors in the next chapter and 
in the investigation of native P2X7 receptors in Chapter 5.
Chapter 4 
 94
Chapter 4: P2X7 receptor antagonists 
 
4.1. Introduction 
 
P2X7 receptors have been proposed as a pharmacological target for the therapy of a 
number of disease states, including Alzheimer’s disease (Parvathenani et al. 2003), 
epilepsy (Rappold et al. 2006), multiple sclerosis (Yiangou et al. 2006) and the focus of 
the work here inflammatory and neuropathic pain (Donnelly-Roberts and Jarvis 2007). 
Underlying much of the aetiology of these diseases is inflammation and there is 
considerable evidence for a role of P2X7 receptors in regulating inflammatory processes 
(Ferrari et al. 2006). This is reviewed in the Introduction, Chapter 1. 
  
In order to further evaluate P2X7 receptors as a possible target for novel analgesics, tool 
compounds must be made available. The current tools include a number of ligands first 
identified some years ago, which are limited in their use by pan-P2X pharmacology, or 
species specificity (See Introduction, Chapter 1, section 1.2.2.2). More recently a number 
of new P2X7 antagonists have been described including compounds across a range of 
chemical series, (Donnelly-Roberts and Jarvis 2007; Romagnoli et al. 2008) some of 
which display an improved potency, selectivity and less species dependence (Honore et 
al. 2006; Nelson et al. 2008).  
 
Here a novel P2X7 antagonist, GSK314181A (Alcaraz et al. 2000) from the AstraZeneca 
patent, WO2000061569A1, has been profiled using whole-cell patch-clamp techniques to 
define it’s potency at P2X7 receptors and investigate its possible mechanisms of action 
and selectivity profile at other P2X receptors. 
 
4.2 Methods Summary 
 
4.2.1. Electrophysiological studies 
Experiments were performed using whole-cell patch-clamp electrophysiology to study 
P2X7 and P2X4 receptors stably expressed in HEK293 cells, and P2X2/3 heteromeric 
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receptors stably expressed in CHO cells. Cells were voltage-clamped at -60mV unless 
otherwise stated. For intracellular application of GSK314181A, pipettes were back filled 
using the standard intracellular solution containing GSK314181A. 
 
4.3 Results  
 
4.3.1 P2X7 Antagonists 
PPADS and Brilliant Blue G were used as tool compounds for pharmacological 
characterisation of HEK cells stably expressing rP2X7 receptors. PPADS, a non-selective 
P2X antagonist (30μM), inhibited 30μM BzATP-activated rat P2X7 currents by 97±1 % 
(n=3) and was slowly reversible over a 12 minute period (78% of control; Figure 4.1A). 
BBG is a commonly used antagonist of P2X7 as is one of the more potent tools. Figure 
4.1B illustrates the potency and reversibility of BBG as 10 nM inhibits currents by 41 ± 
6% (n=4) and the current is fully reversed back to baseline within 2 minutes. To enable 
an estimate of the IC50 concentration for inhibition of the BzATP-activation of rat P2X7 
by BBG to be made, additional experiments were conducted in the 1 nM to 100 nM 
concentration range, allowing the production of a concentration-response curve that had 
an IC50 value of 11 ± 1 nM, (Hill slope 1.4, n=3-4; Figure 4.1C) for the inhibitory activity 
of BBG at rP2X7.  
Zn2+ ions are known inhibitors of P2X7 currents and are a useful tool with which to 
distinguish P2X7 mediated currents as they potentiate P2X2 and P2X4 currents (see 
Introduction, section 1.2.2.2). The concentration-response relationship for Zn2+ ion 
inhibition of BzATP evoked currents was established. Zn2+ (10 µM) inhibited BzATP-
activated rat P2X7 currents by 86 ± 2 % (n=5), reaching a peak inhibition after 2 minutes 
preincubation and was fully reversible within 2 minutes (see Figure 4.1D). Additional 
concentrations were tested from 100nM to 100 µM allowing the production of a 
concentration-response curve, which yielded an IC50 value of 1.9 ± 0.2 µM, (Hill slope 
1.2, n=3-6) (Figure 4.1E). 
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Figure 4.1: Pharmacological characterisation of rP2X7 
A. Example recording showing P2X antagonist PPADS (30 µM) inhibiting 30 µM BzATP-
activated rP2X7 current by 97 ± 1%, n=3. The recovery from inhibition is slow, with 17% 
recovery within 4 min and 78% after 12 min.  
B. Example recording showing Brilliant Blue G (BBG, 10nM) inhibiting 30 µM BzATP-activated 
rP2X7 current by 41 ± 6% and the recovery to pre-addition levels in 2 min.  
C. Concentration response curve for BBG at rP2X7 activated by 30 µM BzATP, IC50 = 11 ± 1 
nM, Hill slope n = 1.4 (n=3-4). 
D. Zn2+ (10µM) inhibits 30 µM BzATP-activated rP2X7 currents by 89 ± 2% (n=5). Inhibition in 
the presence of Zn2+ peaked within 2 minutes and was fully reversible. 
E. Concentration response curve for Zn2+ inhibition of rP2X7 currents, produces an IC50 = 1.9 ± 
0.2 µM (Hill slope = 1.2, n=3-6). 
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4.3.2 GSK314181A is a potent antagonist of rat P2X7 receptors 
GSK314181A (Figure 4.2A) has been identified from the Astrazeneca patent 
WO2000061569A1 (Alcaraz et al. 2003; Romagnoli et al. 2005), as an inhibitor of P2X7 
currents (pIC50 > 4.5). GSK314181A (100 nM) inhibited BzATP-activated rat P2X7 
currents by 93 ± 1.3 % (n=4), reaching a peak inhibition after 2 minutes preincubation 
and was fully reversible within 4 minutes (see Figure 4.2B). Additional concentrations 
were tested from 10nM to 1 µM allowing the production of a concentration-response 
curve, which yielded an IC50 value of 1 ± 0.2 nM, (Hill slope 0.7, n=3-7) (Figure 4.2C). 
All concentrations of GSK314181A produced a maximum inhibition of BzATP-activated 
currents within 4 minutes of preincubation (2 agonist additions) and currents were fully 
reversible within 4 minutes of washout of GSK314181A (Figure 4.2B). The inhibition of 
BzATP-activated currents by GSK314181A was not affected by holding cells at a 
positive potential. The inhibition produced by 100nM GSK314181A at +60mV (89 ± 1 % 
inhibition, n=4, Figure 4.2D) was not significantly different to that recorded at a holding 
potential of -60mV (93 ± 1 % inhibition, n=4, p=0.07). 
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Figure 4.2: GSK314181A is a potent inhibitor of rat P2X7 receptors 
A. Molecular Structure of GSK314181A (Romagnoli et al, 2005; WO2000061569A1).  
B. GSK314181A 100 nM inhibits 30 µM BzATP-activated rP2X7 current by 93 ± 1 %, n=4. 
Inhibition with GSK314181A peaked within 4 minutes on average and currents recovered to 
baseline levels within 4 min. 
C. Concentration response curve for GSK314181A inhibition at rP2X7 receptors, IC50= 1 ± 0.2 
nM, Hill slope n= 0.7 (n=3-7). 
D. The inhibition of BzATP-activated currents by GSK314181A was not voltage-dependent. 
GSK314181A 100 nM inhibits 30 µM BzATP-activated rP2X7 current by 95%. Recovery to 
baseline levels is within 4 min. The inhibition produced by 100nM GSK314181A at +60mV (89 
± 1 % inhibition, n=4, Figure 4.2D) was not significantly different to that recorded at a holding 
potential of -60mV (93 ± 1 % inhibition, n=4, p=0.07).  
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In addition, we examined whether GSK314181A was capable of blocking BzATP-
activated rP2X7 current when applied intracellularly (Figure 4.3A). A high concentration 
of GSK31418A (1 µM) was included in the standard whole-cell recording solution. In all 
recordings a robust BzATP-activated current was observed following the first application 
of BzATP (361 ± 102 pA, n=4). Subsequent applications of BzATP resulted in the 
normal increase in the current amplitude and no abnormal changes in the kinetics of the 
responses were observed. In all 4 cells a subsequent extracellular application of 1 µM 
GSK31418A produced its signature inhibition of currents to 5 ± 2 % of control, n=4, 
which was reversible on washout of the drug (Figure 4.3A and 4.3B).  
 
Finally the ability of GSK31418A to inhibit BzATP-activated currents without 
preincubation was tested. rP2X7 receptors were activated by BzATP (30 µM) and after 
currents had peaked the solution was changed to one also containing 1 µM GSK31418A, 
resulting in a full inhibition of the current (94 ± 1 % block) inhibited by co-application of 
GSK31418A (1 µM). This inhibition was fully reversible on removal of the antagonist, 
and was not significantly different from that produced with GSK314181A preincubated 
for 2 minutes (p=0.1; Figure 4.3C).   
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Figure 4.3: GSK314181A inhibits rat P2X7 receptors at +60mV and does not require 
intracellular access to the ion channel. 
A. Example recording showing the first current response to BzATP (30 µM) recorded with 1 µM 
GSK314181A within the recording electrode and then after 8 minutes. The other trace shows the 
inhibition of the response to 30 µM BzATP in the presence of extracellular application of 
GSK314181A (1 µM).  
B. Graph showing the peak current amplitude in response to BzATP applications from the 
recording in (A). The clear bar indicated the presence of GSK314181A (1 µM) in the intracellular 
pipette solution and the black bar shows the addition of this drug extracellularly. A partial 
reversal of the inhibited current can be viewed following removal of GSK314181A. 
C. Example trace showing BzATP-activated current inhibited by co-application of GSK31418A 
(1 µM) by 94 ± 1% (n=5). This inhibition was fully reversible on removal of the antagonist.   
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4.3.3 GSK314181A is an antagonist of human P2X7 receptors 
GSK314181A (10nM) inhibited BzATP-activated human P2X7 currents by 88 ± 2 % 
(n=3), reaching a peak inhibition after 10 minutes preincubation. GSK314181A inhibition 
of human P2X7 receptors took on average 7 ± 2 minutes to reach peak, and there was 
very little reversal of the inhibition recorded up to 20 minutes washout (Figure 4.4A). 
Additional concentrations were tested from 1nM to 1 µM allowing the production of a 
concentration-response curve, which yielded an IC50 value of 5 ± 0.7 nM, (Hill slope 1.5, 
n=3-4) (Figure 4.4B).  
 
Although BzATP is an analogue of ATP, it was thought prudent to confirm that 
GSK314181A could inhibit human P2X7 receptors activated by the endogenous ligand, 
ATP. GSK314181A (100nM) inhibited ATP-activated human P2X7 currents by 89 ± 2 % 
(n=3), reaching a peak inhibition after 8 minutes preincubation. The currents did not 
reverse on washout of the drug (Figure 4.4C). Therefore a range of concentrations of 
GSK314181A were applied to 5 mM ATP-activated currents, allowing the production of 
a concentration-response curve which yielded an IC50 value of 16 ± 3 nM, (Hill slope n= 
0.9, n=3-4).  
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Figure 4.4: GSK314181A is a potent inhibitor of human P2X7 receptors 
A. Example trace showing the effect of GSK314181A (10 nM) on 100 µM BzATP-activated 
currents. hP2X7 currents were inhibited by 83 ± 2 %, n=3. The effect of inhibition of 
GSK314181A peaked after 10 minutes on average. Little recovery of the current was seen. 
B. Concentration response curve for GSK314181A inhibition at human P2X7 receptors, activated 
by BzATP (100µM) IC50= 5 ± 0.7 nM, Hill slope = 1.5. 
C. Example trace showing the effect of GSK314181A (100 nM) on 5 mM ATP-activated 
currents. hP2X7 currents were inhibited by 89 ± 2 %, n=3. The effect of inhibition of 
GSK314181A peaked after 8 minutes on average. Little recovery of the current was seen. 
D. Concentration response curve for GSK314181A inhibition at human P2X7 receptors, activated 
by ATP (5mM) IC50= 16 ± 3 nM, Hill slope = 0.9. 
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4.3.4 GSK314181A reverses FCA-induced hypersensitivity in rats 
This work was completed by Nick Clayton and Lisa Winyard (Lappin et al. 2005). See 
the Appendix A for information on the methods for this study. 
 
One of the most commonly used pain models for assessing the efficacy of tool 
compounds to reduce inflammatory pain is the Freunds Complete Adjuvant model 
(FCA). GSK314181A has been shown to be a potent antagonist at rat P2X7 receptors and 
so is an ideal tool compound with which to try to address the role P2X7 plays in pain 
processing in vivo. Naïve rats distributed their weight equally between the two hindpaws 
(left: 83.8 ± 1.7 g, right: 88.1 ± 1.9 g, n= 35). Following an intraplantar injection of FCA 
(100 µl of 1 mg/ml) into the left hindpaw there was a significant reduction in the weight 
bearing on the ipsilateral hindpaw resulting in an 69.5 ± 5.7g difference in weight bearing 
between the pre-FCA and pre-dose. GSK314181A produced a significant reversal of 
FCA-induced hypersensitivity at 1.5 hours post dose, 30mg/kg s.c (86.3 ± 17.2%) and the 
positive control, Celebrex (COX-2 Inhibitor, Celecoxib, (10mg/kg)) significantly 
reversed FCA-induced hypersensitivity at 1.5 hours, 3 hours and 6 hours post-dose 
(Figure 4.5). The effect of Celebrex peaked at 3 hours post-dose with an almost complete 
reversal of the deficit in weight bearing of 95.6 ± 19.4%. The mean data for the 
difference in weight bearing post FCA injection is shown in Figure 4.5B.  
The blood and brains of the rats that had received the dose of 30 mg/kg GSK314181A 
were taken 3 hours post dose for pharmacokinetic analysis. This yielded mean blood and 
brain concentrations of GSK314181A of 5.5 µM and 2.5µM, respectively, with a brain: 
blood ratio of 0.45:1. 
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Figure 4.5: GSK314181A reverses FCA-induced hypersensitivity 
A. GSK314181A produced a significant reversal of FCA-induced hypersensitivity at 1.5 hours 
post dose, 30mg/kg s.c (p<0.05 *) (86.3 ± 17.2%) Celebrex (10mg/kg) as a positive control 
significantly reversed FCA-induced hypersensitivity (p<0.05 #).   
B. Mean data for the difference in weight bearing (g) post FCA injection.  GSK314181A gave 
equal efficacy to that seen with the COX-2 inhibitor, Celebrex. 
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The reversal of the FCA-induced hypersensitivity by the P2X7 antagonist GSK314181A 
were encouraging and provided some evidence for a pivotal role of P2X7 activation in 
pain processing. However due to the relatively high (total) concentrations of 
GSK314181A found in the bloods and brains of these animals selectivity studies with 
GSK314181A were required to allow more definite conclusions to be drawn from this 
work. 
 
4.3.5 Selectivity of GSK314181A 
As GSK314181A had been confirmed as a potent antagonist of P2X7 its selectivity for 
P2X7 over the other P2X receptor subtypes was investigated. As detailed in the 
Introduction (Chapter 1, section 1.1.1.5.), P2X4 receptors are located on the same 
chromosome as P2X7 and share the most homology out of all P2X receptor subtypes 
(North 2002). Recombinant cell lines of stably transfected human and rat P2X4 receptors 
were used for these selectivity studies and were established and maintained as described 
in the methods. P2X4 receptors were activated with 10 µM ATP, approximately an EC80 
concentration at rat and human P2X4 receptors (Jones et al. 2000). PPADS (100µM) 
inhibited ATP-activated human P2X4 currents by 82 ± 1% (n=3; Figure 4.6A). 
GSK314181A (10 µM) inhibited ATP-activated rat and human P2X4 currents by 27 ± 3 
% (n=7) and 16 ± 3 % (n=6), respectively (Figure 4.6C). As can be seen from Figure 
4.6B, the inhibition peaked rapidly, within 4 minutes, following incubation and was fully 
reversible within 4 minutes (see Figure 4.6B). Additional concentrations of 
GSK314181A were tested at rat P2X4 receptors, from 1 µM to 300 µM, allowing the 
production of a concentration-response curve, which produced an IC50 value of 26 ± 3 
µM, (Hill slope 0.9, n=3-7; Figure 4.6D).  
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Figure 4.6: Effect of GSK314181A on P2X4 receptors 
A. Recording showing PPADS (100 µM) inhibits a 10 µM ATP-activated hP2X4 current by 82 ± 
1% (n=3), and reversal of the inhibition after 8 min (wash). 
B. Example recording showing GSK314181A (10 µM) inhibits 10 µM ATP-activated rat P2X4 
current by 27 ± 3% (n=7). Recovery to baseline levels is within 4 min. 
C. Mean data for the inhibition of human P2X4 receptors (15 ± 4 %, n=5) and rat P2X4 receptors 
(27 ± 3 %, n=7) by 10 µM GSK314181A. IC50 value > 10 µM 
D. Concentration response curve for GSK314181A inhibition at rat P2X4 receptors, activated by 
ATP (10µM) IC50= 26 ± 3 µM, Hill slope n= 0.9, n=3-7. 
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The activity of GSK314181A at P2X2/3 and P2X3 receptors was also investigated using 
recombinant cell lines stably expressing human P2X2 and P2X3 receptors. αβme-ATP, 
(7.5μM) is the most potent agonist at hP2X2/3 receptors and also activates hP2X3 
receptors, but crucially not hP2X2 at this concentration. The protocol is detailed in 
Chapter 2, Materials and Methods, and also an example trace is shown in Figure 4.7i. The 
subtraction step and resulting uncovering of the P2X3 current component is shown in 
Figure 4.7ii. TNP-ATP (1nM) was used as a positive control antagonist of these currents 
and inhibited P2X3 current by 78 ± 8%, n=3 and P2X2/3 currents by 32 ± 3%, n=3 
(Figure 4.7B). GSK314181A (10 μM) was preincubated and co-applied and inhibited 
P2X3 and P2X2/3 currents by 60 ± 9 %, n=6 and 61 ± 3 %, n=8, respectively (Figure 
4.7C and 4.7D). Due to the previously reported high positive correlation between ligand 
binding at heteromeric P2X2/3 and homomeric P2X3 receptors (Jarvis et al. 2004), a 
range of concentrations of GSK314181A (1-100 µM) were tested at P2X2/3 receptors 
activated by αβ-meATP only, and when data were plotted an IC50 value of 4.6 ± 0.8 µM 
was obtained (Hill slope n= 0.7, n= 4-8; Figure 4.7E). 
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Figure 4.7: Effect of GSK314181A on P2X3 and P2X2/3 receptors 
Ai. Example recording showing αβ-meATP activated hP2X2/3 currents using the dual activation 
protocol. Aii Traces from the final example from Ai. The second trace (grey) has been subtracted 
from the first trace (black) to dissect out the P2X3 mediated current which is overlayed in red. B. 
Example recording showing TNP-ATP (1 nM) inhibits a 7.5 µM αβ-meATP-activated hP2X2/3 
and hP2X3 current by 78 ± 8% and 32 ± 3% respectively. C. Example recording showing 
GSK314181A 10 µM) inhibits a 7.5 µM αβ-meATP-activated hP2X2/3 and hP2X3 current by 60 
± 9% and 61 ± 3% respectively.  
D. Mean data for the inhibition of human P2X2/3 and hP2X3 receptors by GSK314181A (10µM). 
E. Concentration response curve for GSK314181A inhibition at human P2X2/3 receptors, 
activated by αβ-meATP (7.5µM) IC50= 4.6 ± 0.8 µM, Hill slope n= 0.7 (n=4-8).  
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4.4 Discussion 
In this study we demonstrated that GSK31418A is a potent antagonist of rat and human 
P2X7 receptors stably expressed in HEK293 cells. GSK314181A blocked BzATP-
activated and ATP-activated rat and human P2X7 currents in a reversible, voltage-
independent manner and was >10000 fold selective over the closely related P2X4 
receptors and >1000 fold selective over P2X2/3 receptors. When profiled in vivo, a 
subcutaneous administration of GSK314181A produced a significant reversal of FCA-
induced hypersensitivity at the highest dose tested.  
 
4.4.1 Pharmacological characterisation of rP2X7 cell line 
The rat P2X7-HEK293 stable cell line has been used previously but pharmacological 
validation was needed before novel compounds were assessed using it. PPADS and 
Brilliant blue G (BBG) are non-specific P2X antagonists. The almost complete inhibition 
of rat P2X7 receptors with PPADS (30μM) shown here demonstrates a higher potency 
for this compound compared to previously reported values (IC50 value of 45 µM) 
(Surprenant et al. 1996). However PPADS potency is incubation-time dependent with 
previously reported IC50 values for its inhibition of human P2X7 receptors ranging from 
62mM (Rassendren et al. 1997) to 1µM, (Chessell et al. 1998a). Indeed in the Chessell et 
al, study they demonstrated its dependence on incubation time as little antagonism was 
apparent when the agonist and antagonist were co-applied, without any prior pre-
incubation. It was a particularly difficult tool antagonist to use due to slow wash-out 
periods (Chessell et al. 1998a), and so no further characterisation work was done using 
this compound.  
The inhibition produced by BBG peaked within 4 minutes of preincubation for all 
concentrations tested and was concentration dependent, producing an IC50 value of 11 ± 1 
nM, inline with previously reported data for this cell line (IC50=10nM; Jiang et al. 
2000a). However the inhibition of currents in the presence of BBG reported here was 
rapidly reversible and when the experiment was continued could show complete recovery 
back to baseline levels. This is at odds with reported data in Jiang et al, where slow 
reversals of block were recorded with incomplete reversals after a 16- to 20-min wash 
(Jiang et al. 2000a). The protocols used are almost identical and so unlikely to underlie 
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the differences seen here. It may be partly due to the run-up recorded following multiple 
agonist applications to rat P2X7 receptors in this cell line (see Results Chapter 3; Figure 
3.1C). The increasing baseline currents observed during multiple application of agonist 
may contaminate true reversal of inhibition where experiments were performed with cells 
showing increasing current amplitude responses. 
The inhibition of P2X7 receptor function by Zn2+ ions was confirmed here and produced 
and IC50 values of 1.9 µM (Figure 4.1E). This is around 6 fold higher than the value 
reported by Virginio and colleagues (IC50 =11.2 µM; Virginio et al. 1997), but is likely 
to be explained by differences in the protocols used to construct these curves, and a 
higher divalent ion concentration in the standard extracellular solution used in these 
studies. 
  
4.4.2 A novel antagonist of rP2X7 receptors 
The data presented here demonstrate that GSK314181A is a potent antagonist of rat and 
human P2X7 receptors, with IC50 values of 1 and 5 nM, respectively (Figure 4.2C and 
4.4B). Therefore GSK314181A represents one of the most potent compounds reported to 
date, and shows little species difference often associated with P2X7 antagonists. 
Subsequent to the work described in this chapter, GSK314181A has also been shown to 
be efficacious against the other measures of receptor activation. Ca2+ uptake experiments 
showed similar potency values for GSK314181A to inhibit rat and human P2X7 receptor 
activation (IC50 values of 29nM at rat P2X7and 18nM at human P2X7 (Broom et al. 
2008). Pore formation can be measured by assessing the uptake of the fluorescent dyes 
YO-PRO or ethidium bromide (Hibell et al. 2000). GSK314181A was also able to inhibit 
pore formation, although the potency was 50-200 times less than that recorded using 
electrophysiology (IC50 values of 980nM at rat P2X7 (Broom et al. 2008).  IC50 value of 
288nM at rat P2X7 (Fonfria et al. 2005) and there was much greater species variability 
(16-70 time less potent at rat P2X7 than human in these assays (Broom et al. 2008) and 
(Fonfria et al. 2005). This is of particular importance and interest as considerable species 
differences in P2X7 receptor pharmacology have been previously reported. It is well 
known that agonist potency is greater at rat and human P2X7 receptors than at mouse 
receptors (Rassendren et al. 1997; Chessell et al. 1998b). With regards to antagonists, 
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many of the previously identified compounds differentiate between the species 
orthologues, and often exhibiting a much greater potency at the human P2X7 orthologues 
and limited rodent P2X7 activity (North and Surprenant 2000). This reduction or absence 
of rodent P2X7 activity can be a serious problem when considering performing the 
preclinical experiments required to progress compounds into the clinic. Examples of this 
are seen with the commonly used tool compounds such as PPADS and Suramin which 
show 5 to10 fold greater potency at human P2X7 receptors than at rat (Rassendren et al. 
1997; Chessell et al. 1998a; Chessell et al. 1998b), KN-62, a more P2X7 specific 
antagonist, only inhibits human receptors and is ineffective at other P2X7 orthologues 
(Gargett and Wiley 1997; Humphreys et al. 1998). However this problem has extended to 
newer compounds like AZ116453743 which shows a similar potency reduction at the rat 
receptors (> 500-fold less effective at inhibiting rat P2X7 currents (Stokes et al. 2006) 
and for the Triazole-based compounds reported by Carroll and colleagues (Carroll et al. 
2007). The obvious exceptions to this are BBG and Calmidazolium where the reverse is 
true, and greater potency is seen in their ability to inhibit rat P2X7 receptors compared to 
human P2X7 (Virginio et al. 1997; Jiang et al. 2000a).  
 
When comparing the effect of GSK314181A at rat and human P2X7 receptors the 
potency of the inhibition produced is very similar, however the rate of onset of block and 
the recovery from block of BzATP-activated currents were much slower at the human 
P2X7 receptor than for the rat (Figure 4.2B, 4.4A). The human P2X7 is 80% identical to 
the rat receptors (Rassendren et al. 1997) and 48 amino acid differences have been 
identified on the proposed extracellular part of the receptor. These amino acid changes 
are likely to account for the disparity in the time it takes for GSK314181A to produce its 
inhibitory effects and will be related to the strength of binding of GSK314181A to the 
protein. However as the binding site for GSK314181A remains unknown it is difficult to 
hypothesise which amino acid changes, in particular, are critical. Further work would be 
needed using site-directed mutagenesis techniques to pinpoint important residues that 
may underlie this differential interaction between the two orthologues.  
 
Chapter 4 
 112
The mechanism by which GSK314181A interacts to inhibit P2X7 receptors can be an 
important factor in determining its potency and efficacy. GSK314181A did not need to be 
preincubated in order to inhibit BzATP-activated rat P2X7 currents, and inhibition was 
not significantly different from that produced with GSK314181A preincubated for 2 
minutes (p=0.1). Therefore it is possible that GSK314181A interacts with the agonist 
binding site or with a site that is uncovered following agonist binding and hence 
conformation change. Further site-directed mutagenesis work would be required to gain 
binding site information and detailed pharmacological analysis is required to ascertain 
whether GSK314181A has a competitive or non-competitive mechanism of action. These 
studies can only be done by looking at shifts in the agonist concentration-response curves 
which are not possible here due to current run-up in the presence of multiple agonist 
additions. Intracellular application of GSK314181A produced no inhibition of BzATP-
activated currents in rat P2X7 expressing cells, strongly suggesting an extracellular 
binding site of the molecule and no requirement for intracellular access to produce 
inhibition. The voltage-dependence of inhibition was also assessed, and equal inhibition 
was recorded at a holding voltage of -60mV or +60mV (Figure 4.2D), indicating a 
voltage-independence to the activity of GSK314181A. From this we can infer that 
GSK314181A would have equal effectiveness to antagonise P2X7 receptors whether the 
cell expressing P2X7 receptors is depolarised or at resting membrane potentials, which 
may be particularly important if the site of action has a neuronal basis. The neuronal 
expression of P2X7 receptors is still subject to debate. P2X7 receptors have been 
localised to presynaptic terminals (Deuchars et al. 2001; Sperlagh et al. 2002; Ishii et al. 
2003) and P2X7 activation, with BzATP, enhanced the release of glutamate and GABA 
(Deuchars et al. 2001; Sperlagh et al. 2002), and increased evoked EPSC amplitude 
(Armstrong et al. 2002; Ireland et al. 2004). P2X7 receptors may also have a role in 
increasing synaptic strength postsynaptically through AMPA receptor insertion (Gordon 
et al. 2005). However, some caution should be used when interpreting data from such 
studies as the enhancement of synaptic transmission has been mimicked in slices from 
P2X7 knock-out mice (Kukley et al. 2004), and there is evidence that some of these 
effects may be mediated through neuronal adenosine A1 receptors (Kukley et al. 2001; 
Ireland et al. 2004; Kukley et al. 2004). Finally one should not discount glutamate release 
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from murine cortical astrocyte cultures following the activation of P2X7 receptors as a 
non-neuronal source of this neurotransmitter (Duan et al. 2003). 
 
When considering the ability of GSK314181A to inhibit P2X7 receptors in vivo, we 
deemed it necessary to confirm that the compound would inhibit P2X7 currents following 
ATP activation. BzATP is the most widely used agonist for activating P2X7 receptors 
due to its greater potency (North and Surprenant 2000). However it is an analogue of 
ATP and not the endogenous ligand for the receptor. GSK31418A was as efficacious and 
only slightly less potent at inhibiting ATP-activated P2X7 currents as those activated by 
BzATP (Figure 4.4), and also demonstrated the same kinetics of block, indicating no 
potential issues for its use in vivo. 
 
4.4.3 In Vivo activity of GSK314181A 
Subcutaneous administration of the P2X7 receptor agonist GSK314181A inhibited the 
FCA-induced decrease in weight bearing, a measure of inflammatory hypersensitivity. 
GSK314181A was effective at a dose of 30mg/kg at 1.5 hours post dose (86.3 ± 17.2% 
reversal). The FCA model is a well known and described model used to measure 
inflammatory hypersensitivity, where the hypersensitivity peaks at about 24–72 h after 
FCA injection (De Alba et al. 2006). These results are consistent with results seen in 
previous studies showing efficacy for P2X7 antagonists in inflammatory models of pain. 
Honore at al, demonstrated a significant reversal in both the carrageenan and FCA 
induced inflammatory pain models with A-740003, 30 minutes after dosing (ED50 = 54 
mg/kg and ED50 = 38 mg/kg respectively). Since the publication of the data reported here 
(Lappin et al. 2005), further work with this compound, renamed AACBA, confirms our 
data and reported efficacy of GSK314181A in the carrageenan model of inflammatory 
pain, and also shows a positive effect on the oedema associated with injection to the 
hindpaw (Broom et al. 2008).  
 
These antinociceptive effects of GSK314181A in the FCA model are consistent with the 
proposed role of P2X7 receptors in inflammatory pain. There is substantial evidence to 
indicate a role for P2X7 receptors in mediating inflammation (Ferrari et al. 2006) and so 
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as a potential therapeutic target with which combat chronic inflammatory pain 
(Romagnoli et al. 2008). Gene knock-out studies showing that P2X7 null mice have 
reduced pain sensitivity following both complete Freund’s adjuvant-induced 
inflammation and partial injury of the sciatic nerve (Chessell et al. 2005) adding 
confidence for a small molecule antagonist strategy. The rationale for the proposed 
efficacy of P2X7 receptor antagonists centres around the activation of microglial and 
astrocytic P2X7 receptors, causing the release of proinflammatory cytokines such as IL-
1β, TNF-α and IL-18 (Lister et al. 2007). The maturation and release of IL-1β following 
P2X7 receptor activation (Perregaux and Gabel 1994; Solle et al. 2001; Ferrari et al. 
2006), may be of particular importance not only as a key mediator in the inflammatory 
cascade, but also because it causes an increase in P2X7 receptor expression levels and 
function in astrocytes after a 24 hour exposure (Narcisse et al. 2005). This corresponds 
well to the efficacy produced with GSK314181A in the FCA model investigated here. 
Animals were assessed 24 hours following the FCA administration, and previous studies 
document the upregulation of cytokines, including TNF-α, IL-1β, IL-6 and NGF in the 
inflamed paw 3 hours to 14 days following the FCA injection (Woolf et al. 1997; 
Raghavendra et al. 2004b). Although not documented in this study, GSK314181A has 
been shown to inhibit IL-1β release from rat microglia (IC50= 2.1µM) and human THP-1 
cells (IC50= 151 nM) (Fonfria et al. 2005) and this prevention of the release of active IL-
1β is a likely mechanism by which GSK314181A is producing its antihyperalgesic 
actions. 
 
Another mechanism by which GSK31418A may be producing its effects is by the 
prevention of the formation of the P2X7 activated pore. The P2X7 pore is activated 
following high concentration or prolonged application of ATP, as might be found in a 
pathological situation (Surprenant et al. 1996). In astrocytes, pore activation may result in 
the release of neurotransmitters including Glutamate (Duan et al. 2003), possibly 
contributing to an increase in synaptic strength. Although this was not investigated here, a 
subsequent study demonstrated that GSK314181A can inhibit YO-PRO and Ethidium 
bromide uptake, used as measures of pore formation, at IC50 values well within the 
exposures of the compound (IC50 values of 980nM at Rat P2X7 (Broom et al. 2008)); 
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IC50 value of 288nM at rat P2X7, see Table 4.1 for summary), and previously reported 
data confirm a high correlation between the potency of compounds at the many ways to 
record P2X7 receptor activation (YO-PRO, IL-1β release) (Honore et al. 2006; Nelson et 
al. 2008). Although there have been 2 main mechanisms put forward for pore formation 
(detailed in Chapter 1, section 1.2.4.2), the data proposing Pannexin-1 as the P2X7-
activated pore protein has gained the most credence (Pelegrin and Surprenant 2006; 
Locovei et al. 2007). There is also evidence that pannexin-1 is required for the activation 
of caspase-1, the enzyme responsible for the cleavage of pro-IL-1β to its active form 
(Pelegrin and Surprenant 2006). Therefore the convergence of the activation of the P2X7 
pore form and the release of IL-1β provides further rationale for an antinociceptive role 
of P2X7 receptor antagonists. 
  
4.4.4 Selectivity of GSK314181A 
Due to such high circulating concentrations of GSK314181A, the selectivity of the 
compound at closely related receptors and those that may be important in pain processing 
must be established. It is clear that although P2X7 receptors play an important role in 
chronic pain probably through the inflammation associated with the condition (Donnelly-
Roberts and Jarvis 2007), other P2X receptors are also likely to contribute. Evidence for a 
role in pain has been hypothesised for P2X2/3, P2X3 and P2X4 receptors (see Chapter 1; 
section 1.4.6), and so to enable the interpretation of the animal pain data the selectivity of 
GSK314181A over these receptors in particular was required.  
 
P2X4 receptors, like P2X7 receptors have been implicated in pain modulation through 
neuro-glial cell interactions (Tsuda et al. 2003; Zhang et al. 2008). They are the most 
ubiquitously expressed of all the P2X receptors, found throughout the peripheral and 
central nervous systems and also on immune cells (North 2002) and it is their overlapping 
localisation with P2X7, and similar functional effects, that has meant it has been difficult 
to dissect out their role. The IC50 concentration for inhibition of rat P2X4 receptors by 
GSK314181A was 26 µM, and although around 26000-fold less potent than its activity at 
rat P2X7 receptors (See Table 1 for summary of potency data), any activity of 
GSK314181A at other channels known to be involved in pain must be considered. The 
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recent reports of functional heteromeric P2X4/P2X7 receptors are of further interest as 
the potency of GSK314181A has not been defined at these heteromeric channels. Often 
heteromeric channels have pharmacological properties conferred to them from each of the 
subunit type they possess forming a true mixture of the two channel types. An obvious 
example of this is seen with P2X2/3 heteromeric channels, where the sensitivity to αβme-
ATP and inhibition by TNP-ATP is conferred to the heteromer by P2X3 subunits and the 
potentiation of currents by low pH and little or no desensitisation to agonist is from the 
P2X2 subunit (North and Surprenant 2000). Therefore it is difficult to predict whether 
GSK314181A would inhibit heteromeric P2X4/7 receptors to the same degree as it is 
effective at P2X7 homomeric receptors. This is unlikely to be able to be elucidated until 
novel receptor-selective tool P2X4 antagonists are developed. 
 
 
Table 4.1: Comparison of the potency of GSK314181A at P2X receptors  
P2X7
Ca2+ uptake YO-PRO/Ethidium IL-1β release WC-PC WC-PC WC-PC
IC50 (nM) IC50 (nM) IC50 (nM) IC50 (nM) IC50 (µM)
x fold cf 
P2X7 IC50 (µM)
x fold cf 
P2X7
Rat 29 980 2100 1 26 26000 nt nt
 (Fonfria 2005)
Human 18 288 151 5 >10 >2000 5 1000
(Broom 2008) (Broom 2008)  (Fonfria 2005)
P2X4 P2X2/3
 
YOPRO/Ethidium - YOPRO or Ethidium Bromide uptake assay 
WC-PC - Whole-Cell patch-clamp;      nt - Not tested 
 
 
GSK314181A was tested at hP2X3 homomeric and hP2X2/3 heteromeric channels and 
10 µM was shown to inhibit both subtypes by 60%. The IC50 value of 5 µM at hP2X2/3 
receptors represents a 1000 fold less potent effect at P2X2/3 receptors compared to the 
potency at hP2X7 receptors (See Table 4.1 for summary of potency data). 
 
As mentioned above, it is important to consider the concentration of GSK3141781A in 
the blood and brain of the animals in the model of inflammatory pain when analysing the 
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efficacy produced by GSK314181A. Although the blood and brain concentrations of 5.5 
µM and 2.5µM respectively, are a measure of the concentration present systemically in 
the blood and in whole brain, but do not give us an actual concentration of the drug at the 
receptor. This may vary from the reported values due to enzymatic breakdown, uptake 
into cells or tissues or a reduced access to the site of action. Interestingly, the potency of 
GSK314181A to inhibit IL-1β release from rat microglia (IC50= 2.1µM) (Fonfria et al. 
2005), was a lot lower than reported potency data for other measures of P2X7 receptor 
activation (IC50= 1nM whole-cell patch-clamp; IC50 = 980nM for ethidium bromide 
inhibition). There are many differences between the assay formats used to measure 
potency, such as agonist concentration and incubation times, but the higher temperature 
needed to record IL-1β release was one difference highlighted in (Fonfria et al. 2005). 
The IL-1β release assay is run at the higher temperature of 37ºC, and this can reduce the 
potency of GSK314181A. This is illustrated when the ethidium bromide uptake assay is 
run at this higher temperature a reduction in the IC50 to 3.6µM is recorded. Temperature 
dependent activity of P2X7 receptors have been recorded previously (Chessell et al. 
1997; Wiley et al. 1998) and for antagonists such as KN62 and OxATP (Hibell et al. 
2001b). This should be considered when trying to correlate the in vitro potency of 
antagonists relative to their exposures in vivo. It is also important to note that the values 
quoted here are ‘total’ blood and brain concentrations, and although well above the 
inhibitory effect of GSK314181A at rat P2X7 receptors (1nM), they do not take into 
account what proportion of GSK314181A is bound by plasma proteins, something that 
can severely limit the biological efficacy of drugs. GSK314181A has been profiled in a 
human serum albumin binding assay using High Performance Liquid Chromatography 
(HPLC) and was found to be 94.5% protein bound. There is often a good correlation of 
plasma protein binding levels between species and so this data has been extrapolated and 
applied in the study detailed here. This provides an estimate of the circulating “free” 
concentrations of GSK314181A in the blood and brain samples of 275nM and 125nM 
respectively. In Figure 4.8 below, the concentration-response curves for P2X7 (rat and 
human), P2X4 and P2X2/3 are overlayed with the proposed window of circulating 
GSK314181A concentration (grey bar), illustrating that although GSK314181A inhibits 
both P2X4 and P2X2/3 receptors, due to the ‘free’ concentrations in the blood and brain, 
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their inhibition may have little role in the reversal of hypersensitivity produced in this 
inflammatory pain model. 
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Figure 4.8: Effect of GSK314181A on P2X receptors 
Concentration response curve for GSK314181A inhibition at P2X7, P2X4 and P2X2/3 receptors. 
Grey bar illustrates range of concentrations of GSK314181A found in the blood and brains of rats 
from the FCA inflammatory pain study, adjusted for protein plasma binding. 
  
 
 
 
Taken together, the present data demonstrate that the acute in vivo blockade of P2X7 
receptors significantly reduces nociception in animal models of persistent neuropathic 
and inflammatory pain. Although there is growing appreciation for the role of P2X7 
modulation of proinflammatory IL-1β processing (Ferrari et al. 2006), the analgesic 
activity of A-740003 and other recently described selective P2X7 receptor antagonists 
(Nelson et al. 2008) suggests a specific role for P2X7 in neuronal-glial cells interactions 
associated with ongoing pain (Zhang et al. 2007).
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Chapter 5: Identification and Characterisation of native P2X7 receptors 
 
5.1. Introduction 
Although there is evidence for P2X7 receptor expression on DRG non-neuronal cells 
(Chessell et al. 2005; Kobayashi et al. 2005; Zhang et al. 2005b), and some functional 
pharmacological characterisation, the kinetic response to agonist activation was not 
investigated. Recombinantly expressed P2X7 receptors are widely used to define the 
biophysics and kinetics of the response to agonist activation of these receptors, and the 
assumption is made that these properties are also found when the receptors are expressed 
in native cells. The P2X7 receptor has some interesting properties, such as a non-static 
response to agonist activation recorded as changes in current amplitude and deactivation 
rates, as detailed in Chapter 3, which may have important consequences for the 
physiological and pathophysiological functioning of the receptor. Therefore it is 
interesting to determine whether these effects are inherent to the receptor function or if 
they are a property of the expression systems for recombinantly expressed P2X7 
receptors. 
 
The dorsal root ganglia (DRG) contain the cell bodies of the fibres that innervate the skin 
and viscera. Primary cultures of the cells from these ganglia are often used in research 
because of the ease of which cells can be harvested and prepared, and their importance in 
the transmission of sensory signal. They are proposed to express the same channels and 
receptors that are found at the nerve terminals, and so represent an easy way to 
investigate the function of these native channels or receptors. There is also evidence for a 
contribution to pain states, as changes in the electrical activity and morphology of DRG 
neurones have been observed following peripheral insult. For example, changes in 
sodium channel expression in nerve injury (Rizzo et al. 1995; Cummins and Waxman 
1997) and an increase in TRPV1 expression in DRG following a peripheral inflammatory 
insult (Amaya et al. 2003). 
 
Although the focus of previous studies has been on the neuronal component of DRG, the 
ganglia itself contains a mixture of non-neuronal cells, including Schwann cells, 
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fibroblasts, macrophages and endothelial cells, as well as satellite cells (Olsson 1990; 
Nascimento et al. 2008). More recent evidence has shown that the satellite glial cells that 
surround neurones in these ganglia may have many important roles in cell 
communication and can influence neuronal activity through the uptake or release of 
neurotransmitters, cytokines and growth factors (Hanani 2005 for review; Zhang et al. 
2007). As P2X7 receptors may be present on these cells, and have been shown to have a 
role in the processes detailed above in astrocytes (Ballerini et al. 1996; Duan et al. 2003), 
it was interesting to compare the functioning of this receptor in native cells, define the 
cell types they are expressed on, and also hypothesise as to the role these receptors have 
in normal and pathophysiology.  
 
5.2 Methods Summary 
 
5.2.1 Whole Cell patch Clamp 
Experiments were performed using whole-cell patch-clamp electrophysiology to study 
P2X7 receptors on the non-neuronal cells from acutely dissociated dorsal root ganglia 
neurones (DRG). The non-neuronal cells from which whole-cell recordings were made 
were phase-bright, spindle shaped cells (Wilkinson et al. 1999). 
 
5.2.2 Dorsal Root Ganglia dissociation and culturing 
Dissociated DRG cells were prepared as detailed in the Material and Methods section 
(Chapter 2). 
 
5.2.3 Immunocytochemistry (ICC) 
ICC was performed as detailed in the Material and Methods section (Chapter 2). Rat 
DRG cells as prepared for whole-cell patch-clamp electrophysiology were fixed 1-3 days 
post-plating and ICC was performed within 2 weeks. 
 
5.3 Results 
 
 
Chapter 5 
 121
 
5.3.1 The response of DRG non-neuronal cells to agonist 
5.3.1.1 Agonist efficacy 
Applications of ATP (100 μM) and BzATP (100 μM) to non-neuronal cells in these 
cultures produced large non-desensitising inward currents that resembled those recorded 
from recombinant P2X7 receptors expressed in HEK293 cells (Figure 5.1A).  The mean 
peak current amplitude in response to BzATP (100 µM) was 538 ± 103 pA and the peak 
current response of the same cell to the same concentration of ATP was 247 ± 64 pA, 
significantly smaller than the BzATP response (46% of BzATP-activated current peak 
amplitude, n=8, p=0.001; Figure 5.1B). 
 
5.3.1.2 Current-Voltage Relationship 
To investigate the current-voltage relationship of these ATP and BzATP-gated currents, 
cells were voltage-clamped at -60mV before a voltage ramp protocol from -90 mV to 
+60mV was applied. A small current, termed non-specific leak current, was produced in 
control solution (standard extracellular solution), and a linear increase in the current 
amplitude was produced by the application of BzATP and ATP (Figure 5.1C). Pooled 
data showed BATP and ATP activated currents that were almost linear and reversed at -5 
± 0.2 mV (n=3) and -5 ± 1 mV (n=9) respectively, as expected for a non-selective cation 
channel (Figure 5.1D). 
 
5.3.1.3 Agonist Potency 
The concentration-response relationship of BzATP on these cells was carried out as 
previously described. A concentration response curve was generated for BzATP and 
results in sigmoidal curve with an EC50 value of 10 ± 1 µM (n = 3-9, Hill slope = 1.0 ± 
0.1; Figure 5.1E). The same was done for ATP producing an EC50 value of 534 ± 65 µM 
(n= 4-6, Hill slope = 1.6; Figure 5.1F). 
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Figure 5.1: Response to agonist in DRG non-neuronal cells 
A. Representative currents recorded in response to 10-12 s applications of BzATP (100 µM) and 
ATP (100 µM).  
B. Graph plotting pooled data from experiments in (A) after mean peak current amplitudes were 
calculated. BzATP (100 µM) mean peak current was significantly larger than the current in 
response to ATP (100 µM).  
C. Representative current trace in control solution and following the addition of 100 µM BzATP 
during the voltage ramp. The voltage was ramped from -90mV to +60mV over 500ms, every 
second. 
D. Graph plotting pooled data Voltage ramps (-90 mV to +60 mV, 500 ms) applied in the 
presence of BzATP (30 µM) resulted in linear currents.  
E. The graph illustrates the mean concentration response curve to BzATP, EC50 value of 10 ± 1 
µM (n = 3-9). Data was normalised to 300 µM BzATP application. 
F. The graph illustrates the mean concentration response curve to ATP, EC50 value of 534 ± 65 
µM (n= 4-6). Data was normalised to 1mM ATP application.  
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5.3.1.4 Multiple applications of Agonist 
One of the characteristics of rat P2X7 receptors when they are expressed in HEK293 cells 
is the changing response to multiple applications of the same concentration of agonist. 
Here, the first application of BzATP (100 µM) gave peak current amplitudes ranging 
from 155pA to 806pA, and produced a mean current amplitude of 294 ± 78 pA (n=10). 
Following further applications of agonist, the peak current amplitude was relatively 
stable, and was 112 ± 13% of control at the 6th application (n=6; ranging from 90% to 
173% of control; see Figure 5.2A). 
 
5.3.1.5 Deactivation 
BzATP-activated current deactivation was calculated, as done previously for the 
recombinant rP2X7 receptor, as the time for the current to return 50% of its maximum 
(95-50%) and was 211 ± 34 ms (n=8). The rate of slowing of deactivation was found to 
be dependent upon the individual cell, with the decay time ranging from 221ms to 662ms 
after 6 BzATP (100µM) applications. When data was pooled and mean values were 
calculated, the average decay time at the 6th application of BzATP was 400 ± 66ms, 
(n=7), and was significantly different from the deactivation time of the first application 
(p=0.02). When comparing this to the data for the rat P2X7-HEK293 cells (see section 
3.3.1.4 Deactivation kinetics) the values are significantly different for the first application 
of BzATP (211 ± 34 ms rDRG; 117 ± 7ms rP2X7-HEK, p=0.002).  However by the 6th 
application, no significant difference in the decay times was recorded (400 ± 66ms 
rDRG; 459 ± 64ms rP2X7-HEK, p=0.7, Figure 5.2B). 
 
The deactivation rate changes are also voltage-dependent. Figure 5.2C shows a 
representative recording of consecutive response to BzATP (100 µM), normalised to the 
peak current within each responses. The cell was voltage-clamped at -60mV for the first 
and third applications of BzATP (sweep 1 and 3) and between these two, was clamped at 
+60 mV for the second application of agonist (sweep 2). The deactivation rate was 
significantly slower at +60 mV compared to the rates at -60 mV (p<0.05). 
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Figure 5.2: Current response of DRG non-neuronal cells to multiple applications of agonist 
A. Representative currents recorded in response to 2 s application of BzATP (100 µM). The time 
between agonist application is 2 minutes. Note the small changes in the peak current amplitude 
reached following each agonist addition.  
B. Representative traces of the first and sixth applications of BzATP overlayed for rat DRG non-
neuronal cells and Rat P2X7-HEK293 cells. Currents have been normalised to the peak current. 
Note the change in the deactivation rate for both cell types.  
C. Representative trace showing consecutive responses to BzATP (100 µM), normalised to the 
peak current within each responses. The cell was voltage clamped at -60mV for sweep 1 and 3 
and at +60 mV for sweep 2. Note the slowing of deactivation at +60 mV. 
D. Bar graph to illustrate the current density in rat P2X7 expressing HEK293 cells (rP2X7) and 
rDRG non-neuronal cells (rDRG) in response to the first application of BzATP.  
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5.3.1.6 Current Density 
The current density can be used to give an indication as to the number of functional 
receptors expressed at the cell membrane. This was measured for DRG non-neuronal 
cells in response to the first application of BzATP and gave a value of 67 ± 20 pA/pF 
(n=10). When compared to the data that was recorded from HEK cells stably expressing 
rat P2X7 receptors, the current density for the recombinant cells was significantly larger 
(172 ± 19 pA/pF, n=12; p=0.001) possibly indicating a greater number of channels 
expressed in the recombinant cells compared to the native cells. 
 
 5.3.2 Pharmacological evaluation of DRG non-neuronal cells 
A novel P2X7 antagonist, GSK314181A, was discussed and its potency defined at rat 
P2X7 receptors expressed in HEK293 cells in Chapter 4. GSK314181A (100 nM) 
inhibited BzATP (100 µM)-activated currents by 91 ± 2 % (n=3) and was fully reversible 
within 6 minutes (Figure 5.3A). Additional concentrations were tested from 10 nM to 1 
µM allowing the production of a concentration-response curve, which yielded an IC50 
value of 23 ± 2 nM, (Hill slope 2 ± 0.3, n=3-4) (Figure 5.3B). This is a 20 fold decrease 
in the potency of GSK314181A in comparison to the IC50 value (1 ± 0.2 nM, Hill slope 
0.7, n=3-7), recorded for recombinantly expressed rat P2X7 receptors (Figure 5.3B). 
  
Zn2+ ions have been shown to inhibit rat P2X7 receptors stably expressed in HEK293 
cells with an IC50 value of 1.9 µM (Chapter 4, Figure 4.1). BzATP-activated currents in 
DRG non-neuronal cells were rapidly and reversibly inhibited by Zn2+ ions (10 µM) by 
77 ± 7% (n=4; Figure 5.4A). Concentrations from 1 µM to 100 µM were added and 
plotted yielding an IC50 value of 1.4 ± 0.2 µM, (Hill slope 0.8 ± 0.1, n=3-5) (Figure 
5.4B). 
 
Chapter 5 
 126
Ai
B
Aii
5s
200 pA
100 nM GSK314181A
1E-111E-10 1E-9 1E-8 1E-7 1E-6 1E-5
0
20
40
60
80
100
RatP2X7-HEK
DRG 
non-neuronal 
%
 in
hi
bi
tio
n
[GSK314181A] (M)
1
2
3
0 500 1000 1500 2000
0
-200
-400
-600
-800
-1000
I (
pA
)
Time (s) 
100 nM 
GSK314181A
1 2 3
 
 
 
 
 
Figure 5.3: GSK314181A inhibits BzATP-activated currents in DRG non-neuronal cells 
A. Ai: Graph plotting the time-course data for the effect of GSK314181A (100nM) on BzATP-
activated currents. Black squares denote the peak current in response to a BzATP (100 µM) 
application. The white bar indicates where GSK314181A was applied. In Aii, example traces 
from Ai are shown.  
B. Concentration response curve for GSK31418A at DRG non-neuronal cells in red, compared to 
the data produced for GSK314181A at rP2X7 stably expressed in HEK293 cells (see Figure 
4.2C). 
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Figure 5.4: Zn2+ ions inhibit BzATP-activated currents in DRG non-neuronal cells 
A. Representative recording showing the inhibition of the current produced in response to BzATP 
(100 µM; White bar) with the addition of Zn2+ ions (10 µM) into the bathing solution (black 
bar). This was reversible on return to BzATP alone. 
B. Graph plotting pooled data from experiments in (A) after mean peak current amplitudes were 
calculated.  
 
 
 
 
 
 
 
 
5.3.3 P2X7 expression in DRG non-neuronal cells 
The data above shows that the non-neuronal cells in the DRG cultures have functional 
P2X7 receptors. The cell types expressing these functional P2X7 receptors were then 
investigated using immunocytochemistry techniques. 
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5.3.3.1 Characterisation of a P2X7 monoclonal antibody (MoAb; Buell et al. 1998a) 
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Figure 5.5 Human P2X7 monoclonal antibody labels human P2X7 receptors stably 
expressed in HEK293 cells.  
A,B: Images showing cells labelled with the mouse monoclonal antibody to human P2X7 in green 
(A, 1:1000; B 1:500 dilution). To-Pro-3 (red) was used (1:1000) as a nuclear label. 
C: Example image showing the selectivity of the secondary antibody, Donkey anti-mouse, Alexa-
Fluor 488. Nuclei are labelled with To-Pro-3. 
D: Example image showing the absence of autofluorescence of the primary antibody, mouse anti-
human P2X7 (1:500). Nuclei are labelled with To-Pro-3. 
E: Example image showing HEK293 non-transfected cells and the absence of fluorescence with 
the mouse anti-human P2X7 (1:500) and Alex Fluor 488 (1:200). Nuclei are labelled with To-
Pro-3. 
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5.3.3.1.1 Human and Rat P2X7 Receptors stably expressed in HEK293 cells. 
Mouse monoclonal anti-human P2X7 antibody (MoAb) labelled human P2X7 receptors 
stably expressed in HEK293 cells at a dilution factor or 1:1000 and 1:500 (Figure 5.5A 
and 5.5B). Rat P2X7 receptors stably expressed in HEK293 cells were also labelled by 
this antibody, at slightly more concentrated levels of 1:500 and 1:250 dilutions (Figure 
5.6A and 5.6B). There was no background fluorescence seen with the primary or the 
secondary antibody in either cell type (Figures 5.5C, 5.5D, and 5.6C). To confirm the 
specificity of the fluorescence in these cells to the P2X7 protein, rather than non-specific 
binding, wild-type, non-transfected HEK293 cells were also tested at 1:500 dilution and 
showed no immunofluorescence (Figure 5.5E). 
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Figure 5.6 Human P2X7 monoclonal antibody labels rat P2X7 receptors stably expressed in 
HEK293 cells.  
A,B: Images showing cells labelled with the mouse monoclonal antibody to human P2X7 in green 
(A, 1:500; B 1:250 dilution). To-Pro-3 (red) was used (1:1000) as a nuclear label. 
C: Example image showing the selectivity of the secondary antibody, Donkey anti-mouse, Alexa-
Fluor 488. Nuclei are labelled with To-Pro-3. 
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5.3.3.1.2 Other P2X receptors 
The sequence homology between P2X7 and other P2X receptors ranges from 40-50%, 
with P2X4 sharing the most similarity. Due to the overlapping nature of P2X4 and P2X7 
expression it was considered important to assess the potential interaction of the antibody 
with P2X4. Other P2X receptors of interest are the P2X3, P2X2 and P2X2/3 heteromer, 
as these are found both on non-neuronal and neuronal cells. As neurones are also present 
in these cultures a cross-reactivity of P2X2, P2X3 and P2X2/3 was considered.  
 
HEK293 cells stably expressing human P2X4 or rat P2X4 were incubated with the anti-
human P2X7 antibody (1:250 dilution) and then the secondary antibody (Alex Fluor 488) 
(Figure 5.7Ai,Bi) with no specific labelling visible. This was further confirmed with the 
control experiment in Figure 5.7 Aii and Bii, where only the secondary antibody was 
applied.  
CHO cells stably expressing human P2X2 and human P2X3 were incubated with the anti-
human P2X7 antibody (1:250 dilution) and then the secondary antibody (Alex Fluor 488) 
(Figure 5.7Ci). As can be seen from the control, only secondary incubated, (Figure 
5.7Cii), the green labelling is non-specific and quite different in morphology to the 
positive immunofluorescence, thought to be P2X7 protein, seen in Figures 5.5 and 5.6. 
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Figure 5.7 Selectivity of hP2X7 monoclonal antibody over other P2X receptors 
A,B: HEK293 cells stably expressing Human P2X4 receptors (A) or Rat P2X4 receptors (B), 
incubated with hP2X7 monoclonal antibody (1:250, Ai, Bi) and Donkey anti-mouse conjugated to 
Alexa Fluor 488 (green) , or only secondary antibody incubation (Aii, Bii). Nuclei are labelled 
with To-Pro-3 (red). 
C: CHO-K1 cells stably expressing Human P2X2 and Human P2X3 receptors, incubated with 
hP2X7 monoclonal antibody (1:250, Ci) and Donkey anti-mouse conjugated to Alexa Fluor 488 
(green), or only secondary antibody incubation (Cii). 
 
 
5.3.3.2 P2X7 labelling in rat DRG cultures 
The anti-human P2X7 antibody was then use to label P2X7 subunits present in the rat 
DRG cultures that had been used for the electrophysiological experiments previously 
detailed in this chapter. The spindle-shaped cells in these rat DRG cultures had positive 
immunofluorescence at 1:500 (Figure 5.8B) and more clearly at 1:250 (Figure 5.8C) 
dilution of the antibody. This was well above any non-specific background fluorescence 
seen following incubation with either only the secondary antibody (Figure 5.8D), or only 
the primary antibody (Figure 5.8E). However, as can be seen in Figure 5.8C, there is also 
distinct labelling of round structures that are around 15-20µm in diameter and look more 
neuronal in morphology (labelled with * on this figure). This is also highlighted in Figure 
5.8F where a number of more neuronal-like cells have been labelled (*). 
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Figure 5.8  P2X7 localization in rat DRG cultures 
A,B,C,G: rat DRG cultures with P2X7 receptor labelling using hP2X7 monoclonal antibody 
(Dilutions factors of A,1:1000, B,1:500, C, G, 1:250) and Donkey anti-mouse conjugated to 
Alexa Fluor 488. Examples of non-neuronal cell labelling are marked with →. Unlabelled cells 
are marked with >. 
D: Example image showing the selectivity of the secondary antibody, Donkey anti-mouse, Alexa-
Fluor 488. 
E: Example image showing the absence of autofluorescence of the primary antibody, mouse anti-
human P2X7 (1:250). Nuclei are labelled with To-Pro-3. 
F: Rat DRG cultures with P2X7 receptor labelling using hP2X7 monoclonal antibody (1:250) and 
Donkey anti-mouse conjugated to Alexa Fluor 488. Note the labelling of cells with apparent 
neuronal morphology in these cultures (*). 
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5.3.3.3 Identification of P2X7 positive cell types 
5.3.3.3.1 P2X7 labelling on neuronal cells 
In order to confirm that the larger, round cells that had been positive for P2X7 
immunofluorescence were indeed neurones, an antibody to β3-tubulin was used. The 
antibody was characterised using the rat DRG cultures and showed neuronal labelling 
only in the mixed cell population (Figure 5.9). Co-labelling studies were performed on rat 
DRG cultures to define the cell population that is brightly labelled by the hP2X7 
monoclonal antibody (see Figure 5.8F). P2X7 labelling was co-localised with β3-tubulin 
on cells with round morphology rather than cells with a spindle shaped structure. There 
was also evidence of co-labelling of processes but it was unclear as to their origin. The 
labelling was specific as determined by the lack of non-specific background fluorescence 
recorded following incubation with only secondary or primary antibodies (Figure 5.10). 
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Figure 5.9 β3-Tubulin antibody labels neurones in rDRG cultures 
A,B,C: Rat DRG cultures labelling using β3tubulin polyclonal antibody (Dilutions of A: 0.5 
µg/ml. B: 1µg/ml. C:3 µg/ml) and Donkey anti-mouse conjugated to Alexa Fluor 647 (Red). 
Nuclei are labelled with Sytox Green (1:5000, Green). Note the labelling of neuronal cell bodies 
and processes.  
D: Rat DRG cultures with P2X7 receptor labelling using hP2X7 monoclonal antibody (1:250; 
Green) and Donkey anti-mouse conjugated to Alexa Fluor 488. Nuclei are labelled with To-Pro-3 
(1:1000, red). 
E: Maximum view of labelled Rat DRG cultures using β3tubulin polyclonal antibody (0.5 µg/ml) 
and Donkey anti-mouse conjugated to Alexa Fluor 647 (Red). Nuclei are labelled with Sytox 
Green (1:5000, Green). 
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Figure 5.10 β3-Tubulin antibody co-localised with P2X7 labelling 
AB: Example image showing rat DRG cultured cells with (A) P2X7 receptor labelling using 
hP2X7 monoclonal antibody (1:250) and Donkey anti-mouse conjugated to Alexa Fluor 488 
(green). (B) β3tubulin labelling using β3tubulin rabbit polyclonal antibody (0.5 µg/ml) and 
Donkey anti-rabbit conjugated to Alexa Fluor 647 (red).  
C: Merged image of (A) and (B) showing double immunofluorescence with a hP2X7 positive cell 
also labelled with β3tubulin, indicating neuronal cell type. 
D: Example image of rat DRG cultured cells showing double immunofluoresecent labelling of 
P2X7 receptors using hP2X7 monoclonal antibody (1:250) and Donkey anti-mouse conjugated to 
Alexa Fluor 488 (green) and β3tubulin using β3tubulin rabbit polyclonal antibody (0.5 µg/ml) 
and Donkey anti-rabbit conjugated to Alexa Fluor 647 (red). This is using the 63x water 
immersion lens. Note the overlapping labelling on the neurone and not on the non-neuronal cells.  
E: Example image showing the absence of fluorescence of the primary antibody to β3tubulin, 
when applied to P2X7 labelled cells (1:250).  
F: Example image showing the absence of fluorescence of the secondary antibody used to label 
β3tubulin (Alexa Fluor 647), when applied to P2X7 labelled cells (1:250).  
G: Example image showing the absence of fluorescence of the primary antibody to hP2X7, when 
applied to β3tubulin labelled cells (0.5 µg/ml).  
H: Example image showing the absence of fluorescence of the secondary antibody used to label 
hP2X7 (Alexa Fluor 488), when applied to β3tubulin labelled cells (0.5 µg/ml).  
I: Example image showing the selectivity of the primary antibodies, hP2X7 β3tubulin.  
J: Example image showing the selectivity of the secondary antibodies, Donkey anti-mouse, 
Alexa-Fluor 488, and Donkey anti-rabbit Alexa Fluor 647. 
 
 
 
5.3.3.3.2 P2X7 co-localisation with astrocytic markers 
P2X7 expression was identified on cells of non-neuronal origin but the exact nature of 
these cells is not known, therefore co-localisation studies were done to try to define the 
cell type. 
 
S100beta (S100β) is a member of the S100 family of proteins containing 2 EF-hand 
calcium binding motifs, localised to the cytoplasm and/or nucleus of a wide range of 
neurones and non-neuronal cells  (Zimmer and Van Eldik 1987; Sugimura et al. 1989; 
Vega et al. 1991). The proteins are involved in the regulation of a number of cellular 
processes such as cell cycle progression and differentiation (Zimmer et al. 1995). In these 
cultures of DRG, S100β labels two types of non-neuronal cells, the elongated spindle-
shaped cells most clearly (→), but also more diffuse labelling is seen in cells marked with 
(     ) (Figure 5.11A-C). This is highlighted at higher magnification in Figure 5.11E. No 
labelling was seen in any cells following incubation with the secondary antibody only 
(Figure 5.11D). DRG cultures were then incubated with anti-S100β antibody and anti-
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hP2X7 antibodies and co-immunofluorescence was seen in many cells (Figure 5.12A-C). 
Relevant controls were performed to show the lack of an effect of the co-addition of the 
S100β to hP2X7 labelling and vice versa (Figures 5.12D-F), and no non-specific labelling 
was observed.  
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Figure 5.11 S100β labels a subset of non-neuronal cells in DRG cultures 
A,B,C: rat DRG cultures labelled with anti-S100beta (Dilutions factors of A,1:100, B,1:200, 
C,1:400) and Donkey anti-rabbit conjugated to Alexa Fluor 647 in red. Nuclei are labelled with 
Sytox Green.D: Example image showing the selectivity of the secondary antibody, Donkey anti-
rabbit, Alexa-Fluor 647.E: Example image showing the S100beta labelling (1:100 dilution) using 
a water immersion 63x lens. Nuclei are labelled with Sytox Green.Note the 2 different cells types 
labelled by S100beta. Spindle shaped cells marked with →, and more diffusely labelled cells 
marked with      . 
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Figure 5.12 S100β co-localised with P2X7 in DRG cultures 
A,B: Example image showing rat DRG cultured cells with (A) P2X7 receptor labelling using 
hP2X7 monoclonal antibody (1:250) and Donkey anti-mouse conjugated to Alexa Fluor 488 in 
green. (B) S100beta labelling using S100beta rabbit monoclonal antibody (1:400) in red and 
Donkey anti-rabbit conjugated to Alexa Fluor 647 in red. 
C: Merged image of (A) and (B) showing double immunofluorescence with many S100beta 
positive cells also showing P2X7 labelling. 
D: Example image showing rat DRG cultured cells labelled with S100beta rabbit monoclonal 
antibody (1:400) and both donkey anti-rabbit conjugated to Alexa Fluor 647, and donkey anti-
mouse conjugated to Alexa Fluor 488. 
E: Example image showing rat DRG cultured cells labelled with hP2X7 mouse monoclonal 
antibody (1:250) and both donkey anti-rabbit conjugated to Alexa Fluor 647, and donkey anti-
mouse conjugated to Alexa Fluor 488.  
 
The antibody to Glutamine Synthetase labelled most of the cells in the DRG cultures 
(Figure 5.13A,B), with no labelling was observed in any cells following incubation with 
the secondary antibody only (Figure 5.13C). Cell were then incubated with Anti-
glutamine synthetase antibody and anti-hP2X7 antibodies and co-immunofluorescence 
was seen in all spindle-shaped cells (Figure 5.13D-G). Relevant controls were performed 
to show the lack of an effect of the co-addition of the glutamine synthetase to hP2X7 
labelling and vice versa (Figures 5.13H), and no non-specific fluorescence was observed. 
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Figure 5.13 Glutamine Synthetase is co-localised with P2X7 in DRG cultures 
A: Example image showing rat DRG cultured cells labelled with Glutamine snythetase polyclonal 
antibody 1:2000) in red and Donkey anti-rabbit conjugated to Alexa Fluor 647. Nuclei are 
labelled with Sytox green. B: Example image showing the Glutamine Synthetase labelling 
(1:2000 dilution) using a water immersion 63x lens.  
C: Example image showing the selectivity of the secondary antibody, Donkey anti-rabbit, Alexa-
Fluor 647. Nuclei are labelled with Sytox Green. 
D,E: Example image showing rat DRG cultured cells with (D) P2X7 receptor labelling using 
hP2X7 monoclonal antibody (1:250) and Donkey anti-mouse conjugated to Alexa Fluor 488 in 
green. (E) Glutamine Synthetase labelling using Glutamine synthetase rabbit polyclonal antibody 
(1:2000) and Donkey anti-rabbit conjugated to Alexa Fluor 647 in red. 
F:  Merged image of (D) and (E) showing double immunofluorescence with Glutamine synthetase 
positive cells also showing P2X7 labelling. 
G: Example image showing rat DRG cultured cells labelled with Glutamine synthetase rabbit 
polyclonal antibody (1:2000) and both donkey anti-rabbit conjugated to Alexa Fluor 647, and 
donkey anti-mouse conjugated to Alexa Fluor 488. 
H: Example image showing rat DRG cultured cells labelled with hP2X7 mouse monoclonal 
antibody (1:250) and both donkey anti-rabbit conjugated to Alexa Fluor 647, and donkey anti-
mouse conjugated to Alexa Fluor 488.  
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5.4 Discussion 
 
In this study the satellite and Schwann cells present in DRG primary cultures were shown 
to express functional P2X7 receptors by pharmacological, biophysical and 
immunofluorescence techniques. Native P2X7 receptor expressed on DRG non-neuronal 
cells were shown to have many of the properties of recombinant P2X7 receptors that have 
been detailed in Chapter 3, in regards to the response to agonist activation and 
pharmacology. However a number of the characteristics present in the recombinant 
receptor may be a consequence of the expression system as they are absent from native 
cells expressing P2X7.  
 
5.4.1 Defining P2X7 receptor expression on non-neuronal cells in DRG cultures 
The data reported here show that the non-neuronal cells from DRG cultures possess 
functional P2X7 receptors. However a number of measures were needed in order to 
confirm this, due to the co-localisation and overlapping pharmacology and biophysical 
profiles of P2X7 receptors with P2Y receptors (Lyons et al. 1994; Kobayashi et al. 2006), 
and other P2X receptors, including P2X2 (Vulchanova et al. 1997), P2X4 (Irnich et al. 
2001) and P2X6 possibly as heteromeric receptors with P2X2 and P2X4 (Kobayashi et al. 
2005).  
 
Firstly, all of the non-neuronal cells that were recorded responded to BzATP (100 µM), 
an agonist at P2X2, P2X4 receptors, as well as at P2X7 receptors (Bianchi et al. 1999), 
with inward currents. These currents activated quickly and showed little desensitisation in 
the presence of the agonist, exhibiting many of the hallmarks of P2X receptor activation 
(North 2002). The currents produced following BzATP addition were greater, in 
amplitude, compared to those produced by same concentration of ATP (Figure 5.1A,B), 
and it is this difference in potency that is one of the key features of P2X7 receptor 
activation (North and Surprenant 2000). It was also important to make this comparison 
with ATP due to the activity of BzATP at other P2X receptor subtypes (Bianchi et al. 
1999). Secondly, the linear current-voltage relationship recorded for both BzATP and 
ATP activated currents is as expected for P2X7 (Surprenant et al. 1996), and P2X4 
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receptors (Jones et al. 2000), but rules out any involvement of P2X2 receptors as these 
channels usually show strong inward rectification (Brake et al. 1994; Evans et al. 1996).  
 
The potency of BzATP and ATP at the receptors in these cells was determined and for 
BzATP produced values (EC50 = 10 µM) in line with previously reported data from 
recombinantly expressed rat P2X7 receptors (6-10 µM; Surprenant et al. 1996; Hibell et 
al. 2000), and also from DRG non-neuronal cells (26 µM; Zhang et al. 2005b). It was 
difficult to determine the maximum current response to ATP, possibly due to a change in 
affinity at the receptor (discussed in Chapter 3) or due to the activation of other P2X 
receptors. The EC50 value of 534 µM for the effect of ATP was a little higher than that 
recorded in other studies on the recombinant rat P2X7 receptor (EC50=100µM;  
Surprenant et al. 1996; EC50=407µM;  Hibell et al. 2000). However, it is unlikely that 
P2X4 receptors were being activated as the proposed EC50 values for the effect of ATP at 
rat P2X4 receptors has been reported as 7-20 µM (Seguela et al. 1996; Soto et al. 1996) 
so a much greater current response would have been expected at the lower concentrations 
applied.   
 
The biophysical properties of the currents activated in non-neuronal cells exhibit many of 
the properties associated with P2X receptors and in particular P2X7 receptors. As 
mentioned above, they activate rapidly and have little desensitisation throughout the 
agonist application. They deactivate slowly, and there is some evidence for a slowing of 
deactivation in some cells (Figure 5.2B), a property of P2X7 receptors that has been 
extensively detailed in previous studies (Surprenant et al. 1996; Hibell et al. 2001a), and 
here in Chapter 3.  
 
Finally, pharmacological evaluation of these BzATP-activated currents was conducted. 
BzATP-activated currents in these cells were blocked by the novel P2X7 antagonist, 
GSK314181A (Figure 5.3B), and by Zn2+ ions (Figure 5.4). GSK314181A is a potent 
antagonist of BzATP- and ATP-activated recombinant P2X7 receptors (Chapter 4; Figure 
4.2C and 4.4C). Although GSK314181A inhibited BzATP-activated currents in the non-
neuronal cells, it was around 20-fold less potent compared to its activity at recombinant 
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rat P2X7 receptors (IC50 value of 23 ± 2 nM compared to 1 ± 0.2 nM; see Figure 4.2C). It 
was unlikely that GSK314181A was acting through inhibition of other P2X receptors, 
specifically, P2X4 and P2X2/3 receptors (See Chapter 4, Figure 4.6 and 4.7), as it is 
around 200-400 fold less potent at these subtypes, with IC50 >10 µM and = 5µM, 
respectively. One other difference between the native and recombinant groups was in the 
Hill slope reported for inhibition with the compound, which were 2 for native cells and 
nearer to 1 for rP2X7 recombinant cells. The difference in the slope can be seen in Figure 
5.3B, and may be indicative of a change in the number of ATP molecules that are needed 
to be bound the receptor in the recombinant system (lack of positive cooperativity), or 
could imply that the native cells express a heteromeric receptor that requires the binding 
of GSK314181A to multiple subunits for inhibition to occur. 
  
Modulation of P2X7 responses have been extensively studied with many ions, including 
Ca2+, Mg2+, Cu2+, H+ and Zn2+ ions, all of which inhibit P2X7 currents (Virginio et al. 
1997; Acuna-Castillo et al. 2007; Jiang 2008). Zn2+ is particularly useful, as it 
differentiates between P2X receptors, potentiating current through P2X2 and P2X4 
receptors with EC50 values of 20 µM and 2 µM respectively (Wildman et al. 1998; 
Wildman et al. 1999). The inhibition of BzATP-activated currents by Zn2+ ions in these 
cells (IC50 = 1.4µM), provides further evidence for P2X7 mediated currents, and is also 
very similar to values reported here for Zn2+ inhibition of rat P2X7 recombinant receptors 
of 1.9 µM (see Chapter 4, Figure 4.1).  
 
Another possible complication of studying P2X7 receptors is the possible existence of 
P2X4/P2X7 heteromeric receptors in these cells. Although initially P2X7 receptors were 
believed to only be homo-oligomeric receptors (Torres et al. 1998b), more recent data 
from Guo and colleagues provided both biochemical and electrophysiological evidence 
for a P2X4/P2X7 heteromeric receptor (Guo et al. 2007). P2X7 and P2X4 receptors are 
located on the same chromosome and have the greatest sequence homology of all the 
P2X subunits (North 2002). Although they have an overlapping distribution in immune 
cells, epithelial and microglia (Brandle et al. 1998a; Bowler et al. 2003; Ma et al. 2006), 
their expression on astrocytes is not conclusive. Initial localisation data from juvenile 
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hippocampus (Kukley et al. 2001) was not backed up by more recent studies only 
identified P2X4 receptors on microglia in spinal dorsal horn (Tsuda et al. 2003; Zhang et 
al. 2008). Previous work has highlighted the changes in pharmacology that can occur 
with heteromerisation of P2X receptors. P2X2/3 heteromeric receptors are a perfect 
example of this. Pharmacologically they are activated by αβme-ATP and inhibited by 
TNP-ATP, properties from P2X3 receptor; but potentiated by low pH and show little 
desensitisation, properties from P2X2 (Evans et al. 1996; Virginio et al. 1998).  
 
The agonist potency data and biophysical and pharmacological data provide solid 
functional evidence for P2X7 receptors present on the non-neuronal cells in DRG 
cultures. 
  
Due to the overlapping biophysical properties and pharmacology of P2X receptors, the 
expression of P2X7 receptors in DRG culture was investigated. A monoclonal antibody 
to the extracellular loop of the human P2X7 receptor (Buell et al. 1998a), was used. It 
labelled the hP2X7 stably expressed in HEK293 cells, as also shown in Buell et al, 
(1998a), with no background labelling in HEK293 wild-type cells, and no non-specific 
binding following the incubation of the primary antibody or secondary antibody alone 
(Figures 5.5). The rP2X7 expressing HEK293 cells were also labelled following 
incubation with the hP2X7 monoclonal antibody at slightly more concentrated antibody 
levels (1:500; 2µg/ml and 1:250; 4µg/ml; Figure 5.6). This is at odds with a lack of a 
functional effect on rat and mouse P2X7 currents reported for this antibody at 1 µg/ml 
(Buell et al. 1998a). One explanation for this discrepancy in the data may be that although 
the hP2X7 monoclonal antibody binds to the rat P2X7 receptor as shown here, this 
binding does not affect the receptors ability to function as a non-selective cation channel. 
As the exact epitope of the antibody is unknown it is difficult to determine where on the 
extracellular domain of the P2X7 receptor protein it is binding. The binding site for the 
antibody on the human P2X7 protein may be more involved in the functioning of the 
channel either through a direct occlusion of the pore or through a conformational change 
following binding, compared to the other P2X7 orthologues. The extracellular domain of 
the P2X7 receptor is around 226-280 amino acids (Surprenant et al. 1996; Rassendren et 
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al. 1997) and so chimera and site-directed mutagenesis work would be required in order 
to try and ascertain the extracellular amino acids that constitute the epitope for the hP2X7 
antibody before further conclusions can be made. 
 
As previously mentioned, there is some evidence for P2X2 and P2X4 expression in these 
cells and so the selectivity of the hP2X7 monoclonal antibody was tested at these P2X 
subtypes when they are stably expressed in HEK cells (rat and human P2X4) and CHO 
cells (P2X2 and P2X3 homomeric and P2X2/3 heteromers). There was some non-specific 
immunofluoresence recorded for the P2X2/3 expressing cells defined as such from the 
pattern of green fluorescence that was seen following incubation of the secondary 
antibody (Alex-Fluor 488) only (Figure 5.7Cii), in the absence of the primary antibody. 
No specific immunofluoresence was observed in rat or human P2X4 expressing HEK 
cells, confirming data from Buell et al (Buell et al. 1998a). 
 
P2X7 immunofluoresence was detected in DRG cultured cells in a subset of cells 
(Figures 5.9C, 5.9F, 5.9G and 5.10D) in all cultures tested at concentrations of antibody 
of 4µg/ml and above. The labelling was specific as no fluorescence was observed when 
only primary or secondary antibodies were applied. Previously, P2X7 protein has been 
detected in non-neuronal cells from rat DRG cultures (Zhang et al. 2005b), and was 
present in satellite cells surrounding neurones in sections from human DRGs (Chessell et 
al. 2005). The immunofluoresence recorded in these cultures was variable depending 
upon the number of non-neuronal cells present following the initial ganglia dissociation 
and although cultures were fixed within 3 days following dissociation, the fixation and 
immunocytochemical methods can lead to the loss of cells that have not stuck to the 
coverslip sufficiently.  See Figures 5.9F and 5.10D for comparison. Surprisingly, there 
was more intense immunofluoresence seen in cells that had the morphology of neurones 
in these cultures (Figure 5.8F) and this is discussed later.  
 
5.4.2 Differences between recombinant and native P2X7 receptors 
There are some studies detailing the electrophysiological characteristics of P2X7 
receptors in native cells, although often in the context of defining P2X receptor subtype 
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expression (Brandle et al. 1998a; Grubb and Evans 1999; Kukley et al. 2001; North 2002; 
Kobayashi et al. 2005), rather than as a comparison as to their functioning when 
expressed recombinantly. The P2X7 receptor stably expressed in HEK293 cells has some 
interesting properties, such as a non-static response to agonist activation recorded as 
changes in current amplitude and deactivation rates, little of which has been commented 
on in native cells, and some of which could have important consequences for physiology. 
Therefore it is interesting to determine whether these effects are inherent to the receptor 
function or if they are a property of the different expression systems for native and 
recombinant cells. 
 
The currents recorded in response to BzATP were similar in their kinetics to those 
recorded from recombinant cells. However there is very little change in the peak current 
amplitude in response to multiple agonist additions (112 ± 13% of control at the 6th 
application; Figure 5.2A). A much greater and consistent increase in the current 
amplitude was recorded in all rP2X7-HEK cells in response to BzATP (335 ± 49% of 
control at the 6th application; Figure 3.3B). The current growth associated with multiple 
applications of agonist was initially proposed to be due to pore dilation of the P2X7 
channel (Chessell et al. 1997). Therefore, the lack of current growth in these cells may 
represent an absence of pore formation, as proposed for these cells in Zhang et al, where 
pore formation was measured using an extracellular NMDG-containing solution (Zhang 
et al. 2005b). However, a failure to detect current growth with supramaximal agonist 
applications, and a change in agonist potency following pre-exposure to ATP (Hibell et 
al. 2000), suggests that a change in agonist affinity may be occurring instead. More recent 
data suggested that current growth recorded in P2X7 expressing HEK293 cells was 
thought to underlie a secondary, dilated state of the P2X7 receptor (Yan et al. 2008) 
through which large organic ions, such as NMDG, may permeate, but which is distinct 
from entry pathways for YOPRO (Jiang et al. 2005; Yan et al. 2008). Therefore the lack 
of current growth may also be due to a change in the functioning of the receptor in these 
cells, where no change to the agonist affinity occurs following multiple P2X7 activation. 
It has been shown previously that the pathway for YOPRO uptake, Pannexins proteins, 
are present in glial cells (Lai et al. 2007; Liu et al. 2008a), although the expression in 
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these cultured cells is currently unknown. Further work in these cells using NMDG 
containing solutions and measuring ethidium bromide uptake, make prove useful to 
determine whether these cells form large diameter pores, and whether they are through 
P2X7 receptor dilation or via activation of Pannexin proteins.  
 
The deactivation of BzATP-activated currents in the non-neuronal cells in these cultures 
was very similar to that recorded for the rP2X7 receptors stably expressed in HEK293 
cells. Deactivation of currents slowed with multiple applications of agonist (6th 
application of BzATP was significantly different from the deactivation time of the first 
application; p=0.002), and was voltage-dependent. However, there was a difference 
between these 2 groups as the 95-50% deactivation time of the first agonist application is 
significantly different to that recorded in the rP2X7-HEK recombinant cells. This 
difference was unexpected, and may represent a real change in the activation time of the 
receptor, but is probably of little importance as the deactivation time did slow with each 
subsequent agonist application in line with data from the recombinantly expressed P2X7 
receptor. 
   
There are many possible reasons why differences would be seen between native receptors 
and those expressed in a recombinant system. Previously differences between expression 
systems, in both pharmacology and biophysics, have been described previously, for 
example, GABAA receptors (Sapp and Yeh 1998) and voltage-gated proton channels 
(Musset et al. 2008). The most likely reasons for disparity are differences in the receptor 
expression levels, the interactions with auxiliary subunits and post-translational 
modification, in the form of phosphorylation, dephosphorylation and glycosylation, all of 
which occur at P2X7 receptors (Kim et al. 2001a; North 2002; Feng et al. 2005). There 
were significantly lower receptor expression levels in the native cells than recorded for 
the recombinant cells, an assumption made from the lower current density measurements, 
although changes in single channel conductance would also manifest itself in this way. 
Noise analysis or single channel analysis would be needed to rule this out.  
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There is much evidence for the requirement for auxiliary subunits for the modification of 
voltage-gated channels (Arikkath and Campbell 2003; Jerng et al. 2005; Chahine et al. 
2005), but this has not been reported for P2X7 receptors. P2X7 does interact with a 
number of proteins such as those involved in the cytoskeleton of cells, e.g. β-actin, heat 
shock proteins, phosphatidylinositol 4-kinase and receptor protein tyrosine phosphatase-β 
(RPTPβ) (Kim et al. 2001a), and is thought to exist in a multimeric complex (Kim et al. 
2001b), but this work was completed in HEK293 cells stably expressing rat P2X7 
receptors and so may not account for any of the biophysical differences reported here.  
 
5.4.3 Neuronal labelling using anti-hP2X7 antibody 
As mentioned above, P2X7 monoclonal antibody also labelled cells with a neuronal 
morphology in these cultures and to a much greater intensity compared with the non-
neuronal cells (Figure 5.8F). The cell type was confirmed as neuronal by co-expression of 
P2X7 and β3-tubulin (Figure 5.10C) in all neurones viewed in these cultures. β3-tubulin 
is a protein that, in combination with α-tubulin, forms microtubules. These are hollow 
tubes involved in cellular movement and in the maintenance and changing of cell 
morphology (Wade 2007). β3-tubulin is considered a neuron-specific marker, and is 
found throughout the peripheral and central nervous system (Katsetos et al. 2003), and 
the lack of non-neuronal distribution of this protein is further highlighted at a higher 
magnification (63x water immersion lens, Figure 5.10D). The neuronal expression of 
P2X7 receptors is still subject to some debate (review in Introduction and Chapter 4 
discussion). However, in these cells the expression of P2X7 receptors on DRG neurones 
was particularly unexpected as work using the same antibody on sections of human DRG 
gave no neuronal labelling (Chessell et al. 2005). Further validation of the antibody 
would usually be required, with preincubation of it with the epitope, often called 
exhaustion of the antibody. However as the exact sequence of the epitope is unknown, it 
is not possible to perform such an experiment. The previous work done using 
commercially available P2X7 antibodies have highlighted an apparent ‘P2X7-like’ 
protein that is present in rat brain and astrocytes from 2 different P2X7 knock-out mice, 
but not in peripheral tissues or microglia (Sim et al. 2004). The epitopes recognised by 
the antibody are identical to the genuine P2X7 receptor but differ in the sequence that has 
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been disrupted by genetic manipulation in the Pfizer knockout mouse (Sanchez-Nogueiro 
et al. 2005). Functional studies in cerebellar granule neurons taken from the Pfizer 
knockout mouse showed a similar, but not identical, Ca2+ uptake response following 
agonist application (Sanchez-Nogueiro et al. 2005). Unfortunately, the work using the 
hP2X7 monoclonal antibody detailed here cannot be replicated using cells from WT and 
knockout mice as the antibody does not label the mouse P2X7 orthologue. These 
experiments are often used to determine the specificity of antibodies, and would also be 
of use to determine any other off-target interactions the antibody may have. It remains to 
be investigated whether this protein is an alternative splicing product of P2X7 or a novel 
‘P2X7-like’ protein, and whether it is also expressed in genetically intact animals. Further 
work to investigate the neuronal P2X7 expression could focus on whether other neuronal 
cultures, such as cortical, hippocampal or spinal dorsal horn primary cultures express 
neuronal P2X7 receptors. Extension of this work could involve assessment of the 
phenotype of positively labelled DRG neurones with dual staining experiments assessing 
the expression of chemicals known to be present in subsets of DRG neurones, e.g. the 
NGF receptor trkA, IB4 binding, Substance P or CGRP.  
 
5.4.4 Non-neuronal cell type expressing P2X7 receptors  
Robust labelling of non-neuronal cells was detected in these cultures and matched the 
morphological identification of cells chosen for electrophysiological experiments. 
However the culture of cells from DRG will contain a mixture of non-neuronal cells, 
including Schwann cells, satellite glial cells and fibroblasts, macrophages and endothelial 
cells (Olsson 1990; Nascimento et al. 2008), and so the exact cell type expressing P2X7 
receptors needed to be determined.  
 
S100β is a member of the S100 family of proteins that participate in the regulation of 
intracellular Ca2+ homeostasis (Baimbridge et al. 1992; Barger and Van Eldik 1992). 
S100β was located in the spindle shaped cells in these cultures and was fully co-localised 
with P2X7 protein (Figure 5.12C) as previously reported in hippocampal astrocytes 
(Kukley et al. 2001). From previous data it is known that S100β labels satellite glial cells 
and Schwann cells (Albuerne et al. 1998; Gonzalez-Martinez et al. 2003), in the 
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periphery, indicating that the cells co-labelled here are likely to be a mixture of both these 
cell types. Although S100β proteins have also been found in a few large and intermediate 
sized neurons (Vega et al. 1991), no neuronal labelling was observed here, possibly due 
to the pre-plating step (See Methods), that removes many of the large DRG neurones. In 
an effort to remove the possible contamination of neuronal labelling and to confirm the 
results, antibodies to glutamine synthetase were also tested in these cultures. Glutamine 
synthetase is an enzyme that converts ammonia and glutamate to glutamine. Therefore it 
has an important role in the regulation of the neurotransmitter glutamate. Glutamine 
synthetase was co-localised with P2X7 in all of the spindle shaped non-neuronal cells and 
so allowed the identification of satellite glial cells and Schwann cells as those that are 
expressing P2X7 receptors in these cultures. Previously it is been localised to astrocytes 
(Norenberg and Martinez-Hernandez 1979) and oligodendrocytes (D'Amelio et al. 1990) 
in the central nervous system, and in satellite glial cells and Schwann cells in peripheral 
ganglia (Miller et al. 2002), but importantly not in neurones and so is an ideal tool with 
which to identify these cells in mixed cell populations such as this DRG preparation.  
 
These two immunocytochemical studies define the expression of P2X7 receptors as 
localised to satellite and Schwann cells, but do not allow differentiation between these 2 
cell types. It is known that in cultures more than 1 day old, satellite cells tend to migrate 
away from the neurones, and so distinguishing them from Schwann cells is problematic 
(Hanani 2005). Also, morphologically Schwann cells and satellite cells are very similar 
when dissociated from DRG ganglia. They have a bipolar, spindle shape morphology and 
over time will proliferate and begin to align in parallel, forming tracks (Li et al. 1996; 
Wilkinson et al. 1999) (Figure 5.8G and 5.9D). The overlapping molecular characteristics 
of these 2 cell types also make the use of markers to distinguish between them difficult 
(Hanani 2005). In Wilkinson et al, the close anatomical association of satellite cells with 
primary neurones was utilised in order to get a pure satellite cell primary culture 
(Wilkinson et al. 1999). This technique could be a way to determine the expression and 
function of P2X7 receptors in this cell type alone. Another possible way to clarify the 
expression profile would be to prepare sections from DRG in order to confirm the 
satellite cell labelling, and also use either an established rat schwann cell line or primary 
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cultures from sciatic nerve (Brockes et al. 1979) in order to confirm Schwann cell 
labelling. 
 
5.4.5 Possible roles for P2X7 receptors in these cells 
As functional P2X7 receptor expression has been demonstrated in the non-neuronal cells 
in DRG cultures, and is likely to be on satellite glial cells and possibly Schwann cells, the 
role of the receptors on these cell types must be investigated further. It is known that 
satellite cells can influence neuronal activity through the uptake or release of 
neurotransmitters, cytokines and growth factors (Hanani 2005 for review; Zhang et al. 
2007). The activation of P2X7 receptors on satellite cells, from neuronal ATP release, 
can lead to the release of TNF-α, which can in turn increase the excitability of neurones, 
through potentiation of P2X3 responses (Zhang et al. 2007). Information from the same 
group confirmed this interaction between P2X7 and P2X3 receptors, showing that a 
reduction in P2X7 expression or activity resulted in an upregulation of P2X3 expression., 
and produced abnormal nociceptive behaviours in vivo (Chen et al. 2008). This suggests 
that neuronal somata have a significant role in inter-cell signalling and satellite cells can 
influence neuronal activity. It would have been interesting to have assessed the release of 
cytokines, especially, IL-1β, IL-6 and TNF-α, from the non-neuronal cells in these 
cultures, following priming and P2X7 receptor activation. The pharmacology of this 
response could also have been assessed to determine whether it was specific to P2X7 
receptors. It would also be interesting to further the work done previously and establish 
neuronal-glial co-cultures to investigate if activating or inhibiting P2X7 receptors could 
affect neuronal function. As would further investigation of the full repertoire of P2X7 
receptors, including the relevance of slowing of deactivation of P2X7 receptors, pore 
formation and cytokine release, when expressed in native cells. This could provide an 
insight into the relevance of these results to the physiological, or more likely, 
pathophysiological role of P2X7 receptors when expressed in DRG. 
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Chapter 6: Lamotrigine antagonism of P2X7 – A possible role in pain and epilepsy 
 
6.1. Introduction 
 
Lamotrigine (Lamictal™, Figure 6.1A) is approved for use as an anticonvulsant and is 
primarily known as an effective broad-spectrum anti-epileptic agent with efficacy in 
absence seizures and Lennox-Gastaut syndrome (Matsuo 1999; McCabe 2000). The 
proposed mechanisms of action of Lamotrigine are use-dependent inhibition of voltage-
gated sodium channels (Xie et al. 1995), inhibition of calcium channels (Stefani et al. 
1996; Wang et al. 1996; Hainsworth et al. 2003) leading to inhibition of pre-synaptic 
glutamate release (Leach et al. 1986), but whether or not other pharmacological activities 
contribute to its overall mechanism of action has not been determined unequivocally. 
Sipatrigine (Figure 6.1B), an effective neuroprotective agent (Leach et al. 1993; Graham 
et al. 1994; Smith et al. 1997) and chemical analogue of Lamotrigine is known to have a 
similar pharmacological profile to Lamotrigine; inhibiting voltage-gated Na+ channels 
(Xie and Garthwaite 1996; Stefani et al. 1998) and Ca2+ channels (McNaughton et al. 
1997; McNaughton et al. 2000; Hainsworth et al. 2003).  
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Figure 6.1: Chemical Structure of Lamotrigine and Sipatrigine 
 
Neuropathic pain results from chronic injury to, or disease of, neurons, and often 
responds poorly to commonly used analgesics and to standard doses of opioid analgesics 
(Tremont-Lukats et al. 2000). Antiepileptic drugs, including Lamotrigine, are often used 
“off label” to treat a wide range of neuropathic pain disorders (Zaremba et al. 2006 for 
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review). The efficacy of a number of antiepileptic drugs in the treatment of pain 
syndromes suggests common features of their respective pathophysiology.  
 
Given the target validation data implicating IL-1β in neuropathic pain (see Introduction), 
I investigated whether the upstream trigger for IL-1β release, P2X7 receptor activation, 
represents a potential target for the action of Lamotrigine. It was also interesting to 
investigate whether this is an effect specific to Lamotrigine, or a compound class effect 
that can be recorded across chemical analogues, and specifically for the Lamotrigine 
analogue and neuroprotective agent Sipatrigine.  
 
6.2. Methods Summary 
 
6.2.1 Whole Cell patch Clamp 
Experiments were performed using whole-cell patch-clamp electrophysiology. The 
following cells were used in this study; P2X7 and P2X4 receptors stably expressed in 
HEK293 cells, satellite cells from DRG culture expressing P2X7 receptors and P2X2/3 
receptors stably expressed in CHO cells. Detailed methods can be found in Chapter 2. 
 
6.2.2 Hippocampal Slice Recordings 
Hippocampal slices were prepared as detailed in the Material and Methods section 
(Chapter 2), and extracellular recordings were obtained following modification of the 
perfusing solution by either the combined addition of the GABAA and GABAB receptor 
antagonists Bicuculline (10 μM) and CGP55845 (10 μM), or by the removal of 
extracellular magnesium ions from the perfusing medium. 
 
6.3. Results 
 
6.3.1 Lamotrigine inhibits rat and human P2X7 currents  
In this study, the effect of Lamotrigine on P2X7 receptors was evaluated using whole-cell 
patch clamp technique on HEK293 cells stably transfected with rat or human P2X7 
receptors. Lamotrigine was preincubated and co-applied with BzATP and the peak 
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current response recorded. Lamotrigine (300 µM) inhibited BzATP-activated rP2X7 
currents by 82 ± 3% (n=6) and was fully reversible within 2 minutes (see Figure 6.2A). 
Additional concentrations were tested from 30 µM to 100 µM allowing the production of 
a concentration-response curve, which yielded an IC50 value of 100 ± 9 µM, (Hill slope 
1.4 ± 0.2, n=3-6) (Figure 6.2C). 
 
Given the many examples of  differences in the potency of ligands acting at rat and 
human P2X7 receptors (North and Surprenant 2000), the inhibitory effects of 
Lamotrigine were examined at the human P2X7 receptor stably expressed in HEK293 
cells. Lamotrigine (10 µM) inhibited BzATP-activated hP2X7 currents by 57 ± 4% (n=4) 
and was fully reversible within 2 minutes (see Figure 6.2B). In the example traces, Figure 
6.2B, the currents did not fully deactivate over the time scale shown (see the lack of 
return to baseline), although they did return to the pre-activated level over the 2 minutes 
between BzATP applications. This has been reported for these currents previously 
(Klapperstuck et al. 2000a). Additional concentrations were tested from 1 µM to 300 µM 
allowing the production of a concentration-response curve, which yielded an IC50 value 
of 6.4 ± 0.7 µM, (Hill slope 0.9 ± 0.1, n=4-5) (Figure 6.2C). 
 
Although BzATP is an analogue of ATP, it was thought prudent to confirm that 
Lamotrigine could inhibit human P2X7 receptors activated by the endogenous ligand, 
ATP. Human P2X7 receptors were activated by ATP (5mM) and a range of 
concentrations of Lamotrigine were applied allowing the production of a concentration-
response curve which yielded an IC50 value of 8 ± 1 µM, (Hill slope of 0.9 ± 0.1, n=4; 
Figure 6.2D), indicating a similar potency to Lamotrigine’s inhibition of BzATP-
activated hP2X7 receptors. 
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Figure 6.2: Lamotrigine inhibits rat and human P2X7 currents 
A. Example recording showing Lamotrigine (LTG, 300 µM) reversibly inhibiting 30 µM BzATP-
activated rP2X7 current by 82 ± 3% and the recovery to pre-addition levels in 2 min.  
B. Lamotrigine 10 µM inhibits 100 µM BzATP-activated hP2X7 current by 57 ± 4 %, n=4. 
Inhibition with Lamotrigine peaked within 2 minutes and currents recovered to baseline levels 
within 4 min.  
C. Concentration-response curves for Lamotrigine at rP2X7 and hP2X7 activated by 30 µM 
BzATP or 100 µM BzATP respectively. Curves were fit to raw data and yielded IC50 value of 
100 ± 9 µM, Hill slope of (1.4 ± 0.2, n=3-6) for rat P2X7 receptors and IC50 value of 6.4 ± 0.7 
µM (Hill slope 0.9 ± 0.1, n=4-5) for human P2X7 receptors. 
D. Concentration-response curves for LTG at hP2X7 activated by 5 mM ATP. Curve was fit to 
raw data and yielded IC50 value of 8 ± 1 µM, (Hill slope of 0.9 ± 0.1, n=4).  
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The effect of holding cells at positive potentials on the inhibition with Lamotrigine was 
assessed at hP2X7 receptors. Lamotrigine inhibited BzATP-activated currents by 59 ± 
2% (n=4) when cells were voltage-clamped at +60mV, a value that is not significant 
different to that recorded at a holding potential of -60mV (57 ± 5 % inhibition, n=4, 
p=0.64, Figure 6.3A). 
In addition, the ability of Lamotrigine to inhibit BzATP-activated hP2X7 current when 
applied intracellularly was investigated (Figure 6.3B). A high concentration of 
Lamotrigine (100 µM) was included in the standard whole-cell intracellular solution. In 
all recordings a robust BzATP-activated current was observed following the first 
application of BzATP (183 ± 38 pA, n=5). Subsequent applications of BzATP resulted in 
the normal increase in the current amplitude and no abnormal changes in the kinetics of 
the responses were observed. In all 4 cells a subsequent extracellular application of 100 
µM Lamotrigine produced its signature inhibition of currents to 9 ± 3 % of control, n=5, 
which was reversible on washout of the drug (Figure 6.3B).  
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Figure 6.3: Lamotrigine inhibits hP2X7 currents at +60mV and but does not inhibit 
currents when applied intracellularly. 
A. Example traces for the effect of Lamotrigine (10 µM) on BzATP-activated hP2X7 currents 
while cells were voltage-clamped at +60mV. Lamotrigine was preincubated for 2 minutes before 
being co-applied with 100µM BzATP and reversibly inhibited peak hP2X7 currents by 59 ± 2% 
(n=4).  
B. Example traces showing the first current response to BzATP (100 µM) recorded with 100 µM 
Lamotrigine within the recording electrode and then after 18 minutes. The other trace shows the 
inhibition of the response to 100 µM BzATP in the presence of extracellular application of 
Lamotrigine (100 µM).   
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6.3.2 Lamotrigine inhibits native rat P2X7 currents  
Confirmation of the inhibitory activity of Lamotrigine was sought at native P2X7 
receptors. The satellite cells that surround DRG neurones have been shown to express 
functional P2X7 receptors and robust currents can be recorded following the addition of 
BzATP (100µM) (see Chapter 5, Figure 5.1). We confirmed that Lamotrigine could 
inhibit the native rat P2X7 receptor in non-neuronal dorsal root ganglia cells, with 100 
µM Lamotrigine producing 35 ± 6 % (n=6) inhibition of the peak current (Figure 6.4A). 
Additional concentrations of Lamotrigine were applied allowing the production of a 
concentration-response curves which yielded an IC50 value of 262 ± 50 µM, (Hill slope 
0.7 ± 0.1, n=3-6, Figure 6.4B).  
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Figure 6.4: Lamotrigine inhibits native rat P2X7 currents 
A. Example traces for the effect of Lamotrigine (100 µM) on 100 µM BzATP-activated rat P2X7 
current in DRG non-neuronal cells. Lamotrigine (100µM) was preincubated for 2 minutes before 
being co-applied with 100µM BzATP (Black bar) and reversibly inhibited peak currents by 35 ± 
6 % (n=6).  
B. Concentration-response curves for Lamotrigine at native rP2X7 activated by 100 µM BzATP. 
The curve was fit to raw data and yielded IC50 value of 262 ± 50 µM, (Hill slope 0.7 ± 0.1, n=3-
6).  
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6.3.3 Investigation of Lamotrigine’s activity at closely related P2X receptors 
Given the activity of Lamotrigine at P2X7 receptors, it is interesting to assess it’s 
selectivity for P2X7 over the other P2X receptor subtypes. P2X4 receptors are located on 
the same chromosome as P2X7 and share the most homology out of all P2X receptor 
subtypes (North 2002; for review). As Lamotrigine was most potent at human P2X7 
receptors, recombinant cell lines of stably transfected human P2X4 receptors were used 
for these selectivity studies. P2X4 receptors were activated by ATP (10μM). Lamotrigine 
(100 μM) was preincubated for 4 minutes and co-applied and had no significant effect on 
currents at 100 µM (0.03 ± 1.92 % block, n=4; Figure 6.5A). TNP-ATP (30 µM) was 
used as a positive control and inhibited currents by 98 ± 1 %, (n=4) (Virginio et al. 1998). 
 
P2X3 and P2X2/3 receptors have been implicated in mediating ATP-related nociception 
(See Introduction; Burnstock 2006). An inhibitory effect of Lamotrigine on these 
receptors was considered important to investigate when considering other mechanisms 
that would account for its analgesic action. Due the previously reported high positive 
correlation between ligand binding at heteromeric P2X2/3 and homomeric P2X3 
receptors (Jarvis et al. 2004), only the effect of Lamotrigine at P2X2/3 receptors was 
investigated here. Following multiple applications of αβmeATP, the peak current 
decreased and so the peak current values were baseline gradient adjusted to enable the 
effects of the compounds to be more accurately analysed (see Chapter 2 - 2.3.4.4 and 
2.3.4.6). Using this protocol for analysis, Lamotrigine (100 μM) reversibly inhibited 
P2X2/3 mediated currents by 14 ± 3 %, n=7 (Figure 6.5B). A greater degree of inhibition 
of P2X2/3 receptors was confirmed by the use of Compound X, which reversibly 
inhibited P2X2/3 currents by 84 ± 1% (n=3), (Figure 6.5B). 
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Figure 6.5: Effect of Lamotrigine at P2X4 and P2X2/3 receptors 
A. Example traces for the effect of Lamotrigine (100 µM) on 10 µM ATP-activated rat P2X4 
currents. Lamotrigine (100µM) had no effect on ATP-activated hP2X4 currents (0.0 ± 1.9% 
inhibition, n=4), where as TNP-ATP (30 µM) reversibly inhibited currents by 98 ± 1 %, (n=4).  
B. Example recording showing Lamotrigine (100 µM) inhibits 7.5 µM αβ-meATP-activated 
hP2X2/3 current by 14 ± 3% (n=7). Clear bars show 7.5 µM αβmeATP application alone and the 
black bars show the application of 7.5 µM αβmeATP in the presence of Lamotrigine. Compound 
X (3 µM), a GSK P2X2/3 antagonist, reversibly inhibited currents by 84 ± 1 %, (n=3).  
 
 
 
 
 
6.3.4 Lamotrigine analogues are P2X7 inhibitors 
Although we have shown that Lamotrigine is a potent inhibitor of human P2X7 receptors, 
it is interesting to establish if an analogue of the compound also has inhibitory actions at 
P2X7 receptors. Sipatrigine (GV230822) is a chemical derivative of Lamotrigine (Figure 
6.1B). Sipatrigine (10 µM) reversibly inhibited BzATP-activated currents in human 
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P2X7-HEK293, reaching a maximum inhibition of 77 ± 5% (n=4) within 4 minutes 
(Figure 6.6A).  To enable an estimate of the IC50 concentration for inhibition of BzATP-
activation of hP2X7 by Sipatrigine, additional experiments were conducted from 10 nM 
to 100 µM. Raw data were fit and yielding an IC50 value of 2.6 ± 0.7 µM (Hill slope 0.6 ± 
0.1, n=3-6; Figure 6.6B). Also included in Figure 6.6B is the concentration-response 
curve for Lamotrigine at hP2X7 receptors, due to the closeness of the IC50 values for the 
inhibition of hP2X7 receptors by both of these compounds. 
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Figure 6.6: Lamotrigine analogue, Sipatrigine, is a P2X7 antagonist 
A. Example traces for the effect of Sipatrigine (10 µM) on 100 µM BzATP-activated hP2X7 
currents. Sipatrigine (10µM) was preincubated for 2 minutes before being co-applied with 100µM 
BzATP and reversibly inhibited peak currents by 77 ± 5 % (n=4).  
B. Concentration-response curves for Sipatrigine at hP2X7 activated by 100 µM BzATP. Curves 
were fit to raw data and yielded IC50 value of 2.6 ± 0.7 µM (Hill slope 0.6 ± 0.1, n=3-6). 
Lamotrigine concentration-response curve is also included for comparison.  
 
 
 
6.3.5 Role of P2X7 receptors in epileptiform activity 
P2X7 receptors have been implicated in epileptogenesis based around their expression 
and function in astrocytes (Ballerini et al. 1996; Kukley et al. 2001). Therefore, it is 
interesting to speculate on whether any of Lamotrigine’s antiepileptic effects could be via 
inhibition of P2X7 receptors. To try to establish what effect, if any, P2X7 inhibition 
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would have on epilepsy, in vitro hippocampal slice models of epileptiform activity were 
used.  
 
6.3.5.1 Compound A inhibits rat P2X7 currents  
Compound A was identified from high throughput screening as an inhibitor of P2X7 
receptors. It was used instead of GSK314181A to investigate the function of P2X7 
receptors in hippocampal epileptiform activity models due to its more attractive in vivo 
pharmacokinetic profile. This would enable the work detailed here to be extended to 
assess the activity of the compound in animal models of epilepsy.  
 
Confirmation of the potency of compound A at rat P2X7 receptors was sought using 
whole-cell patch-clamp techniques. Compound A (3 µM) inhibited BzATP-activated 
rP2X7 currents by 75 ± 6 % (n=3) and was fully reversible within 2 minutes (see Figure 
6.7A). Additional concentrations were tested from 100nM to 20 µM allowing the 
production of a concentration-response curve, which yielded an IC50 value of 1.4 ± 0.2 
µM, (Hill slope 0.7, n=3-7) (Figure 6.7B). 
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Figure 6.7: Compound A inhibits rat P2X7 currents 
A. Example recording showing Compound A (3 µM) reversibly inhibiting 30 µM BzATP-
activated rP2X7 current by 75 ± 6% (n=3), and the recovery to pre-addition levels in 2 min.  
B. Concentration-response curves for Compound A at rP2X7 activated by 30 µM BzATP. Curves 
were fit to raw data and yielded IC50 values of 1.4 ± 0.2 µM (Hill slope 0.7, n=3-7).  
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6.3.5.2 Low Mg2+ model of epileptiform activity 
In this model, the epileptiform activity was induced by modulating the ionic composition 
of the extracellular artificial cerebrospinal fluid (aCSF). The removal of extracellular 
Mg2+ from the aCSF is an established brain slice model of epileptiform bursting, which 
produces synchronous, stable frequency, bursting activity in the CA3 cell body region of 
the hippocampal slice. The model was chosen because astrocytic glutamate release 
produced prolonged neuronal depolarization which contributed to the epileptiform 
activity (Tian et al. 2005). 
  
Extracellular recordings were made in stratum pyramidale of area CA3, and within 30 
minutes of removal of Mg2+ from the aCSF, inter-ictal bursts, comprising of 1-2 
population spikes were recorded. The epileptiform bursting occurred at a mean frequency 
of 0.18 ± 0.11 Hz (range 0.06 – 0.50 Hz) and with a mean burst duration of 750 ± 61 ms, 
(varying between 622 ms to 896 ms; n=4; see figure 6.8). Bath application of Compound 
A (10-100µM) had no significant effect on the frequency or duration of bursts (Figure 
6.8B, 6.8C). Lamotrigine was tested in all slices and reduced the frequency of 
epileptiform bursting by 38 ±5 % (n=4, p=0.006), and caused a small but non-significant 
increase in the duration of bursts (128 ± 12 %; n=4). 
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Figure 6.8: Compound A has no effect on low Mg2+ induced spontaneous epileptiform 
activity.  
A. The traces from top to bottom are excerpts of raw data showing spontaneous burst firing 
recorded extracellularly over a 2 minute period in control conditions (low Mg2+ aCSF), in the 
presence of 100 µM Compound A, washout, and in the presence of 100 µM LTG. To the right of 
each excerpt is an expanded example of the first burst recorded under each experimental 
condition.  
B. The bar graph shows the effect of 30 µM and 100 µM Compound A, and 100 µM LTG on the 
frequency of events in the low Mg2+ model.  
C. The bar graph shows the effect of 30 µM and 100 µM Compound A, and 100 µM LTG on the 
bursting event duration in the low Mg2+ model.   
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6.3.5.3 Disinhibition Model of epileptiform activity 
Having established that Compound A had no significant effect on epileptiform activity 
induced by removal of extracellular Mg2+ ions, the effect of Compound A on epileptiform 
activity induced by changing the balance of inhibitory to excitatory synaptic transmission 
using antagonists of GABA-mediated synaptic transmission was assessed. Again, there is 
evidence for an involvement of glutamate released from astrocytes in this model (Tian et 
al. 2005). 
 
Here the combined application of the GABAA and GABAB  receptor antagonists, 
Bicuculline (10 μM) and CGP55845 (10 μM), respectively, in the bathing solution 
consistently induced synchronous interictal-like, burst discharges in CA3 pyramidal 
neurones. Under these conditions bursting events occurred at a mean frequency of 0.25 ± 
0.03 Hz (range 0.12 – 0.33 Hz), and were comprised of a primary burst, sometimes 
comprising multiple population spikes. Overall the mean individual burst duration was 
1333 ± 290 ms, ranging from 862 to 2356 ms (Figure 6.9A); values consistent with 
activity reported previously (Empson and Jefferys 2001). Bath application of Compound 
A (10 µM - 200 µM) had no significant effect on the frequency of spontaneous 
synchronous bursting (75 ± 14% of control in 200 µM, p=0.1) or the duration of 
individual bursts (112 ± 21% of control in 200 µM) (Figure 6.9B and 6.9C). Lamotrigine 
(100 µM) significantly reduced epileptiform bursting frequency in 3 out of 4 slices to 38 
± 17% (n=4, p=0.01), but this was not accompanied by a change in the duration of the 
events that were left (112 ± 9 % of control, n=4; Figure 6.9C).  
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Figure 6.9: Compound A has no effect on the disinhibition model of spontaneous 
epileptiform activity.  
A. The traces from top to bottom are excerpts of raw data showing spontaneous burst firing 
recorded extracellularly over a 1 minute period in control conditions (10µM Bicuculline and 
10µM CGP55845), in the presence of 100 µM Compound A, washout, and in the presence of 100 
µM LTG. To the right of each excerpt is an expanded example of the first burst recorded under 
each experimental condition.  
B. The graph shows the effect of 10µM -200µM Compound A, and 100µM LTG on the 
frequency of bursting events in the disinhibition model. 4 separate cells are shown illustrating the 
variability of the effect of the compound, and the mean data (red dots). LTG (100µM) inhibited 
the frequency of events in 3 out 4 recordings. 
C. The bar graph shows the effect of 30µM and 100µM Compound A, and 100µM LTG on the 
bursting event duration in the disinhibition model.  
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6.4. Discussion  
 
In this study we investigated whether the marketed anti-epileptic, Lamotrigine, 
(Lamictal™), and the neuroprotective agent and chemical analogue, Sipatrigine were 
antagonists at P2X7 receptors. Lamotrigine inhibited both rat P2X7 receptors which were 
stably expressed in HEK293 cells and native P2X7 receptors expressed on the non-
neuronal cells in DRG cultures. It had a much higher potency at the human P2X7 
receptor, inhibiting BzATP-activated currents with an IC50 value of 6µM, one of the most 
potent actions of Lamotrigine reported to date. This effect at human P2X7 was also 
evident with Sipatrigine and produced an IC50 value of 3µM. Following on from this 
work the effect of a novel P2X7 antagonist, Compound A, was assessed in two models of 
epileptiform activity. No significant effect on the duration or frequency of epileptiform 
bursting activity was produced by Compound A in either model. 
 
6.4.1 Rationale for the assessment of Lamotrigine’s activity at P2X7 receptors 
P2X7 receptors were considered as a possible target for Lamotrigine for a number of 
reasons. Firstly, although Lamotrigine is marketed as an anticonvulsant and as a 
treatment for bipolar disorder, it has demonstrated efficacy in a number of animal 
neuropathic pain studies (Nakamura-Craig and Follenfant 1995; Hunter et al. 1997; 
Erichsen et al. 2003; Fox et al. 2003; Joshi et al. 2006), and has also been under clinical 
evaluation for neuropathic pain. Efficacy has been demonstrated in some of these clinical 
studies, including in diabetic neuropathy (Eisenberg et al. 1998), and trigeminal neuralgia 
patients (Canavero and Bonicalzi 1997; Zakrzewska et al. 1997; McCleane 2000). 
 
Secondly, although the pathophysiology of neuropathic pain is complex and dependent 
upon the aetiology, there is accumulating evidence of the role of P2X7 receptors in 
mediating this disorder (See Chapter 1, Introduction, section 1.4.6.1). The rationale 
highlights the key role of glial cells in spinal cord in the pathogenesis of pain (Watkins et 
al. 2001; DeLeo and Yezierski 2001), with both microglia and astrocyte activation 
observed in the spinal cord of rodents in models of chronic pain (Colburn et al. 1999; 
Sweitzer et al. 2001; Raghavendra et al. 2002; Milligan et al. 2003). Activation of P2X7 
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receptors located on microglia and astrocytes cause the release of cytokines including 
tumor necrosis factor-α (TNF-α) (Hide et al. 2000), interleukin-6 (IL-6) (Shigemoto-
Mogami et al. 2001), and interleukin-1β (IL-1β) (Ferrari et al. 1996; Sanz and Di Virgilio 
2000), providing further evidence for an important role for these receptors in this disease. 
IL-1β may be of further importance as its release, after P2X7 activation, caused an 
increase in the expression levels of P2X7 receptors in astrocytes (Narcisse et al. 2005). 
This is also mimicked in satellite cells in nerve and DRG sections from patients suffering 
with persistent neuropathic pain conditions (Chessell et al. 2005). 
 
Finally, there is also precedence for a wide-ranging pharmacological profile of 
Lamotrigine. The proposed mechanisms of action of Lamotrigine are use-dependent 
inhibition of voltage-gated sodium channels (Xie et al. 1995), inhibition of calcium 
channels (Stefani et al. 1996; Wang et al. 1996; Hainsworth et al. 2003) and inhibition of 
pre-synaptic glutamate release (Leach et al. 1986). However a number of other actions of 
Lamotrigine have been reported, including inhibition of hERG currents, (IC50 = 229 µM; 
Danielsson et al. 2005), A-type potassium currents (IA) (IC50=160µM Huang et al. 
2004), and nicotinic acetylcholine receptors (nAChR) (Valles et al. 2007), and positive 
modulation of transient potassium currents (100 µM increased ID in hippocampal 
neurones) (Grunze et al. 1998a; Grunze et al. 1998b); (EC50=226µM; Zona et al. 2002), 
with the latter two considered as possible contributors to Lamotrigine’s efficacy.  
 
6.4.2 Inhibition of P2X7 receptors by Lamotrigine  
The majority of the data for the receptors and channels that Lamotrigine has been found 
to interact with are recorded from recombinantly expressed channels or from native 
(rodent) tissue/cells. When comparing the potency of Lamotrigine to inhibit rat P2X7 
receptors (rP2X7-HEK IC50 = 100µM, Figure 6.2C; rDRG IC50 = 262 µM, Figure 6.4B) 
reported here, it is within this range of concentrations previously considered as candidates 
for underlying Lamotrigine’s efficacy in vivo.  
 
The activity at human P2X7 receptors (IC50 = 6µM) is one of the most potent effects of 
Lamotrigine reported to date, and higher than many of the reported potencies for 
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Lamotrigine at voltage-gated sodium (IC50 = 100 µM at Vh of -60mV; (Xie et al. 1995) 
and calcium channels (IC50 = 12.3 µM, (Stefani et al. 1996); the proposed primary sites of 
its action. Unlike Lamotrigine’s effect on hP2X7 receptors, where an equal degree of 
inhibition was recorded at a holding voltage of -60mV or +60mV (Figure 6.3A), the 
action of Lamotrigine on sodium channels has been shown to be enhanced at depolarised 
potentials, consistent with use-dependent inhibition (Xie et al. 1995). Therefore the 
holding voltage must be taken into account when comparing its potency at different 
channels. A measurement of the affinity of Lamotrigine for the inactivated state of 
sodium channels is a more useful and possibly a more accurate value to use when 
considering its activity to reduce action potential firing. Ki values of 9 µM, (Vh of -
70mV) in rat hippocampal neurones (Kuo and Lu 1997), and 38 µM (Vh of -70mV) for 
TTX-sensitive sodium currents in rat DRGs (Ilyin et al. 2006) have been previously 
reported, highlighting a more potent activity of Lamotrigine at key targets that are likely 
to mediate it’s efficacy in vivo.  
 
Intracellular application of Lamotrigine produced no inhibition of BzATP-activated 
currents in hP2X7 expressing cells, strongly suggesting an extracellular binding site of 
the molecule and no requirement for intracellular access to produce inhibition. However, 
as this was also the case for Lamotrigine’s inhibition of sodium channels (Kuo 1998), 
even though binding occurs within transmembrane regions (Liu et al. 2003), definitive 
conclusions on the site of binding cannot be deduced from this study. 
 
6.4.3 Sipatrigine and P2X7 receptor inhibition 
There have been a few chemical analogues of Lamotrigine reported in the literature but 
by far the most widely investigated has been Sipatrigine (BW619C89). It is known to 
have a similar pharmacological profile to Lamotrigine; inhibiting voltage-gated Na+ 
channels (Xie and Garthwaite 1996; Stefani et al. 1998) and Ca2+ channels (McNaughton 
et al. 1997; McNaughton et al. 2000; Hainsworth et al. 2003). However it has a much 
weaker in vivo anticonvulsant activity in seizure models (Meldrum 1994; Reddy et al. 
1998) compared to Lamotrigine, and instead is a more effective neuroprotective agent in 
models of stroke (Graham et al. 1994; Smith et al. 1997). There is also rationale for a role 
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for P2X7 receptors in neurodegenerative processes that underlie brain trauma such as 
stroke. Prolonged activation of P2X7 receptors can be cytotoxic and releases cytokines 
such as IL-1β (Di Virgilio 1995; Le Feuvre et al. 2002b). Blockade of P2X7 receptors 
using Oxidised ATP increased neuronal survival in LPS-injected brain (Choi et al. 2007) 
and improved functional recovery following spinal cord injury (Wang et al. 2004a). 
However studies using P2X7 KO mice saw no change in neuronal death in various 
middle cerebral artery occlusion (MCAO) models, and no effect of P2X7 antagonists on 
ischemic or excitotoxic cell death (Le Feuvre et al. 2003), suggesting that P2X7 receptors 
are not primary mediators of experimentally induced neuronal death. Conflicting data 
was also reported using ischemia models to show that activation of P2X7 receptors may 
be beneficial when treating ischemic brain damage (Yanagisawa et al. 2008). Therefore 
although Sipatrigine is an equipotent antagonist of P2X7 receptors as Lamotrigine (IC50 = 
3 µM), this may just represent an interesting addition to the list of its pharmacological 
activities and further work must be done to establish whether it is of relevance as a 
mechanism involved in neurodegeneration (Le Feuvre et al. 2002a).  
 
6.4.4 The role of P2X7 receptor inhibition by Lamotrigine in pain 
The inhibition of P2X7 receptors by Lamotrigine represents a potent activity when put in 
context with existing data for the effects of Lamotrigine at other ion channels. However, 
to link the effect of Lamotrigine to inhibit P2X7 receptors and its efficacy in neuropathic 
pain, the therapeutic concentrations required for efficacy must be considered. As 
mentioned above, there have been many positive animal neuropathic pain studies 
(Nakamura-Craig and Follenfant 1995; Hunter et al. 1997; Erichsen et al. 2003; Fox et al. 
2003; Joshi et al. 2006), but the pharmacokinetic data relating the therapeutic effects to 
the plasma or brain concentrations are not included. Therefore patient data must be 
considered to assess the relationship between the pharmacokinetic and pharmacodynamic 
effects of Lamotrigine. Lamotrigine was assessed in a number of neuropathic pain patient 
groups, initially showing efficacy in trigeminal neuralgia open label trials (Lunardi et al. 
1997), and then in larger randomised controlled trials across a number of different patient 
populations (Eisenberg et al. 2005; Eisenberg et al. 2007). The reported therapeutic total 
concentrations for the effect of Lamotrigine in neuropathic pain are 3-7 µg/ml according 
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to 2 open-label trials (Peck 1991), corresponding to 12-30 µM approximately. A similar 
value (4.5 µg/ml, or 15 µM) was recorded in healthy volunteers, and in both trials and 
volunteer studies these correlated well to pain scores (Webb and Kamali 1998). In the 
work reported here, a corresponding concentration of Lamotrigine (10 µM) produced a 
large inhibition (61 ± 5 % block) of ATP-activated hP2X7 currents.  
 
When considering the impact of these findings it was interesting to know if this activity 
of Lamotrigine represents a specific action at P2X7 receptors as opposed to a more non-
specific purinergic receptor activity. We focused on P2X receptors that are known to be 
involved in pain processing so their activity could be excluded as a mechanism by which 
Lamotrigine is analgesic. The role of P2X2/3 receptors in mediating ATP-related 
nociception (Burnstock 2006), and P2X4 receptors in chronic pain (Inoue et al. 2004) are 
well established (see Chapter 1, Introduction section 1.4.6). Lamotrigine had no effect at 
human P2X4 receptors at a concentration that gives full inhibition of human P2X7 
receptors (100 µM, Figure 6.5A). The inhibition of human P2X2/3 receptors, (14% 
inhibition at 100 µM, Figure 6.5B) is around 16 fold higher than the IC50 value for 
Lamotrigine’s activity at human P2X7 receptors, and so very little inhibition of P2X2/3 
receptors would be expected at the circulating concentrations detailed above.  
 
Therefore, although one can hypothesise as to the effect this degree of hP2X7 receptor 
inhibition may have in vivo, it is difficult to relate these data presented here to an 
endogenous activation of the receptor. As mentioned in Chapter 4 discussion, the 
pharmacokinetic values only provide a measure of the circulating drug concentrations and 
do not represent the concentration of the drug at the site of action. Lamotrigine has been 
reported to be around 50% bound to plasma proteins (Morris et al. 1998), which can also 
affect the availability of active drug concentrations, and would imply that the total 
Lamotrigine concentrations reported in the studies by Peck, and Webb and Kamali, 
would be reduced by half. Despite these caveats, the potency with which Lamotrigine 
inhibits P2X7 receptors and the rationale that inhibition of P2X7 receptors is analgesic 
means that this activity must be considered as a contributing factor to the efficacy seen in 
these trials.   
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6.4.5 The role of P2X7 receptor inhibition by Lamotrigine in epilepsy 
Lamotrigine’s inhibition of P2X7 receptors led to an assessment of the potential of P2X7 
receptor antagonists in epileptiform activity. There is evidence for a role of P2X7 
receptors in mediating epileptic discharges in vivo through a variety of mechanisms. 
These are detailed in the Introduction in Chapter 1, and include increases in presynaptic 
neurotransmitter release (Deuchars et al. 2001; Sperlagh et al. 2002), changes in the 
responsiveness or expression of P2X7 receptors in epilepsy (Vianna et al. 2002), a role 
for IL-1β in epileptogenesis (Vezzani and Baram 2007; for review) and P2X7-mediated 
astrocytic glutamate release leading to neuronal synchronisation (Angulo et al. 2004; 
Fellin et al. 2004). However, the novel P2X7 antagonist, Compound A, had no significant 
effect in two in vitro models of epileptiform activity (Figure 6.8 and 6.9) at 
concentrations up to 100 µM. In both models Lamotrigine inhibited the frequency of 
epileptiform bursting (Figure 6.8 and 6.9). It is unlikely that Compound A was ineffective 
due to inadequate exposure as the concentrations used were 10-100 times the IC50 value 
at rat P2X7 receptors (IC50 = 1.4 ± 0.2 µM, Figure 6.7C). The epileptiform models used 
here were chosen as they may incorporate some of the possible mechanisms of P2X7 
activity including; astrocytic glutamate release, IL-1β release and an upregulation of 
P2X7 receptors in hippocampus. However, as for any in vitro model, there are limitations 
when comparing to an in vivo situation. Glutamate released from astrocytes occurs via a 
number of mechanisms (Parpura et al. 2004), not all P2X7 mediated, and although it 
contributes to the epileptiform activity ‘strength’, it may not be required to produce 
bursting in vitro (Fellin et al. 2006). The upregulation and the release of IL-1β following 
seizures has been detailed in whole animal studies (Vezzani et al. 1999; Vezzani et al. 
2004) but not as yet in the various in vitro models used to study epileptiform activity. 
Therefore it is possible that the mechanisms used to induce synchronous bursting activity, 
or the duration of the models used here, is not sufficient to produce an increase in 
cytokine production. Further work could be done to investigate the role of astrocytes and 
IL-1β in these models in order to more directly assess a contribution of P2X7 receptors. 
The recording of paroxysmal depolarising shifts (PDS) in the presence TTX, may also 
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allow a more specific assessment of the effect of P2X7 antagonists on astrocytic 
glutamate release in an in vitro epilepsy model (Tian et al. 2005). 
 
The fact that Lamotrigine was effective in reducing epileptiform activity in the two in 
vitro models used would suggest that the main mechanism of its action is not via 
inhibition of P2X7 receptors. When considering the clinical situation, it is clear that the 
potency of Lamotrigine inhibition of human P2X7 receptors (IC50 = 6µM) is within the 
proposed range of therapeutic circulating Lamotrigine concentrations that are 
anticonvulsant (1-4 µg/ml, (Brodie et al. 1995); 3-14 µg/ml, (Morris et al. 1998), and the 
measured therapeutic threshold plasma concentrations of 4-42 µM for Lamotrigine 
(Sondergaard et al. 2008). However, although this is true for patients, the data for the 
effect of Lamotrigine at the rat receptors fits less well into therapeutic range of 
concentrations reported the maximal electroshock test (MEST), a model used to test the 
anticonvulsant profile of compounds. The circulating plasma concentrations from MEST 
studies of 4-5 µg/ml (~19 µM) (Castel-Branco et al. 2003), would only inhibit native rat 
P2X7 or rP2X7-HEK923 receptors by around 6-15% (based on 6% inhibition with 10 
µM Lamotrigine at native rP2X7 and 15% inhibition with 30 µM Lamotrigine at rP2X7 
receptors expressed in HEK293 cells; See Figure 6.2C and 6.4) 
 
6.4.6 Conclusions 
In conclusion, the data presented here is the first defined activity of Lamotrigine at P2X 
receptors, and demonstrates Lamotrigine to be an effective inhibitor of rat and human 
P2X7 receptors stably expressed in a recombinant system and native P2X7 receptors 
expressed in DRG non-neuronal cells. The inhibition of human P2X7 is a potent effect of 
Lamotrigine and fits in well with the measured effective plasma concentrations of this 
compound in pain studies. These findings are supportive of another new pharmacological 
action of Lamotrigine and one that must be considered when investigating mechanisms of 
action of the analgesic actions of this drug in a number of diseases but in particular 
neuropathic pain.  
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Chapter 7: General Discussion 
 
7.1 Discussion 
 
The therapeutic potential of P2X7 receptor antagonists in pain has been suggested since 
the work by Dell'Antonio and colleagues using oxidised ATP, (initially thought of as a 
selective P2X7 antagonist), in pain models (Dell'Antonio et al. 2002a; Dell'Antonio et al. 
2002b). In the work detailed in Chapter 4, GSK314181A represents one of the most 
potent P2X7 antagonists reported to date, showing little species differences often 
associated with P2X7 antagonists. The data showing its selectivity over closely related 
P2X receptors adds weight to the interpretation that the reduction in the hypersensitivity 
induced in the in vivo FCA model are mediated through P2X7 receptor antagonism. This 
adds to the wealth of novel compound data published over the last 2 years by a number of 
different pharmaceutical companies (Donnelly-Roberts and Jarvis 2007; Romagnoli et al. 
2008), many of which display improvements in potency, selectivity and have less species 
dependence than older tool antagonists (Honore et al. 2006; Nelson et al. 2008). The data 
produced with GSK314181A is also important when considering its use as a selective in 
vitro tool with which to study P2X7 receptors expressed in native tissue. The study of 
native P2X7 receptors can often by beset by caveats over specificity of the effects 
recorded due to the often overlapping pharmacological profile of P2X receptor 
antagonists (North and Surprenant 2000). Tool P2X7 antagonists validated at 
recombinant and native P2X7 receptors, such as GSK314181A, are very useful 
compounds with which to dissect out P2X7 receptor function in cells containing such 
heterogeneity of P2X receptors.  
 
The proposed mechanism of action of P2X7 receptor antagonists in reversing 
hypersensitivity is thought to centre around the inhibition of IL-1β release from immune 
cells and CNS glial cells, such as astrocytes and microglia (Ferrari et al. 1997a; Ferrari et 
al. 1997b), and suggests a key role for these receptors in neuro-glial interactions. The role 
of glial cells in pain pathophysiology has become more apparent through work from a 
number of different groups (For reviews; Watkins and Maier 2003; Scholz and Woolf 
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2007). Although there is strong evidence for a role of immune cells and CNS glia in pain 
(Watkins and Maier 2003; Tsuda et al. 2005), the role of peripheral glial cells in sensory 
ganglia has, as yet, had little interest, even though their activation following peripheral 
nerve injury has been described and they have many of the hallmarks associated with 
CNS glial activation (Dublin and Hanani 2007). The expression of P2X7 receptors on 
non-neuronal cells in DRG cultures was confirmed here in Chapter 5 using a P2X7 
monoclonal antibody. This work was expanded to define the specific cell types 
expressing P2X7 receptors as satellite glial cells and Schwann cells using dual labelling. 
As DRG are outside the blood-brain and blood-nerve barrier (Wadhwani and Rapoport 
1994), the cells contained in the ganglia are easily accessible to systemic administration 
of drugs, but are often ignored as a potential site of action. The localisation of P2X7 
receptors on these cells highlights a possible previously under investigated site of action 
for P2X7 antagonists or other compounds that influence neuro-glial interactions, and 
hence neuronal excitability. 
 
The role of P2X7 receptor localisation on satellite cells in DRG is yet to be fully 
established. There is evidence that P2X7 receptors are important in bi-directional 
communication between neurones and satellite cells in the DRG (Zhang et al. 2007), and 
also can influence expression levels of neuronal P2X3 receptors (Chen et al. 2008). There 
is also evidence for ectopic discharge of neuronal cells of DRG, an effect that is 
exacerbated following injury (Devor and Seltzer 1999), indicating that neuronal 
stimulation of ATP release from DRG neurones is likely. However, the physiological 
relevance of the interaction between neurones and satellite cells in DRG and the potential 
influence it may have on neuronal excitability needs further exploration, as does the 
specific function of P2X7 receptors in this region. The likelihood of P2X7 receptor 
activation under physiological conditions has always been debated due to the high 
concentration of agonist required to activate them (> 100 µM). Although concentrations 
around this level may be released during normal conditions, the enzymatic degradation of 
ATP by ectonucleotidases will limit the time for P2X receptor activation. However, the 
relevance of ATP activation of P2X7 may be higher if inflammatory cells are exposed 
repeatedly to pulses of ATP released from damaged cells under inflammatory conditions 
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(Hibell et al. 2000). P2X7 receptors may also be “primed” from an initial ATP activation 
to respond to ADP and AMP, which are both products of ectonucleotidase degradation of 
ATP (Chakfe et al. 2002). The slowing of deactivation seen for recombinant and native 
cells, as recorded here in Chapter 3 and 5, may also mean that even short ATP 
applications would produce much longer channel opening times with subsequent P2X7 
receptor activation. There is also evidence for higher extracellular ATP concentrations 
under inflammatory conditions (Bodin and Burnstock 1998), suggesting that P2X7 
receptors may act as a ‘danger sensor’ where activation would mainly occur under 
pathophysiological conditions.  
 
A number of pharmaceutical companies have recognised the therapeutic potential of 
P2X7 antagonists across a range of disorders. The key role P2X7 receptors are known to 
play in regulating inflammatory processes has made them targets for diseases which have 
inflammation underlying their aetiology, including epilepsy (Rappold et al. 2006) and 
inflammatory and neuropathic pain (Donnelly-Roberts and Jarvis 2007), as discussed in 
this thesis. Following on from evidence from preclinical inflammatory and neuropathic 
pain models, a number of pharmaceutical companies are conducting clinical studies. 
These are in rheumatoid arthritis (RA) and pain, and have reported positive data in Phase 
II for Astrazeneca with AZD-9056, and Pfizer with CE-224535. When considering the 
clinical value of P2X7 antagonists, it is also worth noting some of potential problems that 
must be addressed. Many single-nucleotide polymorphisms (SNP) in the P2X7 receptor 
genes have been described, and some of which are found in up to 20% of the population 
(Glu496 to Ala; Gu et al. 2001). These have implicated P2X7 receptors in psychiatric 
illness, especially mood disorders (Reviewed in Bennett 2007), and in Crohn's disease 
(Haas et al. 2007), and have also raised the possibility that low P2X7 receptor function 
may be a genetic susceptibility factor in a range of infections such as tuberculosis and 
Chlamydia (Gu et al. 2004). These associations also highlight risks that must be 
discharged for small molecule P2X7 receptor antagonists during more extensive clinical 
trials.  
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Lamotrigine’s antagonism of P2X7 receptors was an interesting finding when considering 
the clinical use of Lamotrigine as an anticonvulsant and also the investigation of its 
efficacy in neuropathic pain. The lack of an effect of a P2X7 antagonist on epileptiform 
activity may suggest that the inhibition of P2X7 may represent an additional 
pharmacological action of Lamotrigine rather than a mechanism through which it 
produces its anticonvulsant effects. However, the increasing evidence of a crucial role of 
inflammatory processes in epilepsy (Vezzani et al. 2004), specifically around IL-1β 
release (Vezzani and Baram 2007) and the possible limitations of the in vitro models used 
here mean that a role of P2X7 receptors in this mechanism must be considered. Although 
there are many antiepileptic drugs currently available, it is estimated that for around 30% 
of epileptic patients, pharmacoresistance is a significant issue. Many of the most widely 
used therapies act primarily at voltage-gated ion channels (Wuttke and Lerche 2006), and 
even though newer molecules have provided an increase in efficacy and a reduction in 
side effects, an unmet need persists in this subpopulation. Therefore, further investigation 
into new mechanisms, such as P2X7 receptor antagonism, would be extremely beneficial 
to try to extend the range of therapies available. 
 
 
7.2 Future Work 
The work in this thesis presents a number of different directions for future study: 
 
Novel P2X7 Antagonists 
• It would be interesting to determine the mechanism of action of the tool 
compound, GSK314181A, and also its specific binding site in order to provide 
information on how this compound and others that are chemically similar interact 
with the P2X7 receptor, information that may be useful in selectivity studies or in 
comparisons of activity across orthologues. Further work would be needed using 
site-directed mutagenesis techniques to gain binding site information and detailed 
pharmacological analysis is required to ascertain whether GSK314181A has a 
competitive or non-competitive mechanism of action. These studies can only be 
done by looking at shifts in the agonist concentration-response curves and may be 
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better performed using plate-based assay formats such as FLIPR-Ca and ethidium 
bromide uptake experiments. 
 
Neuronal Localisation of P2X7 
• Confirmation of the neuronal localisation of P2X7 receptors in DRGs recorded in 
Chapter 5. This could be looked into through functional electrophysiology 
recordings using the selective pharmacological tools available such as 
GSK314181A, or using immunocytochemical or immunohistochemical 
techniques. This could also be extended to other CNS regions and also 
importantly to human tissues or cells.  
• Investigation into the epitope of the monoclonal antibody used in Chapter 5 would 
be needed in order to further work using this reagent. Chimeric experiments, 
followed by site-directed mutagenesis may be used to try to ascertain the epitope. 
This may then enable validation of the labelling with this antibody e.g. epitope 
preincubation (antibody exhaustion). 
• Investigation of the phenotype of the neuronal P2X7 expressing cells using dual 
labelling experiments, e.g. with calcitonin gene-related peptide (CGRP) or 
isolectin B4 (IB4), may determine if a subset of neurones were expressing P2X7.  
 
Role of P2X7 receptors on satellite cells 
• Further investigation of the function of P2X7 on the satellite cells in DRG is 
required. Specifically focusing on the two other consequences of P2X7 receptor 
activation; pore formation and cytokine release. Whether pore formation is 
occurring via P2X7 receptor dilation or via activation of Pannexin protein would 
investigated. The pharmacology of these responses could also be assessed to 
determine specific P2X7 receptor activity, and also to define if pore formation and 
cytokine release were reversible with small molecule antagonists in these cells. 
These data would give more information as to the role, if any, these cells may 
have in mediating the antihyperalgesic effects of P2X7 antagonists (as the 
rationale is focused on blocking the release of IL-1β), but also add to the data 
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presented in Chapter 5 as to whether these native receptors function in the same 
way as the recombinantly expressed receptor. 
• Neuronal-glial co-cultures, or intact or slices of DRG, could be used to investigate 
if activating or inhibiting P2X7 receptors affects neuronal function. As would 
further investigation of the full repertoire of P2X7 receptors, including the 
relevance of slowing of deactivation of P2X7 receptors, pore formation and 
cytokine release, when expressed in native cells. This could provide an insight 
into the relevance of these results to the physiological, or more likely, 
pathophysiological role of P2X7 receptors when expressed in DRG. 
• Following the results in Chapter 4 it would be interesting to assess the role 
satellite cells in DRG have in mediating the efficacy seen in the inflammatory 
pain model. The experiments detailed above could be replicated in tissues/cells 
taken from animals that have undergone an inflammatory insult to see look for 
significant changes in the various measures of P2X7 function. 
 
Inhibition of P2X7 receptors by Lamotrigine 
• Further work to address whether Lamotrigine can inhibit other consequences of 
P2X7 receptors activation such as YOPRO uptake and IL-1β release. 
• Investigation into whether the activity of Lamotrigine at P2X7 receptors has any 
therapeutic relevance. Due to the analgesic effects of P2X7 receptor inhibition 
and sodium channel inhibition it is difficult to assess the role of P2X7 inhibition 
in the efficacious effects of Lamotrigine in vivo. Therefore an indirect effect of 
P2X7 receptor activation, such as measurement of IL-1β levels in blood following 
FCA-induced hypersensitivity, would have to be assessed. These levels could be 
measured following Lamotrigine or a sodium channel blocker with no P2X7 
activity and compared to vehicle and P2X7 antagonist dosing groups. 
• Further investigation into the role of P2X7 receptors in epilepsy. The effect of 
P2X7 receptor inhibition on the induction and maintenance of epileptiform events 
could be assessed in a range of in vitro models, as could the effect of P2X7 
antagonists in in vivo convulsant models such as MEST or Pentylenetetrazole.  
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Appendix A 
 
1 In Vivo Inflammatory Pain study 
1.1 Animals 
Male Random-Hooded rats (weight, 180–200 g; B & K Universal, Hull, UK) were used 
in weight-bearing studies. Animals were housed in groups of 5 in a temperature-
controlled environment (20°C ± 1°C) maintained on a 12-hour light/dark cycle with 
access to food and water. All experiments were performed in accordance with the 
Animals (Scientific Procedures) Act 1896 under the authority of a Home Office Project 
License and complied with local GlaxoSmithKline (GSK) regulations regarding the care 
of experimental animals. 
 
1.2 Behavioural Readouts -Assessment of Weight-Bearing Capacity 
The distribution of weight between the 2 hind paws was measured using a dual channel 
weight averager (Bioengineering, GlaxoSmithkline; (Clayton et al. 1997)). Normal rats 
distribute their body weight equally between the 2 hind paws, but when a hind paw is 
inflamed and/or painful, the weight is redistributed so that less weight is put on the 
affected paw. Assessment of this change using the dual channel weight averager is a 
sensitive method for measuring the development of hypersensitivity. The 2 hind paws 
were placed on separate sensors, and the drug-induced percent reversal of FCA-induced 
weight-bearing deficit was calculated over a period of 4 seconds (De Alba et al. 2006). 
 
1.3 Established Inflammation-Induced Hyperalgesia 
FCA (100 µl of 1 mg/ml M. tuberculosis (1 mg/ml)) was injected intraplantar into the left 
hind paw (n = 7 per group). GSK314181A (3-30 mg/kg s.c.), and Celecoxib (10 mg/kg 
p.o.) were administered 24 hours post-FCA. The effect on weight bearing of the inflamed 
paw was determined at 0.5, 1, 3, 6 and 24 hours post-dosing.  
 
1.4 Data Analysis and Statistics 
Hypersensitivity to pain was measured as % of decrease in weight bearing on the 
inflamed left hind paw. Weight-bearing ability was recorded in grams and expressed as 
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the difference between the FCA-injected paw and the contralateral paw. The percentage 
reversal was calculated for each animal using the formula: (testΔ - mean vehicleΔ/base-
lineΔ - mean vehicleΔ) x 100, expressed as mean ± S.E.M., and an ED50 (with confidence 
limits). Drug-treated groups were compared with vehicle using Fisher's test. 
 
